Cyclic compounds having selective KRAS inhibition with respect to HRAS and NRAS

Abstract

The present inventors have discovered a cyclic compound that selectively inhibits KRAS. The inventors also found that the cyclic compounds interact with KRAS specific amino acid residues.

Description

Technical Field

[0001] The present invention relates, in one aspect, to cyclic compounds. Background Art

[0002] RAS is a protein belonging to the small GTPase family, and KRAS, NRAS, and HRAS are known. RAS is in an activated state or an inactivated state depending on whether it binds to GTP or GDP. It is activated by an exchange reaction from GDP to GTP carried out by GEF (guanine nucleotide exchange factor) and inactivated by a hydrolysis reaction of GTP carried out by GAP (GTPase-activating protein) (NPL1). Activated RAS induces cell proliferation, survival, and differentiation by activating multiple downstream signals in the MAPK pathway, PI3K / Akt pathway, RAL pathway, etc., and constitutive activation of RAS plays an important role in the development and progression of cancer. In cancer, it is known that the RAS-RAF-MEK-ERK pathway is activated by activation of upstream signals of RAS, constitutive activation of RAS, and / or activating mutations of RAS (NPL 2). These activating mutations of RAS have been found in various cancer types. G12, G13, and Q61 are considered to be hotspots for RAS mutations, and G12 is frequently found mutated in KRAS, and Q61 is frequently found mutated in NRAS. It is also known that these mutations are associated with the prognosis of patients (NPL 3).

[0003] Meanwhile, when it comes to approaching intractable targets represented by inhibition of protein-protein interactions, medium-sized molecules (molecular weight of 500 to 2000 g / mol) may be superior to low molecular weight compounds. In addition, medium-sized molecules may be superior to antibodies because they can migrate into cells. Among medium-sized molecules with biological activity, peptide drugs are a very valuable molecular species, and more than 40 peptide drugs are commercially available (NPL 4). Representative examples of such peptide drugs include cyclosporin A and polymyxin B, which are peptides containing some non-natural amino acids. Non-natural amino acids refer to amino acids that are not naturally encoded on mRNA. Very interestingly, naturally occurring cyclosporin A and polymyxin B contain non-natural amino acids.

[0004] Since the discovery of the pharmaceutical use of naturally occurring peptides, peptides with pharmacological activity and bioabsorbability have attracted attention, and those peptides with a molecular weight of about 500 to 2000 g / mol have been actively studied (NPL 5).

[0005] There are reports on conditions under which medium molecular weight peptides have increased membrane permeability and metabolic stability, which may contribute to improving their biokinetics (conditions required to meet drug-likeness) (PTL 1).

[0006] In addition, for conditions that may contribute to improving the biokinetics of medium molecular weight peptides, cyclic peptides have been shown to meet the conditions required for drug-likeness (PTL 2).

[0007] Peptides that bind to RAS have been discovered, and the binding sites between cyclic peptides and RAS have been studied by X-ray structural analysis (NPL 6, NPL 7, and NPL 8). Additionally, cyclic peptides that significantly inhibit the binding between RAS and SOS have been discovered (PTL 3). Furthermore, competitive assays for binding to RAS have shown that some cyclic peptides inhibit the binding between a specific compound and RAS (PTL 4).

[0008] [Citation List]

[0009] [Patent Documents]

[0010] [PTL 1]WO 2013 / 100132

[0011] [PTL 2]WO 2018 / 225864

[0012] [PTL 3]WO 2012 / 122059

[0013] [PTL 4]WO 2017 / 181061

[0014] [Non-Patent Documents]

[0015] [NPL 1]Nat.Rev.Drug Discov. November 2014; 13(11): 828-851.

[0016] [NPL 2]Nat.Rev.Drug Discov. December 2014; 13(12): 928-942.

[0017] [NPL 3]Nat.Rev.Drug Discov. November 2016; 15(11): 771-785.

[0018] [NPL 4]Future Med.Chem. 2009, 1, 1289-1310.

[0019] [NPL 5]Current Topics in Medicinal Chemistry, 2013, Vol. 13, No. 7, 821-836.

[0020] [NPL 6]Biochem.Biophys.Res.Commun. 2017, 484, 605-611.

[0021] [NPL 7]Bioorg.Med.Chem.Lett.2017, 27, 2757-2761.

[0022] [NPL 8]ACS Med.Chem.Lett.2017, 8, 732-736. Summary of the Invention

[0023] [Technical Problem]

[0024] The present invention relates to cyclic compounds effective against RAS-mutated cancers, as well as unnatural amino acids and peptide compounds useful for their production.

[0025] PTL 1 and PTL 2 describe drug-like peptides, but do not describe peptides having an antitumor effect against cancers including RAS-mutated cancers.

[0026] PTL 3 describes inhibition of the binding between RAS and SOS, and PTL 4 describes peptides that compete with compounds binding to RAS. However, none of these documents show any pharmacological effects, especially on tumor cells. These documents also do not describe drug-like peptides.

[0027] NPL 1 shows in detail the relationship between RAS and cancer. This document describes molecules that bind to RAS. Although their efficacy has been shown in preclinical studies, no compounds effective as drugs specifically against RAS-mutated cancers have been shown. Moreover, no drug-like cyclic peptides have been disclosed.

[0028] NPL 2 provides a detailed description of RAS and the RAF-MEK-ERK pathway downstream of RAS. Although this document suggests the possibility of treating RAS-mutated cancers with RAF, MEK, and ERK inhibitors, it does not show any compounds that directly inhibit RAS.

[0029] NPL 3 describes compounds that bind to the GTP / GDP binding site of RAS and inhibit the function of RAS and their mechanisms. This document describes in detail the interaction with the GTP / GDP binding site, but does not show pharmacological effects, especially on tumor cells.

[0030] NPL 4 describes peptides used as drugs, but does not describe drug-like peptides or peptides useful for RAS-mutated cancers.

[0031] NPL 5 describes the molecular form and pharmacokinetics of cyclic peptides, but does not describe compounds useful for RAS-mutated cancers.

[0032] NPLs 6 to 8 describe peptides that bind to RAS, but they have limited effects on tumor cells and, moreover, do not describe drug-like peptides.

[0033] Furthermore, to the best knowledge of the present inventors, there is no report on compounds that have sufficient selective inhibitory effects on KRAS relative to HRAS and NRAS.

[0034] [Solution to the problem]

[0035] As a result of dedicated research to find cyclic compounds that have selective inhibitory effects on KRAS relative to HRAS and NRAS, the present inventors have found cyclic compounds that selectively interact with KRAS as compared to HRAS and NRAS. Furthermore, the present inventors have found that the cyclic compounds have a pharmacological effect of inhibiting the growth of tumor cells having an RAS mutation.

[0036] In one specific non-limiting embodiment, the present invention encompasses the following:

[0037] [A1] A cyclic compound represented by formula (1) or a salt thereof or a solvate thereof:

[0038] [Formula 1]

[0039]

[0040] wherein

[0041] L1 is a single bond;

[0042] R1 is a C1-C6 alkyl group, a C2-C6 alkynyl group or a C3-C8 cycloalkyl group optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a C3-C6 cycloalkyl group and a C1-C6 alkoxy group,

[0043] P1 is a hydrogen atom or a C1-C6 alkyl group;

[0044] Q1 is a hydrogen atom;

[0045] R2 is a C1-C6 alkyl group or a C3-C6 cycloalkyl group;

[0046] P2 is a hydrogen atom;

[0047] Q2 is a hydrogen atom;

[0048] R3 is a hydrogen atom, or R3 is linked to P3, the carbon atom to which R3 is attached and the nitrogen atom to which P3 is attached to form a 4- to 7-membered saturated heterocycle;

[0049] P3 is a C1-C6 alkyl group or a C2-C6 alkynyl group, except when R3 and P3 form a 4- to 7-membered saturated heterocycle;

[0050] Q3 is a hydrogen atom;

[0051] R4 and P5 are connected together to form a divalent group, and in this case, the partial structure *-CR4Q4-CO-NP5-* in the cyclic compound represented by formula (1) is represented by the following formula:

[0052] [Formula 2]

[0053]

[0054] wherein T is a hydrogen atom or a halogen atom;

[0055] P4 is a C1-C6 alkyl group;

[0056] Q4 is a hydrogen atom,

[0057] R5 is a benzyl group optionally substituted by one or more groups selected from the group consisting of C1-C6 alkyl groups and C1-C6 haloalkyl groups;

[0058] Q5 is a hydrogen atom,

[0059] R6 is a hydrogen atom;

[0060] P6 is a C1-C6 alkyl group,

[0061] Q6 is a hydrogen atom,

[0062] R7 is a phenethyl group optionally substituted by one or more groups independently selected from the group consisting of halogen atoms, C1-C6 haloalkyl groups and C1-C6 alkoxy groups;

[0063] P7 is a hydrogen atom,

[0064] Q7 is a hydrogen atom,

[0065] R8 is connected to P8, the carbon atom to which R8 is attached and the nitrogen atom to which P8 is attached to form a 4- to 7-membered saturated heterocycle, wherein the 4- to 7-membered saturated heterocycle is optionally substituted by one or more groups independently selected from the group consisting of C1-C6 alkyl groups, C3-C6 cycloalkyl groups and C1-C6 alkoxy groups;

[0066] Q8 is a hydrogen atom,

[0067] R9 is a C1-C6 alkyl group, or is connected to Q9 and the carbon atom to which R9 and Q9 are attached to form a 3- to 8-membered alicyclic ring, wherein the 3- to 8-membered alicyclic ring is optionally substituted by one or more C1-C6 alkyl groups;

[0068] P9 is a hydrogen atom or a C1-C6 alkyl group,

[0069] Q9 is a C1-C6 alkyl group, except when Q9, together with R9 and the carbon atom to which R9 and Q9 are attached, forms a 3- to 8-membered alicyclic ring.

[0070] R 10 is a C1-C6 alkyl group or a C3-C8 cycloalkyl group;

[0071] P 10 is a C1-C6 alkyl group,

[0072] Q 10 is a hydrogen atom,

[0073] L 11 is -CH2-,

[0074] R 11 is di-C1-C6 alkylaminocarbonyl or 4- to 8-membered cyclic aminocarbonyl;

[0075] P 11 is a C1-C6 alkyl group, and

[0076] Q 11 is a hydrogen atom,

[0077] wherein

[0078] the cyclic compound represented by formula (1) is selected from the group consisting of:

[0079] PP3169: (2S, 8S, 12R, 14S, 20S, 23S, 27S, 30S, 36S, 38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-[(1S)-1-methoxyethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0080] PP3194: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0081] PP3198: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0082] PP3230: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-prop-2-ynyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0083] PP3234: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-prop-2-ynyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0084] PP3236: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0085] PP3238: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0086] PP3240: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracontane-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0087] PP3255: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,19,22,25,31,34,37,45-undecaoxo-13-prop-2-ynyl-38-(p-tolylmethyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 pentatetracontane-42-ene-23,1′-cyclobutane]-17-carboxamide,

[0088] PP3290: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3-methoxy-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2v,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1"-cyclopropane]-9′-carboxamide,

[0089] PP3299: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-6′,16′-bis((S)-sec-Butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide,

[0090] PP3327: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontene-39′,1"-cyclopropane]-9′-carboxamide,

[0091] PP3328: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-16′-cyclopentyl-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontene-39′,1"-cyclopropane]-9′-carboxamide,

[0092] PP3356: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontacene-39′,1″-cyclopropane]-9′-carboxamide,

[0093] PP3406: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontacene-39′,1″-cyclopropane]-9′-carboxamide,

[0094] PP3418: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1"-cyclopropane]-9′-carboxamide,

[0095] PP3438: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-butyl)-6′-cyclopentyl-35′-(3-methoxy-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1"-cyclopropane]-9′-carboxamide,

[0096] PP3440: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-16′-((S)-sec-Butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-6′-cyclopentyl-N,N,5′,8′,12′,18′,21′,31′-octamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontacene-39′,1″-cyclopropane]-9′-carboxamide,

[0097] PP3456: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-27-butyl-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3′,3′,4,19,22,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetracos-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0098] PP3457: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3′,3′,4,19,22,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.010，14 42-Carbon-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0099] PP3484: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-isobutyl-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 42-Carbon-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0100] PP3496: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-2-[[4-(difluoromethyl)phenyl]methyl]-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-20-(1-ethylpropyl)-12-isopropoxy-30-isopropyl-N,N,4,16,19,22,26,35-octamethyl-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-32-prop-2-ynyl-27-(2,2,2-trifluoroethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 42-Carbon-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0101] PP3516: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38E)-20-Cyclobutyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-38-fluoro-27-isobutyl-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 42-Carbon-38-ene-17,1′-cyclopentane]-23-carboxamide,

[0102] PP3517: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38E)-20-Cyclobutyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-38-fluoro-27-isobutyl-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1'-cyclopentane]-23-carboxamide,

[0103] PP3521: (2S,8S,13S,19S,22S,26S,29S,35S,37E)-19-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-37-fluoro-26-isobutyl-N,N,4,18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-3,6,9,14,17,20,24,27,30,33,41-undecaooxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,15,18,21,25,28,31,34-undecaazatricyclo[33.5.1.0 10,13 hentetracont-37-ene-16,1'-cyclopentane]-22-carboxamide,

[0104] PP3522: (2S,8S,13S,19S,22S,26S,29S,35S,37E)-19-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-37-fluoro-26-isobutyl-N,N,4,18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-3,6,9,14,17,20,24,27,30,33,41-undecaooxo-2-(p-tolylmethyl)spiro[1,4,7,10,15,18,21,25,28,31,34-undecaazatricyclo[33.5.1.0 10,13 hentetracont-37-ene-16,1'-cyclopentane]-22-carboxamide,

[0105] PP3523: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38E)-20-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-38-fluoro-27-isobutyl-N,N,4,17,17,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-(p-tolylmethyl)-1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-en-23-carboxamide, and

[0106] PP3529: (1S,4S,9S,12S,16S,19S,25S,27R,31S,37S,41E)-19-Cyclopentyl-27-ethoxy-42-fluoro-31-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,13,17,20,23,35-octamethyl-9-[(1S)-1-methylpropyl]-3,8,11,14,18,21,24,30,33,36,44-undecaoxo-12-propyl-37-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,7,10,13,17,20,23,29,32,35,38-undecaazatetracyclo[36.5.1.0 4 ,7 .0 25,29 tetratetracont-41-en-22,1′-cyclobutane]-16-carboxamide.

[0107] [A2] The cyclic compound or a salt thereof or a solvate thereof according to [A1], wherein

[0108] The formula (1) is represented by the formula (2):

[0109] [Formula 3]

[0110]

[0111] wherein

[0112] R1, P1, R2, R3, P3, P4, R5, P6, R7, R8, P8, R9, P9, Q9, R 10 , P 10 , R 11 , P 11 and T are the same as defined in [A1], and

[0113] The cyclic compound represented by formula (2) is selected from the group consisting of:

[0114] PP3169: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-[(1S)-1-methoxyethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0115] PP3194: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0116] PP3198: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0117] PP3230: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-prop-2-ynyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1'-cyclobutane]-23-carboxamide,

[0118] PP3234: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-prop-2-ynyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1'-cyclobutane]-23-carboxamide,

[0119] PP3236: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1'-cyclobutane]-23-carboxamide,

[0120] PP3238: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1'-cyclobutane]-23-carboxamide,

[0121] PP3240: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1'-cyclobutane]-23-carboxamide,

[0122] PP3255: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-Cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,19,22,25,31,34,37,45-undecaooxo-13-prop-2-ynyl-38-(p-tolylmethyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4，8 .0 26，30 pentatetracont-42-ene-23,1'-cyclobutane]-17-carboxamide,

[0123] PP3290: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3-methoxy-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopterop[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontene-39′,1″-cyclopropane]-9′-carboxamide,

[0124] PP3299: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-6′,16′-bis((S)-sec-butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopterop[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontene-39′,1″-cyclopropane]-9′-carboxamide,

[0125] PP3327: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1"-cyclopropane]-9′-carboxamide,

[0126] PP3328: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-16′-cyclopentyl-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1"-cyclopropane]-9′-carboxamide,

[0127] PP3356: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaoxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontacene-39′,1″-cyclopropane]-9′-carboxamide,

[0128] PP3406: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaoxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontacene-39′,1″-cyclopropane]-9′-carboxamide,

[0129] PP3418: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopterop[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, ″ -cyclopropane]-9′-carboxamide,

[0130] PP3438: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-butyl)-6′-cyclopentyl-35′-(3-methoxy-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopterop[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide,

[0131] PP3440: (6′S,9′S,13′S,16′S,22'S,29′S,35′S,40a'S,Z)-16′-((S)-sec-Butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-6′-cyclopentyl-N,N,5′,8′,12′,18′,21′,31′-octamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontene-39′,1"-cyclopropane]-9′-carboxamide,

[0132] PP3456: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-27-butyl-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3′,3′,4,19,22,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0133] PP3457: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3′,3′,4,19,22,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.010,14 42-Carbon-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0134] PP3484: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-isobutyl-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 42-Carbon-38-ene-17,1′-cyclobutane]-23-carboxamide, and

[0135] PP3496: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-2-[[4-(difluoromethyl)phenyl]methyl]-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-20-(1-ethylpropyl)-12-isopropoxy-30-isopropyl-N,N,4,16,19,22,26,35-octamethyl-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-32-prop-2-ynyl-27-(2,2,2-trifluoroethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 42-Carbon-38-ene-17,1′-cyclobutane]-23-carboxamide.

[0136] [A3-1]A cyclic compound, which is PP3169: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-[(1S)-1-methoxyethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14Tetratetracont-38-en-17,1′-cyclobutane]-23-carboxamide, or a salt or solvate thereof.

[0137] [A3-2]A cyclic compound, which is PP3194: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 Tetratetracont-38-en-17,1′-cyclobutane]-23-carboxamide, or a salt or solvate thereof.

[0138] [A3-3]A cyclic compound, which is PP3198: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 Tetratetracont-38-en-17,1′-cyclobutane]-23-carboxamide, or a salt or solvate thereof.

[0139] [A3-4]A cyclic compound, which is PP3230: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-prop-2-ynyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, or a salt thereof or a solvate thereof.

[0140] [A3-5]A cyclic compound, which is PP3234: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-prop-2-ynyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, or a salt thereof or a solvate thereof.

[0141] [A3-6]A cyclic compound, which is PP3236: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, or a salt thereof or a solvate thereof.

[0142] [A3-7]A cyclic compound, which is PP3238: (2S, 8S, 12R, 14S, 20S, 23S, 27S, 30S, 36S, 38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetracosa-38-ene-17,1′-cyclobutane]-23-carboxamide, or a salt thereof or a solvate thereof.

[0143] [A3-8]A cyclic compound, which is PP3240: (2S, 8S, 12R, 14S, 20S, 23S, 27S, 30S, 36S, 38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetracosa-38-ene-17,1′-cyclobutane]-23-carboxamide, or a salt thereof or a solvate thereof.

[0144] [A3-9]A cyclic compound, which is PP3255: (1S, 4S, 10S, 13S, 17S, 20S, 26S, 28R, 32S, 38S, 42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,19,22,25,31,34,37,45-undecaooxo-13-prop-2-ynyl-38-(p-tolylmethyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26，30 pentacosa-42-ene-23,1′-cyclobutane]-17-carboxamide, or a salt thereof or a solvate thereof.

[0145] [A3-10]A cyclic compound, which is PP3290: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-butyl)-6′-cyclopentyl-35′-(3-methoxy-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopteropyrrolo[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1"-cyclopropane]-9′-carboxamide, or a salt thereof or a solvate thereof.

[0146] [A3-11]A cyclic compound, which is PP3299: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-6′,16′-bis((S)-sec-butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopteropyrrolo[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1"-cyclopropane]-9′-carboxamide, or a salt thereof or a solvate thereof.

[0147] [A3-12]A cyclic compound, which is PP3327: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-butyl)-6′-cyclopentyl-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, or a salt thereof or a solvate thereof.

[0148] [A3-13]A cyclic compound, which is PP3328: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-16′-cyclopentyl-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, or a salt thereof or a solvate thereof.

[0149] [A3-14]A cyclic compound, which is PP3356: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-butyl)-6′-cyclopentyl-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopteropyrrolo[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecazacyclotetracontene-39′,1"-cyclopropane]-9′-carboxamide, or a salt thereof or a solvate thereof.

[0150] [A3-15]A cyclic compound, which is PP3406: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-butyl)-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopteropyrrolo[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecazacyclotetracontene-39′,1"-cyclopropane]-9′-carboxamide, or a salt thereof or a solvate thereof.

[0151] [A3-16]A cyclic compound, which is PP3418: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopteropyrrolo[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, or a salt thereof or a solvate thereof.

[0152] [A3-17]A cyclic compound, which is PP3438: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-butyl)-6′-cyclopentyl-35′-(3-methoxy-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopteropyrrolo[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, or a salt thereof or a solvate thereof.

[0153] [A3-18]A cyclic compound, which is PP3440: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 351S, 40a′S, Z)-16′-((S)-sec-butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-6′-cyclopentyl-N,N,5′,8′,12′,18′,21′,31′-octamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopyrrolo[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontacene-39′,1″-cyclopropane]-9′-carboxamide, or a salt thereof or a solvate thereof.

[0154] [A3-19]A cyclic compound, which is PP3456: (2S, 8S, 12R, 14S, 20S, 23S, 27S, 30S, 36S, 38Z)-27-butyl-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3′,3′,4,19,22,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetracos-38-ene-17,1′-cyclobutane]-23-carboxamide, or a salt thereof or a solvate thereof.

[0155] [A3-20]A cyclic compound, which is PP3457: (2S, 8S, 12R, 14S, 20S, 23S, 27S, 30S, 36S, 38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3′,3′,4,19,22,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, or a salt or a solvate thereof.

[0156] [A3-21]A cyclic compound, which is PP3484: (2S, 8S, 12R, 14S, 20S, 23S, 27S, 30S, 36S, 38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-isobutyl-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, or a salt or a solvate thereof.

[0157] [A3-22]A cyclic compound, which is PP3496: (2S, 8S, 12R, 14S, 20S, 23S, 27S, 30S, 36S, 38Z)-2-[[4-(difluoromethyl)phenyl]methyl]-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-20-(1-ethylpropyl)-12-isopropoxy-30-isopropyl-N,N,4,16,19,22,26,35-octamethyl-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-32-prop-2-ynyl-27-(2,2,2-trifluoroethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, or a salt or a solvate thereof.

[0158] [A3-23]A cyclic compound, which is PP3516: (2S, 8S, 12R, 14S, 20S, 23S, 27S, 30S, 36S, 38E)-20-cyclobutyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-38-fluoro-27-isobutyl-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetracosa-38-ene-17,1'-cyclopentane]-23-carboxamide, or a salt or a solvate thereof.

[0159] [A3-24]A cyclic compound, which is PP3517: (2S, 8S, 12R, 14S, 20S, 23S, 27S, 30S, 36S, 38E)-20-cyclobutyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-38-fluoro-27-isobutyl-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetracosa-38-ene-17,1'-cyclopentane]-23-carboxamide, or a salt or a solvate thereof.

[0160] [A3-25]A cyclic compound, which is PP3521: (2S, 8S, 13S, 19S, 22S, 26S, 29S, 35S, 37E)-19-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-37-fluoro-26-isobutyl-N,N,4,18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-3,6,9,14,17,20,24,27,30,33,41-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,15,18,21,25,28,31,34-undecaazatricyclo[33.5.1.010,13]hentetracont-37-ene-16,1'-cyclopentane]-22-carboxamide, or a salt or a solvate thereof.

[0161] [A3-26]A cyclic compound, which is PP3522: (2S, 8S, 13S, 19S, 22S, 26S, 29S, 35S, 37E)-19-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-37-fluoro-26-isobutyl-N,N,4,18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-3,6,9,14,17,20,24,27,30,33,41-undecaooxo-2-(p-tolylmethyl)spiro[1,4,7,10,15,18,21,25,28,31,34-undecaazatricyclo[33.5.1.010,13]hentetracont-37-ene-16,1'-cyclopentane]-22-carboxamide, or a salt thereof or a solvate thereof.

[0162] [A3-27]A cyclic compound, which is PP3523: (2S, 8S, 12R, 14S, 20S, 23S, 27S, 30S, 36S, 38E)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-38-fluoro-27-isobutyl-N,N,4,17,17,19,22,26,32,35-decamenthyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-2-(p-tolylmethyl)-1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetracosa-38-ene-23-carboxamide, or a salt thereof or a solvate thereof.

[0163] [A3-28]A cyclic compound, which is PP3529: (1S, 4S, 9S, 12S, 16S, 19S, 25S, 27R, 31S, 37S, 41E)-19-cyclopentyl-27-ethoxy-42-fluoro-31-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,13,17,20,23,35-octamethyl-9-[(1S)-1-methylpropyl]-3,8,11,14,18,21,24,30,33,36,44-undecaooxo-12-propyl-37-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,7,10,13,17,20,23,29,32,35,38-undecaazatetracyclo[36.5.1.04,7.025,29]tetratetracont-41-ene-22,1'-cyclobutane]-16-carboxamide, or a salt thereof or a solvate thereof.

[0164] [A4] The cyclic compound or a salt thereof according to any one of [A1] to [A3-28].

[0165] [A5] The cyclic compound or a solvate thereof according to any one of [A1] to [A3-28].

[0166] [A6] The cyclic compound according to any one of [A1] to [A3-28], or a solvate of a salt thereof.

[0167] [A7] The cyclic compound according to any one of [A1] to [A3-28].

[0168] [B1] A cyclic compound represented by formula (3), or a salt or a solvate thereof:

[0169] [Formula 4]

[0170]

[0171] wherein

[0172] L1 is a single bond or -CHM1-, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m -, or -(CH2) n S(O)2(CH2) m -, where n and m are each independently 1 or 2,

[0173] R1 is any one of the following (a1) to (a6):

[0174] (a1) R1 is a hydrogen atom, C1-C7 alkyl, C2-C7 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy C1-C6 alkyl, C2-C6 alkenoxy C1-C6 alkyl, C1-C6 alkylthio C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, C3-C8 cycloalkoxy C1-C6 alkyl, C7-C 14 arylalkyl or 5- to 10-membered heteroaryl C1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, C1-C6 alkyl, aminocarbonyl (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino or 4- to 8-membered cyclic amino), and C1-C6 alkylsulfonyl;

[0175] (a2) R1 is linked to P1, the carbon atom to which R1 is attached, and the nitrogen atom to which P1 is attached to form a 4- to 7-membered saturated heterocycle;

[0176] (a3) R1 is linked to Q1 and the carbon atom to which R1 and Q1 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;

[0177] (a4) R1 is linked to M1, the carbon atom to which R1 is attached and the carbon atom to which M1 is attached to form a 3- to 8-membered alicyclic ring;

[0178] (a5) R1 is linked to R5 to form a divalent group selected from the group consisting of C1-C 10 alkylene, C2-C 10 alkenylene, C2-C 10 alkynylene, C3-C8 cycloalkylene, C6-C 10 arylene, -CO-NR A -, -NR A -CO- and combinations of two or more thereof, wherein one or more carbon atoms constituting the divalent group are optionally replaced by one or more heteroatoms independently selected from the group consisting of N, O and S, and the divalent group is optionally substituted by one or more groups independently selected from the group consisting of halogen atoms and C1-C6 alkyl groups, and R A is a hydrogen atom or a C1-C6 alkyl group; and

[0179] (a6) R1 is linked to R9 to form a divalent group selected from the group consisting of C1-C 10 alkylene, C2-C 10 alkenylene, C2-C 10 alkynylene, C3-C8 cycloalkylene, C6-C 10 arylene, -CO-NR B -, -NR B -CO- and combinations of two or more thereof, wherein one or more carbon atoms constituting the divalent group are optionally replaced by one or more heteroatoms independently selected from the group consisting of N, O and S, and the divalent group is optionally substituted by one or more groups independently selected from the group consisting of halogen atoms and C1-C6 alkyl groups, and R B is a hydrogen atom or a C1-C6 alkyl group;

[0180] P1 is a hydrogen atom or a C1-C6 alkyl group, except when R1 and P1 form a 4- to 7-membered saturated heterocyclic ring, wherein the C1-C6 alkyl group is optionally substituted by one or more groups independently selected from the group consisting of halogen atoms, hydroxy groups, C1-C6 alkoxy groups and aminocarbonyl groups (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino or 4- to 8-membered cyclic amino);

[0181] Q1 is a hydrogen atom or a C1-C6 alkyl group, except when R1 and Q1 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, and

[0182] M1 is a hydrogen atom or a C1-C6 alkyl group, except when R1 and M1 form a 3- to 8-membered alicyclic ring,

[0183] R2 is any one of the following (b1) to (b4):

[0184] (b1) R2 is a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl C1-C6 alkyl group, a C3-C8 cycloalkoxy C1-C6 alkyl group or a 4- to 7-membered heterocyclic group, each of which is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group and a C1-C6 alkylsulfonyl group;

[0185] (b2) R2, P2, the carbon atom to which R2 is attached and the nitrogen atom to which P2 is attached are linked together to form a 4- to 7-membered saturated heterocyclic ring;

[0186] (b3) R2, Q2 and the carbon atoms to which R2 and Q2 are attached are linked together to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; and

[0187] (b4) R2 and R 11 are linked together to form a divalent group selected from the group consisting of a C1-C 10 alkylene group, a C2-C 10 alkenylene group, a C2-C 10 alkynylene group, a C3-C8 cycloalkylene group, a C6-C 10 arylene group, -CO-NR C -, -NR C -CO-, -C3-C8 alkylene-NR C -, -C3-C8 alkenylene-NR C - and combinations of two or more thereof, wherein one or more carbon atoms constituting the divalent group are optionally replaced by one or more heteroatoms independently selected from the group consisting of N, O and S, and the divalent group is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom and a C1-C6 alkyl group, and R C is a hydrogen atom or a C1-C6 alkyl group;

[0188] P2 is a hydrogen atom or a C1-C6 alkyl group, except when R2 and P2 form a 4- to 7-membered saturated heterocycle, wherein the C1-C6 alkyl group is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group, and an aminocarbonyl group (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or a 4- to 8-membered cyclic amino group),

[0189] Q2 is a hydrogen atom or a C1-C6 alkyl group, except when R2 and Q2 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle,

[0190] R3 is any one of the following (c1) to (c3):

[0191] (c1) R3 is a hydrogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl C1-C6 alkyl group, a C3-C8 cycloalkoxy C1-C6 alkyl group, or a C7-C 14 arylalkyl group, wherein each of them is optionally substituted by one or more groups independently selected from the group consisting of a hydroxyl group and an aminocarbonyl group (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or a 4- to 8-membered cyclic amino group);

[0192] (c2) R3 is linked to P3, the carbon atom to which R3 is attached, and the nitrogen atom to which P3 is attached to form a 4- to 7-membered saturated heterocycle, wherein the 4- to 7-membered saturated heterocycle is optionally substituted by one or more groups selected from the group consisting of a C1-C6 alkyl group and a C1-C6 alkoxy group; and

[0193] (c3) R3 is linked to Q3 and the carbon atoms to which R3 and Q3 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle;

[0194] P3 is a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy C1-C6 alkyl group, or a C3-C8 cycloalkyl group, except when R3 and P3 form a 4- to 7-membered saturated heterocycle, wherein each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, a C1-C6 alkoxy group, and a C1-C6 aminoalkyl group (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or a 4- to 8-membered cyclic amino group, wherein the 4- to 8-membered cyclic amino group is optionally substituted by one or more halogen atoms),

[0195] Q3 is a hydrogen atom or a C1-C6 alkyl group, except when R3 and Q3 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle,

[0196] R4 is any one of the following (d1) to (d4):

[0197] (d1) R4 is a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C2-C6 alkenoxy C1-C6 alkyl group or a C1-C6 carboxyalkyl group, where each of them is optionally substituted with one or more hydroxy groups;

[0198] (d2) R4 is linked to P4, the carbon atom to which R4 is attached and the nitrogen atom to which P4 is attached to form a 4- to 7-membered saturated heterocycle, where the 4- to 7-membered saturated heterocycle is optionally substituted with one or more C1-C6 alkyl groups;

[0199] (d3) R4 is linked to Q4 and the carbon atoms to which R4 and Q4 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle; and

[0200] (d4) R4 is linked to P5 to form a divalent group selected from the group consisting of C1-C 10 alkylene, C2-C 10 alkenylene, C2-C 10 alkynylene, C3-C8 cycloalkylene, 3- to 7-membered heteroarylene, C6-C 10 arylene, -CO-NR D -, -NR D -CO- and combinations of two or more of them, where one or more carbon atoms constituting the divalent group are optionally replaced with one or more heteroatoms independently selected from the group consisting of N, O and S, the divalent group is optionally substituted with one or more groups independently selected from the group consisting of halogen atoms and C1-C6 alkyl groups, and R D is a hydrogen atom or a C1-C6 alkyl group;

[0201] P4 is any one of the following (e1) to (e2), except in the case where R4 and P4 form a 4- to 7-membered saturated heterocycle:

[0202] (e1) P4 is a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group or a C1-C6 alkoxy C1-C6 alkyl group, where each of them is optionally substituted with one or more groups independently selected from the group consisting of halogen atoms, hydroxy, C1-C6 alkoxy and aminocarbonyl (the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino or 4- to 8-membered cyclic amino); and

[0203] (e2) P4 is linked to P5 to form a group selected from the group consisting of C1-C 10 alkylene, C2-C10 Vinylene, C2-C 10 Ethynylene, C3-C8 cycloalkylene, C6-C 10 Arylene, -CO-NR E -, -NR E -, -CO- and combinations of two or more of them, wherein one or more carbon atoms constituting the divalent group are optionally replaced by one or more heteroatoms selected from the group consisting of N, O and S, the divalent group is optionally substituted by one or more groups independently selected from the group consisting of halogen atoms and C1-C6 alkyl groups, and R E is a hydrogen atom or a C1-C6 alkyl group;

[0204] Q4 is a hydrogen atom or a C1-C6 alkyl group, except when R4 and Q4 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring,

[0205] R5 is any one of the following (n) to (f4), except when R1 and R5 form a divalent group:

[0206] (f1) R5 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkenyloxycarbonyl C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxy C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, C3-C8 cycloalkoxy C1-C6 alkyl, C7-C 14 Aralkyl, C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 Aralkyloxy C1-C6 alkyl or 5- to 10-membered heteroaryl C1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen atoms, hydroxyl groups, C1-C6 alkyl groups, C1-C6 haloalkyl groups, C1-C6 alkoxy groups, C2-C6 alkenyloxy groups, C1-C6 haloalkoxy groups, cyano groups, C1-C6 alkylsulfonyl groups, C2-C6 alkenyl groups, C3-C8 cycloalkyl groups and C1-C6 alkylcarbonyl groups;

[0207] (f2) R5 is linked to R8 to form a C4-C8 alkylene group;

[0208] (f3) R5 is linked to P5, the carbon atom to which R5 is attached and the nitrogen atom to which P5 is attached to form a 4- to 7-membered saturated heterocyclic ring; and

[0209] (f4) R5 is linked to Q5 and the carbon atoms to which R5 and Q5 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;

[0210] P5 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy C1-C6 alkyl or C3-C8 cycloalkyl C1-C6 alkyl, except for the cases where R5 and P5 form a 4- to 7-membered saturated heterocycle, where R4 and P5 form a divalent group, and where P4 and P5 form a divalent group, and where the C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group, an aminocarbonyl group (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino or a 4- to 8-membered cyclic amino group) and an amino group,

[0211] Q5 is a hydrogen atom or C1-C6 alkyl, except for the cases where R5 and Q5 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle,

[0212] R6 is any one of the following (g1) to (g3):

[0213] (g1) R6 is a hydrogen atom or C1-C6 alkyl;

[0214] (g2) R6 is linked to P6, the carbon atom to which R6 is attached and the nitrogen atom to which P6 is attached to form a 4- to 7-membered saturated heterocycle; and

[0215] (g3) R6 is linked to Q6 and the carbon atom to which R6 and Q6 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle;

[0216] P6 is C1-C6 alkyl or C3-C8 cycloalkyl, except for the case where R6 and P6 form a 4- to 7-membered saturated heterocycle, and each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group and an aminocarbonyl group (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino or a 4- to 8-membered cyclic amino group),

[0217] Q6 is a hydrogen atom or C1-C6 alkyl, except for the cases where R6 and Q6 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle,

[0218] R7 is any one of the following (h1) to (h6):

[0219] (h1) R7 is C6-C 10 aryloxy C1-C6 alkyl, C7-C 14 arylalkyl, C7-C 14an aralkyloxy C1-C6 alkyl or a 5- to 10-membered heteroaryl C1-C6 alkyl, wherein each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a C1-C6 alkyl, a C1-C6 haloalkyl, a C2-C6 alkynyl, a C1-C6 alkoxy, a C1-C6 haloalkoxy, a cyano, a C1-C6 alkylsulfonyl, SF5, and a C3-C8 cycloalkyl;

[0220] (h2) R7 is linked to P7, the carbon atom to which R7 is attached, and the nitrogen atom to which P7 is attached to form a 4- to 7-membered saturated heterocycle; and

[0221] (h3) R7 is linked to Q7 and the carbon atoms to which R7 and Q7 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle;

[0222] P7 is a hydrogen atom or a C1-C6 alkyl, except when R7 and P7 form a 4- to 7-membered saturated heterocycle, wherein the C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy, and an aminocarbonyl (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or a 4- to 8-membered cyclic amino);

[0223] Q7 is a hydrogen atom or a C1-C6 alkyl, except when R7 and Q7 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle;

[0224] R8 is any one of the following (i1) to (i3), except when R5 and R8 form a C4-C8 alkylene:

[0225] (i1) R8 is a hydrogen atom, a C1-C6 alkyl, a C2-C6 alkenyl, a C2-C6 alkynyl, a C1-C6 alkoxy C1-C6 alkyl, a C2-C6 alkenyloxycarbonyl C1-C6 alkyl, a C3-C8 cycloalkyl, a C3-C8 cycloalkyl C1-C6 alkyl, a C6-C 10 an aryloxy C1-C6 alkyl, a C7-C 14 an aralkyl, a C7-C 14An aralkyloxy C1-C6 alkyl, a 5- to 10-membered heteroaryl C1-C6 alkyl or a 5- to 10-membered heteroaryloxy C1-C6 alkyl, wherein each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a carboxyl group, a C1-C6 alkyl, a C1-C6 haloalkyl, a C2-C6 alkynyl, a C1-C6 alkoxy, a C1-C6 haloalkoxy, a cyano group, an aminocarbonyl group (the amino group being -NH2, a mono-C1-C6 alkylamino, a di-C1-C6 alkylamino or a 4- to 8-membered cyclic amino, wherein each of them is optionally substituted by a halogen atom), a 4- to 7-membered heteroalkylidene group, a protected 4- to 7-membered heteroalkylidene group, a 4- to 7-membered heterocyclic group and a protected 4- to 7-membered heterocyclic group;

[0226] (i2) R8 is linked to P8, the carbon atom to which R8 is attached and the nitrogen atom to which P8 is attached to form a 4- to 7-membered saturated heterocycle, wherein the 4- to 7-membered saturated heterocycle is optionally fused to a saturated carbocyclic ring or an aromatic ring, and the 4- to 7-membered saturated heterocycle is optionally substituted by one or more halogen atoms, oxo, one or more C1-C6 alkyl groups, C1-C6 haloalkyl, C3-C8 spiroalkyl, C6-C 10 An aryl, a 5- to 10-membered heteroaryl, a 4- to 8-membered cyclic amino (the cyclic amino is optionally substituted by one or more halogen atoms) or OS8, and S8 is a hydrogen atom, a C1-C6 alkyl, a C1-C6 haloalkyl, a C1-C6 hydroxyalkyl, a C3-C8 cycloalkyl C1-C6 alkyl, a 4- to 7-membered heterocyclic group, C7-C 14 An aralkyl (the aralkyl is optionally substituted by one or more halogen atoms, C1-C6 alkyl, C1-C6 alkoxy or C1-C6 haloalkoxy), a 5- to 10-membered heteroaryl C1-C6 alkyl or a C3-C8 cycloalkyl; and

[0227] (i3) R8 is linked to Q8 and the carbon atoms to which R8 and Q8 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle;

[0228] P8 is a hydrogen atom, a C1-C6 alkyl, a C1-C6 alkoxy C1-C6 alkyl, a C2-C6 alkenyl, a C1-C6 alkoxy C2-C6 alkenyl, a C3-C8 cycloalkyl, a 4- to 7-membered heterocyclic group, a 4- to 7-membered heterocyclic group C1-C6 alkyl, C6-C 10 An aryl, C7-C 14An aralkyl group, a 5- to 10-membered heteroaryl group, or a 5- to 10-membered heteroaryl C1-C6 alkyl group, except when R8 and P8 form a 4- to 7-membered saturated heterocyclic ring, wherein each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group, and an aminocarbonyl group (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or a 4- to 8-membered cyclic amino group).

[0229] Q8 is a hydrogen atom or a C1-C6 alkyl group, except when R8 and Q8 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring.

[0230] R9 is any one of the following (j1) to (j2), except when R1 and R9 form a divalent group:

[0231] (j1) R9 is a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C2-C6 alkenoxy C1-C6 alkyl group, a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl C1-C6 alkyl group, a C7-C 14 An aralkyl group or a 5- to 10-membered heteroaryl C1-C6 alkoxy C1-C6 alkyl group, wherein each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 alkoxy group, a C1-C6 haloalkoxy group, an aminocarbonyl group (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or a 4- to 8-membered cyclic amino group), and a C1-C6 alkylsulfonyl group; and

[0232] (j2) R9 is connected to Q9 and the carbon atom to which R9 and Q9 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, wherein each of them is optionally substituted by one or more halogen atoms or one or more C1-C6 alkyl groups.

[0233] Q9 is a hydrogen atom or a C1-C6 alkyl group, except when R9 and Q9 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring.

[0234] R 10 is any one of the following (k1) to (k3):

[0235] (k1) R 10 is a C1-C6 alkyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl C1-C6 alkyl group, a C3-C8 cycloalkoxy C1-C6 alkyl group, or a C7-C 14An aralkyl group, wherein each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, and a C1-C6 alkylsulfonyl group;

[0236] (k2)R 10 Connected to P 10 、R 10 The carbon atom connected to and the nitrogen atom connected to P 10 Are connected together to form a 4- to 7-membered saturated heterocycle; and

[0237] (k3)R 10 Connected to Q 10 And R 10 And Q 10 The carbon atoms connected to are connected together to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle;

[0238] P 10 Is a hydrogen atom or a C1-C6 alkyl group, provided that when R 10 And P 10 Form a 4- to 7-membered saturated heterocycle, wherein the C1-C6 alkyl group is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group, and an aminocarbonyl group (the amino group is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or a 4- to 8-membered cyclic amino group);

[0239] Q 10 Is a hydrogen atom or a C1-C6 alkyl group, provided that when R 10 And Q 10 Form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle, and

[0240] L 11 Is a single bond or -CHM 11 -, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m -, or -(CH2) n S(O)2(CH2) m -, where n and m are each independently 1 or 2;

[0241] R 11 Is any one of the following (l1) to (l5), provided that when R2 and R 11 Form a divalent group;

[0242] (l1)R 11is a hydrogen atom, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy C1-C6 alkyl, C7-C 14 aralkyl, aminocarbonyl (the amino group is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, N-C1-C6 alkyl-N-C2-C6 alkenylamino or 4- to 8-membered cyclic amino) or C3-C8 cycloalkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, oxo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, 4- to 7-membered heterocyclic group, aminocarbonyl (the amino group is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino or 4- to 8-membered cyclic amino) and C1-C6 alkylsulfonyl;

[0243] (l2)R 11 is a peptide chain containing 1 to 4 amino acid residues;

[0244] (l3)R 11 is connected to P 11 and the carbon atom to which R 11 is attached and the nitrogen atom to which P 11 is attached are joined together to form a 4- to 7-membered saturated heterocycle;

[0245] (l4)R 11 is connected to Q 11 and the carbon atom to which R 11 is attached and the carbon atom to which Q 11 is attached are joined together to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle; and

[0246] (l5)R 11 is connected to M 11 and the carbon atom to which R 11 is attached and the carbon atom to which M 11 is attached are joined together to form a 3- to 8-membered alicyclic ring;

[0247] P 11 is a hydrogen atom, C1-C6 alkyl, C3-C8 cycloalkyl C1-C6 alkyl or C7-C 14 aralkyl, provided that the case where R 11 and P 11 form a 4- to 7-membered saturated heterocycle is excluded, wherein the C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, hydroxy, C1-C6 alkoxy and aminocarbonyl (the amino group is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino or 4- to 8-membered cyclic amino),

[0248] Q 11is a hydrogen atom or a C1-C6 alkyl group, provided that R 11 and Q 11 except when they form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring,

[0249] M 11 is a hydrogen atom, provided that R 11 and M 11 except when they form a 3- to 8-membered alicyclic ring, and

[0250] at least three of P1 to P 11 are not hydrogen atoms.

[0251] [B2A] The cyclic compound or a salt thereof or a solvate thereof according to [B1], wherein

[0252] (a) R4 and P5 are linked together to form a divalent group which is *-C3-C8 alkylene-#, *-C3-C8 alkenylene-#, *-C1-C3 alkylene-C3-C8 cycloalkylene-C1-C3 alkylene-#, *-C1-C3 alkylene-O-C3-C6 alkenylene-#, *-C1-C3 alkylene-CO-NR D -C1-C3 alkylene-#, *-C1-C3 alkylene-NR D -CO-C1-C3 alkylene-# or *-C1-C3 alkylene-3- to 7-membered heteroalkylene-C1-C3 alkylene-#, each of which is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom and a C1-C6 alkyl group, R D is a hydrogen atom or a methyl group,

[0253] * represents the point of attachment of the carbon atom to which R4 is attached, and

[0254] # represents the point of attachment of the nitrogen atom to which P5 is attached, or

[0255] (b) P4 and P5 are linked together to form a divalent group which is C3-C8 alkylene or C3-C8 alkenylene, wherein each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom and a C1-C6 alkyl group, or

[0256] (c) P5 is a C3-C6 alkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C3-C8 cycloalkyl C1-C6 alkyl group or a C1-C6 aminoalkyl group.

[0257] [B2B]The cyclic compound or a salt thereof or a solvate thereof according to [B1], wherein R4 and P5 are linked together to form a divalent group, and the divalent group is *-C4 to C5 alkylene-# or *-C4 to C5 alkenylene-#.

[0258] [B2C]The cyclic compound or a salt thereof or a solvate thereof according to [B1], wherein R4 and P5 are linked together to form a divalent group, and the divalent group is *-C4 to C5 alkenylene-#.

[0259] [B3]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B2C], wherein R4 and P5 are linked together to form a divalent group, and the partial structure *-CR4Q4-CO-NP5-* in the cyclic compound represented by the formula (3) is represented by the following formula:

[0260] [Formula 5]

[0261]

[0262]

[0263] wherein

[0264] Y 11 is a hydrogen atom, a C1 to C6 alkyl group or a halogen atom,

[0265] Y 12 is a hydrogen atom, a C1 to C6 alkyl group or a halogen atom,

[0266] Y 13 is a hydrogen atom, a C1 to C6 alkyl group or a halogen atom, or

[0267] Y 13 is linked to Y 15 to form a C3 to C8 alkylene group or -O-,

[0268] Y 14 is a hydrogen atom or a C1 to C6 alkyl group,

[0269] Y 15 is a hydrogen atom, a C1 to C6 alkyl group or a halogen atom, provided that Y 13 and Y 15 forming a C3 to C8 alkylene group or -O- is excluded,

[0270] Y 16 is a hydrogen atom or a C1 to C6 alkyl group,

[0271] Y 17 is a hydrogen atom or a C1 to C6 alkyl group,

[0272] Y18 is a hydrogen atom or a C1-C6 alkyl group,

[0273] R D is a hydrogen atom or a C1-C6 alkyl group,

[0274] n is 0, 1 or 2,

[0275] m is 0, 1 or 2; and

[0276] * represents a connection point to an adjacent atom.

[0277] [B4A] The cyclic compound or a salt thereof or a solvate thereof according to [B3], wherein the partial structure: *-CR4Q4-CO-NP5-* is:

[0278] [Formula 6]

[0279]

[0280] [B4B] The cyclic compound or a salt thereof or a solvate thereof according to [B3], wherein the partial structure: *-CR4Q4-CO-NP5-* is the following formula:

[0281] [Formula 7]

[0282]

[0283] [B5] The cyclic compound or a salt thereof or a solvate thereof according to any one of [B2A] to [B2C], wherein P4 and P5 are connected together to form a divalent group, and the partial structure in the cyclic compound represented by formula (3):

[0284] *-NP4-CR4Q4-CO-NP5-*

[0285] is represented by the following formula:

[0286] [Formula 8]

[0287]

[0288] wherein

[0289] X1 is -CR4Q4-CO-,

[0290] Y 21 、Y 22 、Y 23 、Y 24 、Y 25 and Y 26 are each independently a hydrogen atom or a C1-C6 alkyl group,

[0291] n is 0, 1 or 2,

[0292] m is 0, 1 or 2; and

[0293] * represents a connection point to an adjacent atom.

[0294] [B6] The cyclic compound or a salt thereof or a solvate thereof according to [B5], wherein the partial structure: *-NP4-CR4Q4-CO-NP5-* is:

[0295] [Formula 9]

[0296]

[0297] [B7] The cyclic compound or a salt thereof or a solvate thereof according to [B2A], wherein P5 is n-propyl, isopropyl, n-butyl, isobutyl, isopentyl, neohexyl, 3-fluoropropyl, 3,3,3-trifluoropropyl, allyl, 2-methylallyl, propargyl, 3-butenyl, 2-methoxyethyl, 3-methoxypropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl or cyclohexylmethyl.

[0298] [B8] The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B7], wherein R1 and R5 are connected together to form a divalent group, and the divalent group is *-C1 to C8 alkylene-C6 to C 10 arylene-C1 to C3 alkylene-#, *-C1 to C8 alkylene-O-C6 to C 10 arylene-C1 to C3 alkylene-#, *-C2 to C8 alkenylene-O-C6 to C 10 arylene-C1 to C3 alkylene-# or *-C2 to C8 alkenylene-C6 to C 10 arylene-C1 to C3 alkylene-#, wherein each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom and a C1 to C6 alkyl group,

[0299] * represents a connection point of the carbon atom to which R1 is attached, and

[0300] # represents a connection point of the carbon atom to which R5 is attached.

[0301] [B9A] The cyclic compound or a salt thereof or a solvate thereof according to [B8], wherein R1 and R5 are connected together to form a divalent group, and the partial structure in the cyclic compound represented by the formula (3):

[0302] *-CR1Q1-L1-CO-NP2-CR2Q2-CO-NP3-CR3Q3-CO-NP4-CR4Q4-CO-NP5-CR5Q5-*

[0303] is represented by the following formula:

[0304] [Formula 10]

[0305]

[0306] wherein

[0307] X2 is -L1-CO-NP2-CR2Q2-CO-NP3-CR3Q3-CO-NP4-CR4Q4-CO-NP5-,

[0308] Y 31 、Y 32 、Y 33 、Y 34 、Y 35 、Y 36 、Y 37 and Y 38 are each independently a hydrogen atom or a C1-C6 alkyl group,

[0309] n is 0, 1 or 2,

[0310] m is 0, 1, 2, 3 or 4; and

[0311] * represents a connection point to an adjacent atom.

[0312] [B9B] The cyclic compound or a salt thereof or a solvate thereof according to [B8], wherein R1 and R5 are connected together to form a divalent group, and a partial structure in the cyclic compound represented by formula (3):

[0313] *-CR1Q1-L1-CO-NP2-CR2Q2-CO-NP3-CR3Q3-CO-NP4-CR4Q4-CO-NP5-CR5Q5-*

[0314] is represented by the following formula:

[0315] [Formula 11]

[0316]

[0317] wherein

[0318] X2 is -L1-CO-NP2-CR2Q2-CO-NP3-CR3Q3-CO-NP4-CR4Q4-CO-NP5-,

[0319] n is 1, 2, 3 or 4; and

[0320] * represents a connection point to an adjacent atom.

[0321] [B9C]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B8], wherein R4 and P5 are connected together to form a divalent group, and the partial structure *-CR4Q4-CO-NP5-* in the cyclic compound represented by the formula (3) is the following formula:

[0322] [Formula 12]

[0323]

[0324] R1 and R5 are connected together to form a divalent group, and the partial structure in the cyclic compound represented by the formula (3):

[0325] *-CR1Q1-L1-CO-NP2-CR2Q2-CO-NP3-CR3Q3-CO-NP4-CR4Q4-CO-NP5-CR5Q5-*

[0326] is represented by the following formula:

[0327] [Formula 13]

[0328]

[0329] wherein

[0330] X2 is -L1-CO-NP2-CR2Q2-CO-NP3-CR3Q3-CO-NP4-CR4Q4-CO-NP5-,

[0331] n is 1, 2, 3 or 4; and

[0332] * represents a connection point to an adjacent atom.

[0333] [B10]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B9A] to [B9C], wherein the partial structure: *-CR1Q1-L1-CO-NP2-CR2Q2-CO-NP3-CR3Q3-CO-NP4-CR4Q4-CO-NP5-CR5Q5-* is:

[0334] [Formula 14]

[0335]

[0336] [B11]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B7], wherein R1 and R9 are linked together to form a divalent group which is *-C3 to C8 alkylene-#, *-C3 to C8 alkenylene-# or *-C1 to C3 alkylene-O-C1 to C8 alkylene-#, each of which is optionally substituted with one or more groups independently selected from the group consisting of a halogen atom and a C1 to C6 alkyl group,

[0337] * represents the point of attachment of the carbon atom to which R1 is attached, and

[0338] # represents the point of attachment of the carbon atom to which R9 is attached.

[0339] [B12]The cyclic compound or a salt thereof or a solvate thereof according to [B11], wherein R1 and R9 are linked together to form a divalent group, and the partial structure in the cyclic compound represented by formula (3):

[0340] *-CR1Q1-NP1-CO-L 11 -CR 11 Q 11 -NP 11 -CO-CR 10 Q 10 -NP 10 -CO-CR9Q9-*

[0341] is represented by:

[0342] [Formula 15]

[0343]

[0344] wherein

[0345] X3 is -NP1-CO-L 11 -CR 11 Q 11 -NP 11 -CO-CR 10 Q 10 -NP 10 -CO-,

[0346] Y 41 、Y 42 、Y 43 、Y 44 、Y 45 and Y 46 are each independently a hydrogen atom or a C1 to C6 alkyl group,

[0347] n is an integer from 0 to 3,

[0348] m is an integer from 0 to 5, and

[0349] * represents the connection point with an adjacent atom.

[0350] [B13] The cyclic compound or a salt thereof or a solvate thereof according to [B12], wherein the partial structure: *-CR1Q1-NP1-CO-L 11 -CR 11 Q 11 -NP 11 -CO-CR 10 Q 10 -NP 10 -CO-CR9Q9-* is:

[0351] [Formula 16]

[0352]

[0353] [B14] The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B13], wherein R2 and R 11 are connected together to form a divalent group, and the divalent group is *-C3 to C8 alkylene-NR C -# or *-C3 to C8 alkenylene-NR C -#, each of which is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom and a C1 to C6 alkyl group, R C is a hydrogen atom or a methyl group,

[0354] * represents the connection point of the carbon atom connected to R2, and

[0355] # represents the connection point of the carbon atom connected to R 11 connected.

[0356] [B15] The cyclic compound or a salt thereof or a solvate thereof according to [B14], wherein R2 and R 11 are connected together to form a divalent group, and the partial structure in the cyclic compound represented by the formula (3):

[0357] *-CR2Q2-NP2-CO-L1-CR1Q1-NP1-CO-L 11 -CR 11 Q 11 -*

[0358] is represented by:

[0359] [Formula 17]

[0360]

[0361] wherein

[0362] X4 is -NP2-CO-L1-CR1Q1-NP1-CO-L 11 -,

[0363] Y 51 , Y 52 , Y 53 , Y 54 , Y 55 and Y 56 each independently represents a hydrogen atom or a C1-C6 alkyl group,

[0364] R C is a hydrogen atom or a C1-C6 alkyl group,

[0365] n is an integer from 1 to 6, and

[0366] * represents a connection point to an adjacent atom.

[0367] [B16] The cyclic compound or its salt or their solvate according to [B15], wherein the partial structure: *-CR2Q2-NP2-CO-L1-CR1Q1-NP1-CO-L 11 -CR 11 Q 11 -* is:

[0368] [Formula 18]

[0369]

[0370] [B17] The cyclic compound or its salt or their solvate according to any one of [B1] to [B16], wherein L1 is a single bond, -CH2- or -CH2-S-CH2-.

[0371] [B18] The cyclic compound or its salt or their solvate according to any one of [B1] to [B17], wherein R1 is a C1-C7 alkyl group optionally substituted with di-C1-C6 alkylaminocarbonyl; a C1-C6 haloalkyl group; a C1-C6 hydroxyalkyl group; a C2-C7 alkenyl group; a C2-C6 alkynyl group; a C1-C6 alkoxy-C1-C6 alkyl group optionally substituted with one or more halogen atoms; a C2-C6 alkenyloxy-C1-C6 alkyl group; a C1-C6 alkylthio-C1-C6 alkyl group; a C7-C 14 arylalkyl group; a 5- to 10-membered heteroaryl-C1-C6 alkyl group; a C3-C8 cycloalkyl group; a C3-C8 cycloalkyl-C1-C6 alkyl group; or a C3-C8 cycloalkoxy-C1-C6 alkyl group.

[0372] [B19]The cyclic compound or a salt thereof or a solvate thereof according to [B18], wherein R1 is methyl, 2-methylpropyl, isopropyl, ethyl, n-propyl, n-butyl, n-hexyl, n-pentyl, n-heptyl, neopentyl, 3-(dimethylamino)-3-oxopropyl, cyclohexylmethyl, cyclopentylmethyl, cyclobutylmethyl, cyclopropylmethyl, 3,3-difluoropropyl, 2,2,2-trifluoroethyl, 2,2-difluoroethyl, 3,3-dichloropropyl, cyclopropoxymethyl, hydroxymethyl, n-propoxymethyl, methoxymethyl, 1-methoxyethyl, 2-methoxyethyl, ethoxymethyl, (2,2,2-trifluoroethoxy)methyl, allyloxymethyl, methylthiomethyl, allyl, hex-5-en-1-yl, pent-4-en-1-yl, but-3-en-1-yl, propargyl, cyclobutyl, benzyl, phenethyl, 2-cyanobenzyl, 3-cyanobenzyl, 4-cyanobenzyl, 4-chlorobenzyl, 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 2-chlorobenzyl, 3-chlorobenzyl, 3,4-difluorobenzyl, 3,4-dichlorobenzyl, 2-methylbenzyl, 3-methylbenzyl, 4-methylbenzyl, pyridin-3-ylmethyl, thiazol-4-ylmethyl, (thiophen-3-yl)methyl, (thiophen-2-yl)methyl, cyclopropyl, bicyclo[1.1.1]pentyl or hept-6-en-1-yl.

[0373] [B20]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B17], wherein R1 and P1 are connected to the nitrogen atom to which P1 is attached and the carbon atom to which R1 is attached together to form a 4- to 7-membered saturated heterocycle.

[0374] [B21]The cyclic compound or a salt thereof or a solvate thereof according to [B20], wherein the 4- to 7-membered saturated heterocycle is an azepane ring.

[0375] [B22]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B19], wherein P1 is a hydrogen atom or a C1-C6 alkyl group.

[0376] [B23]The cyclic compound or a salt thereof or a solvate thereof according to [B22], wherein P1 is a hydrogen atom, methyl or n-propyl.

[0377] [B24]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B23], wherein Q1 is a hydrogen atom or methyl.

[0378] [B25]The cyclic compound, its salt, or their solvate according to any one of [B1] to [B24], wherein R2 is C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C8 cycloalkyl optionally substituted with one or more halogen atoms, C1-C6 alkoxy C1-C6 alkyl, or a 4- to 7-membered heterocyclic group.

[0379] [B26]The cyclic compound, its salt, or their solvate according to [B25], wherein R2 is ethyl, isopropyl, 1-methylpropyl, pent-3-yl, 2,2,2-trifluoroethyl, hydroxymethyl, allyl, cyclopentyl, cyclobutyl, 3,3-difluorocyclobutyl, 1-methoxyethyl, 1-ethoxyethyl, 1-n-propoxyethyl, tetrahydropyran-4-yl, cyclopropyl, 2-methylpropyl, or cyclohexyl.

[0380] [B27]The cyclic compound, its salt, or their solvate according to any one of [B1] to [B26], wherein P2 is a hydrogen atom.

[0381] [B28]The cyclic compound, its salt, or their solvate according to any one of [B1] to [B27], wherein Q2 is a hydrogen atom.

[0382] [B29]The cyclic compound, its salt, or their solvate according to any one of [B1] to [B28], wherein R3 is a hydrogen atom, C1-C6 alkyl, or C7-C 14 aralkyl.

[0383] [B30]The cyclic compound, its salt, or their solvate according to [B29], wherein R3 is a hydrogen atom, methyl, ethyl, or benzyl.

[0384] [B31]The cyclic compound, its salt, or their solvate according to any one of [B1] to [B28], wherein R3 and P3 are connected to the nitrogen atom to which P3 is attached and the carbon atom to which R3 is attached to form a 4- to 7-membered saturated heterocycle, and the 4- to 7-membered saturated heterocycle is optionally substituted with one or more C1-C6 alkyl or C1-C6 alkoxy groups.

[0385] [B32]The cyclic compound, its salt, or their solvate according to [B31], wherein the 4- to 7-membered saturated heterocycle is a piperidine ring, pyrrolidine ring, azetidine ring, morpholine ring, or thiomorpholine ring.

[0386] [B33]The cyclic compound, its salt, or their solvate according to any one of [B1] to [B28], wherein R3 and Q3 are connected to the carbon atoms to which they are attached to form a 3- to 8-membered alicyclic ring.

[0387] [B34]The cyclic compound or its salt or their solvate according to [B33], wherein the 3- to 8-membered alicyclic ring is a cyclopropane ring.

[0388] [B35]The cyclic compound or its salt or their solvate according to any one of [B1] to [B30] and [B33] to [B34], wherein P3 is a hydrogen atom, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 cyanoalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C3-C8 cycloalkyl group or a C1-C6 alkoxy C1-C6 alkyl group.

[0389] [B36]The cyclic compound or its salt or their solvate according to [B35], wherein P3 is a hydrogen atom, a methyl group, an ethyl group, a n-propyl group, a cyanomethyl group, a 2-fluoroethyl group, a 2,2-difluoroethyl group, an allyl group, a propargyl group, a cyclopropyl group or a 2-methoxyethyl group.

[0390] [B37]The cyclic compound or its salt or their solvate according to any one of [B1] to [B32] and [B35] to [B36], wherein Q3 is a hydrogen atom or a methyl group.

[0391] [B38]The cyclic compound or its salt or their solvate according to any one of [B1] to [B37], wherein R4 is a hydrogen atom, a C1-C6 alkyl group, a C1-C6 hydroxyalkyl group, a C2-C6 alkenyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C2-C6 alkenoxy C1-C6 alkyl group or a C1-C6 carboxyalkyl group.

[0392] [B39]The cyclic compound or its salt or their solvate according to [B38], wherein R4 is a hydrogen atom, a methyl group, an ethyl group, an allyl group, a 2-methylallyl group, a but-3-en-1-yl group, a hydroxymethyl group, a n-propoxymethyl group, an allyloxymethyl group or a carboxymethyl group.

[0393] [B40]The cyclic compound or its salt or their solvate according to any one of [B1] to [B37], wherein R4 and P4 are linked together with the nitrogen atom to which P4 is attached and the carbon atom to which R4 is attached to form a 4- to 7-membered saturated heterocyclic ring, and the 4- to 7-membered saturated heterocyclic ring is optionally substituted with a C1-C6 alkyl group.

[0394] [B41]The cyclic compound or its salt or their solvate according to [B40], wherein the 4- to 7-membered saturated heterocyclic ring is a piperidine ring, a pyrrolidine ring or an azetidine ring, and the 4- to 7-membered saturated heterocyclic ring is optionally substituted with a methyl group.

[0395] [B42]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B39], wherein P4 is a C1-C6 alkyl group or a C2-C6 alkenyl group.

[0396] [B43]The cyclic compound or a salt thereof or a solvate thereof according to [B42], wherein P4 is a methyl group, an ethyl group, a n-propyl group, a n-butyl group or a 3-butenyl group.

[0397] [B44]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B43], wherein Q4 is a hydrogen atom.

[0398] [B45]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B44], wherein R5 is a C2-C6 alkynyl group; a C2-C6 alkenyloxycarbonyl C1-C6 alkyl group; a C3-C8 cycloalkyl group; a C3-C8 cycloalkyl C1-C6 alkyl group optionally substituted with one or more halogen atoms; a C7-C 14 arylalkyl group; a 5- to 10-membered heteroaryl C1-C6 alkyl group; a C3-C8 cycloalkyloxy C1-C6 alkyl group; or a C1-C6 alkoxy C1-C6 alkyl group.

[0399] [B46]The cyclic compound or a salt thereof or a solvate thereof according to [B45], wherein R5 is a benzyl group, a 4-fluorobenzyl group, a 4-chlorobenzyl group, a 4-fluoro-2-methylbenzyl group, a 4-fluoro-3-methylbenzyl group, a 2-chloro-4-fluorobenzyl group, a 3-chloro-4-fluorobenzyl group, a 2,4-difluorobenzyl group, a 3,4-difluorobenzyl group, a 4-fluoro-2-methoxybenzyl group, a 4-fluoro-3-methoxybenzyl group, a 4-bromobenzyl group, a 4-iodobenzyl group, an allyloxycarbonylmethyl group, a 4-methylbenzyl group, a 4-methoxybenzyl group, a 4-allyloxybenzyl group, a 4-(trifluoromethyl)benzyl group, a 4-(trifluoromethoxy)benzyl group, a propargyl group, a cyclopentyl group, a cyclohexylmethyl group, a 4,4-difluorocyclohexylmethyl group, a thiazol-2-ylmethyl group, a benzothiazol-6-ylmethyl group, a benzothiazol-5-ylmethyl group, a cyclobutoxymethyl group, a 3-methylbutoxymethyl group, a 4-vinylbenzyl group, a 4-chloro-2-fluorobenzyl group, a 4-(difluoromethyl)benzyl group, a 4-(trifluoromethyl)benzyl group, a 4-ethylbenzyl group, a 2-fluoro-4-methylbenzyl group, a 3-fluoro-4-methylbenzyl group, a 4-(1,1-difluoroethyl)benzyl group, a 4-cyclopropylbenzyl group, a 4-isopropylbenzyl group, a 4-methoxybenzyl group, a 4-acetylbenzyl group or a 1,1-difluoroindol-5-ylmethyl group.

[0400] [B47]The cyclic compound or its salt or their solvate according to any one of [B1] to [B46], wherein P5 is a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C3-C8 cycloalkyl C1-C6 alkyl group or a C1-C6 aminoalkyl group.

[0401] [B48]The cyclic compound or its salt or their solvate according to [B47], wherein P5 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, isopentyl, neohexyl, 3-fluoropropyl, 3,3,3-trifluoropropyl, allyl, 2-methylallyl, propargyl, 3-butenyl, 2-methoxyethyl, 3-methoxypropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl or 2-aminoethyl.

[0402] [B49]The cyclic compound or its salt or their solvate according to any one of [B1] to [B48], wherein Q5 is a hydrogen atom.

[0403] [B50]The cyclic compound or its salt or their solvate according to any one of [B1] to [B49], wherein R6 is a hydrogen atom or a C1-C3 alkyl group.

[0404] [B51]The cyclic compound or its salt or their solvate according to [B50], wherein R6 is a hydrogen atom or methyl.

[0405] [B52]The cyclic compound or its salt or their solvate according to any one of [B1] to [B49], wherein R6 and P6 are connected to the nitrogen atom to which P6 is attached and the carbon atom to which R6 is attached together to form a 4- to 7-membered saturated heterocycle.

[0406] [B53]The cyclic compound or its salt or their solvate according to [B52], wherein the 4- to 7-membered saturated heterocycle is a pyrrolidine ring.

[0407] [B54]The cyclic compound or its salt or their solvate according to any one of [B1] to [B51], wherein P6 is a C1-C6 alkyl group.

[0408] [B55]The cyclic compound or its salt or their solvate according to [B54], wherein P6 is methyl, ethyl or n-propyl.

[0409] [B56]The cyclic compound or its salt or their solvate according to any one of [B1] to [B55], wherein Q6 is a hydrogen atom.

[0410] [B57]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B56], wherein R7 is C7 to C optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a C1-C6 alkoxy group, and a C3-C8 cycloalkyl group 14 arylalkyl; or a 5- to 10-membered heteroaryl C1-C6 alkyl optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a C1-C6 alkoxy group, and a C3-C8 cycloalkyl group.

[0411] [B58]The cyclic compound or a salt thereof or a solvate thereof according to [B57], wherein R7 is phenethyl optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a C1-C6 alkoxy group, and a C3-C8 cycloalkyl group; or a 5- to 10-membered heteroaryl ethyl optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a C1-C6 alkoxy group, and a C3-C8 cycloalkyl group.

[0412] [B59]The cyclic compound or a salt thereof or a solvate thereof according to [B58], wherein R7 is 4-methylphenethyl, 2-fluoro-4-(trifluoromethyl)phenethyl, 3-fluoro-4-(trifluoromethyl)phenethyl, 3-fluoro-4-(difluoromethoxy)phenethyl, 3,5-difluoro-4-(trifluoromethyl)phenethyl, 3,4,5-trifluorophenethyl, 2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenethyl, 3-chloro-4-(trifluoromethyl)phenethyl, 4-chloro-3,5-difluorophenethyl, 3,4-dichlorophenethyl, 3,5-dichloro-4-(trifluoromethyl)phenethyl, 3,4,5-trichlorophenethyl, 3-methoxy-4-(trifluoromethyl)phenethyl, 3-methyl-4-(trifluoromethyl)phenethyl, benzothiazol-5-ylethyl, benzothiazol-6-ylethyl, 4-chloro-3,5-dimethylphenethyl, 4-(trifluoromethyl)phenethyl, 4-chlorophenethyl, 3-ethyl-4-trifluoromethylphenethyl, 3-methoxy-4-trifluoromethylphenethyl, 3-chloro-4-trifluoromethylphenethyl, 3,5-difluoro-4-trifluoromethylphenethyl, 4-chloro-3-fluoro-5-methoxyphenethyl, 4-ethyl-3-fluoro-5-methoxyphenethyl, 3,5-dimethyl-4-difluoromethylphenethyl, 3-methyl-5-fluoro-4-difluoromethylphenethyl, 3-methyl-5-chloro-4-difluoromethylphenethyl, 3-methoxy-5-fluoro-4-difluoromethylphenethyl, 2-(4-fluoro-2,3-dihydrobenzofuran-6-yl)ethyl, 3-cyclopropyl-4-trifluoromethylphenethyl, 2-(1,1-difluoroinden-6-yl)ethyl, 4-cyclopropyl-3-fluorophenethyl, 4-cyclopropyl-3-chlorophenethyl, 4-cyclopropyl-3-methylphenethyl, 4-ethyl-3-fluorophenethyl, 4-ethyl-3-chlorophenethyl, 3,5-difluoro-4-difluoromethylphenethyl, 4-chloro-3-trifluoromethylphenethyl, 4-chloro-3-methoxyphenethyl, 2-(7-fluoroinden-5-yl)ethyl, 3-methoxy-4-cyclopropylphenethyl, 3,5-dimethyl-4-cyclopropylphenethyl, 3,5-dichloro-4-difluoromethylphenethyl, 3-methoxy-4-difluoromethylphenethyl, 3-methoxy-4-ethylphenethyl, 2-(7-chlorobenzothiophen-5-yl)ethyl, 2-(2,3-dimethylbenzothiophen-5-yl)ethyl, 2-(2-fluoro-3-methylbenzothiophen-5-yl)ethyl, 2-(1,2,3-trimethylindol-5-yl)ethyl, 2-(7-chloro-1-methylindol-5-yl)ethyl, 2-(1,3-dimethylindol-6-yl)ethyl or 2-(1-methylindol-6-yl)ethyl.

[0413] [B60]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B59], wherein P7 is a hydrogen atom.

[0414] [B61]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B60], wherein Q7 is a hydrogen atom.

[0415] [B62]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B61], wherein R8 is a hydrogen atom, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 alkoxy C1-C6 alkyl group or a C3-C8 cycloalkyl C1-C6 alkyl group.

[0416] [B63]The cyclic compound or a salt thereof or a solvate thereof according to [B62], wherein R8 is a hydrogen atom, a methyl group, a n-butyl group, a 2,2-difluoroethyl group, a 3,3-difluoropropyl group, a cyclohexylmethyl group, a methoxymethyl group, a n-propoxymethyl group, a 3-methylbutoxymethyl group or an ethyl group.

[0417] [B64]The cyclic compound or a salt thereof or a solvate thereof according to [B1] to [B61], wherein R8 and P8 are connected to the nitrogen atom to which P8 is attached and the carbon atom to which R8 is attached to form a 4- to 7-membered saturated heterocycle, the 4- to 7-membered saturated heterocycle is optionally fused with a 3- to 8-membered saturated carbocycle, and the 4- to 7-membered saturated heterocycle is optionally substituted with one or more C1-C6 alkyl groups; a C1-C6 haloalkyl group; a hydroxy group; a 4- to 7-membered heterocyclic oxy group; an oxo group; a C1-C6 alkoxy group; a C3-C8 cycloalkyl C1-C6 alkoxy group; a C1-C6 haloalkoxy group; a 4- to 8-membered cyclic amino group optionally substituted with one or more halogen atoms; a C3-C8 spiroalkyl group or a C3-C8 cycloalkoxy group.

[0418] [B65]The cyclic compound or a salt thereof or a solvate thereof according to [B64], wherein the 4- to 7-membered saturated heterocycle is a piperidine ring, a pyrrolidine ring, an azetidine ring, a morpholine ring, a thiomorpholine ring or an azepane ring.

[0419] [B66]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B63], wherein P8 is a hydrogen atom or a C1-C6 alkyl group.

[0420] [B67]The cyclic compound or a salt thereof or a solvate thereof according to [B66], wherein P8 is a methyl group, an ethyl group, a n-propyl group or a n-butyl group.

[0421] [B68]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B67], wherein Q8 is a hydrogen atom or a methyl group.

[0422] [B69]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B68], wherein R9 is C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy C1-C6 alkyl, C2-C6 alkenyloxy C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl or C7-C 14 arylalkyl.

[0423] [B70]The cyclic compound or a salt thereof or a solvate thereof according to [B69], wherein R9 is methyl, ethyl, n-propyl, isopropyl, 1-methylpropyl, 2-methylpropyl, allyl, cyclopropyl, cyclohexylmethyl, methoxymethyl, tert-butoxymethyl, allyloxymethyl or benzyl.

[0424] [B71]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B68], wherein R9 and Q9 are linked together with the carbon atom to which they are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, and the 3- to 8-membered alicyclic ring or 4- to 7-membered saturated heterocyclic ring is optionally substituted with one or more halogen atoms or one or more C1-C6 alkyl groups.

[0425] [B72]The cyclic compound or a salt thereof or a solvate thereof according to [B71], wherein the 3- to 8-membered alicyclic ring is a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclopentene ring or a cyclohexane ring.

[0426] [B73]The cyclic compound or a salt thereof or a solvate thereof according to [B71], wherein the 4- to 7-membered saturated heterocyclic ring is an oxetane ring or a tetrahydropyran ring.

[0427] [B74]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B70], wherein Q9 is a hydrogen atom or C1-C6 alkyl.

[0428] [B75]The cyclic compound or a salt thereof or a solvate thereof according to [B74], wherein Q9 is a hydrogen atom or methyl.

[0429] [B76]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B75], wherein R 10 is C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy C1-C6 alkyl, C3-C8 cycloalkyl or C3-C8 cycloalkyl C1-C6 alkyl.

[0430] [B77]The cyclic compound or a salt thereof or a solvate thereof according to [B76], wherein R 10is methyl, isopropyl, 1-methylpropyl, 2-methylpropyl, tert-butyl, pentan-3-yl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, n-propoxymethyl, cyclobutyl, cyclopentyl, cyclohexyl, 2,2-dimethylpropyl, cyclobutylmethyl or cyclopropylmethyl.

[0431] [B78] The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B77], wherein P 10 is a hydrogen atom or a C1-C6 alkyl group.

[0432] [B79] The cyclic compound or a salt thereof or a solvate thereof according to [B78], wherein P 10 is a hydrogen atom, methyl or ethyl.

[0433] [B80] The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B79], wherein Q 10 is a hydrogen atom or a C1-C6 alkyl group.

[0434] [B81] The cyclic compound or a salt thereof or a solvate thereof according to [B80], wherein Q 10 is a hydrogen atom or methyl.

[0435] [B82] The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B81], wherein L 11 is -CH2- or -CH2-S-CH2-.

[0436] [B83] The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B82], wherein R 11 is a C1-C6 alkyl group; di-C1-C6 alkylaminocarbonyl; N-C1-C6 alkyl-N-C2-C6 alkenylaminocarbonyl; N-C1-C6 alkyl-N-C1-C6 alkoxy C1-C6 alkylaminocarbonyl; a cyclic aminocarbonyl optionally substituted with one or more C1-C6 alkyl groups or a 4- to 7-membered heterocyclic group; or a C3-C8 cycloalkyl group.

[0437] [B84] The cyclic compound or a salt thereof or a solvate thereof according to [B83], wherein R 11is methyl, dimethylaminocarbonyl, diethylaminocarbonyl, N-ethyl-N-methylaminocarbonyl, N-allyl-N-methylaminocarbonyl, N-propyl-N-methylaminocarbonyl, N-butenyl-N-methylaminocarbonyl, N-pentenyl-N-methylaminocarbonyl, N-hexenyl-N-methylaminocarbonyl, N-methoxyethyl-N-methylaminocarbonyl, azetidinylcarbonyl, pyrrolidinylcarbonyl, 3,3-dimethylpyrrolidinylcarbonyl, piperidinylcarbonyl, 4-methylpiperidinylcarbonyl, morpholinylcarbonyl, morpholinocarbonyl, oxazolidin-3-ylcarbonyl, 1-(oxetane-3-yl)piperazin-4-ylcarbonyl, 3-oxa-8-azabicyclo[3.2.1]octan-8-ylcarbonyl, cyclopropyl or 2-methylpropyl.

[0438] [B85] The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B82], wherein R 11 and P 11 connected to P 11 the nitrogen atom and R 11 the carbon atom to which it is attached are linked together to form a 4- to 7-membered saturated heterocycle.

[0439] [B86] The cyclic compound or a salt thereof or a solvate thereof according to [B85], wherein the 4- to 7-membered saturated heterocycle is a pyrrolidine ring.

[0440] [B87] The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B85], wherein P 11 is a hydrogen atom, C1-C6 alkyl, C3-C8 cycloalkyl C1-C6 alkyl or C7-C 14 arylalkyl.

[0441] [B88] The cyclic compound or a salt thereof or a solvate thereof according to [B87], wherein P 11 is a hydrogen atom, methyl, ethyl, n-propyl, 2-cyclobutylethyl, 2-cyclopentylethyl or phenethyl.

[0442] [B89] The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B88], wherein Q 11 is a hydrogen atom.

[0443] [B90] The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B89], wherein at least four of P1 to P 11 are not hydrogen atoms.

[0444] [B91]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B90], wherein at least five of P1 to P 11 are not hydrogen atoms.

[0445] [B92]The cyclic compound or a salt thereof or a solvate thereof according to any one of [B1] to [B91], wherein at least six of P1 to P 11 are not hydrogen atoms.

[0446] [C1]A cyclic compound or a salt thereof or a solvate thereof represented by formula (3):

[0447] [Formula 19]

[0448]

[0449] wherein

[0450] L1 is a single bond;

[0451] R1 is a C1-C6 alkyl group, a C2-C6 alkynyl group or a C3-C8 cycloalkyl group optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a C3-C6 cycloalkyl group and a C1-C6 alkoxy group,

[0452] P1 is a hydrogen atom or a C1-C6 alkyl group;

[0453] Q1 is a hydrogen atom;

[0454] R2 is a C1-C6 alkyl group or a C3-C6 cycloalkyl group;

[0455] P2 is a hydrogen atom;

[0456] Q2 is a hydrogen atom;

[0457] R3 is a hydrogen atom, or R3 is linked to P3, the carbon atom to which R3 is attached and the nitrogen atom to which P3 is attached to form a 4- to 7-membered saturated heterocycle;

[0458] P3 is a C1-C6 alkyl group or a C2-C6 alkynyl group, except when R3 and P3 form a 4- to 7-membered saturated heterocycle;

[0459] Q3 is a hydrogen atom;

[0460] R4 is linked to P5 to form a divalent group, and in this case, the partial structure *-CR4Q4-CO-NP5-* in the cyclic compound represented by formula (3) is represented by the following formula:

[0461] [Formula 20]

[0462]

[0463] wherein T is a hydrogen atom or a halogen atom:

[0464] P4 is a C1-C6 alkyl group;

[0465] Q4 is a hydrogen atom,

[0466] R5 is a benzyl group optionally substituted with one or more groups selected from the group consisting of C1-C6 alkyl groups and C1-C6 haloalkyl groups:

[0467] Q5 is a hydrogen atom,

[0468] R6 is a hydrogen atom;

[0469] P6 is a C1-C6 alkyl group,

[0470] Q6 is a hydrogen atom,

[0471] R7 is a phenethyl group optionally substituted with one or more groups independently selected from the group consisting of halogen atoms, C1-C6 haloalkyl groups and C1-C6 alkoxy groups:

[0472] P7 is a hydrogen atom,

[0473] Q7 is a hydrogen atom,

[0474] R8 is linked to P8, the carbon atom to which R8 is attached and the nitrogen atom to which P8 is attached to form a 4- to 7-membered saturated heterocycle, wherein the 4- to 7-membered saturated heterocycle is optionally substituted with one or more groups independently selected from the group consisting of C1-C6 alkyl groups, C3-C6 cycloalkyl groups and C1-C6 alkoxy groups:

[0475] Q8 is a hydrogen atom,

[0476] R9 is a C1-C6 alkyl group, or is linked to Q9 and the carbon atom to which R9 and Q9 are attached to form a 3- to 8-membered alicyclic ring, wherein the 3- to 8-membered alicyclic ring is optionally substituted with one or more C1-C6 alkyl groups;

[0477] Q9 is a C1-C6 alkyl group, except when Q9 is linked to R9 and the carbon atom to which R9 and Q9 are attached to form a 3- to 8-membered alicyclic ring,

[0478] R 10 is a C1-C6 alkyl group or a C3-C8 cycloalkyl group;

[0479] P 10 is a C1-C6 alkyl group,

[0480] Q 10 is a hydrogen atom,

[0481] L11 is -CH2-,

[0482] R 11 is di -C1 to C6 alkylaminocarbonyl or 4 - to 8 - membered cyclic aminocarbonyl:

[0483] P 11 is C1 to C6 alkyl, and

[0484] Q 11 is a hydrogen atom.

[0485] [C2]A cyclic compound or a salt thereof or a solvate thereof, wherein

[0486] the said formula (3) is represented by formula (4):

[0487] [Formula 21]

[0488]

[0489] wherein

[0490] R1, P1, R2, R3, P3, P4, R5, P6, R7, R8, P8, R9, Q9, R 10 , P 10 , R 11 , P 11 and T are the same as defined in [C1].

[0491] [C3]The cyclic compound or a salt thereof or a solvate thereof according to [C2], wherein

[0492] the cyclic compound represented by formula (4) is selected from the group consisting of:

[0493] PP3376: (2S, 8S, 12R, 14S, 20S, 23S, 27S, 30S, 36S, 38Z)-20 - cyclopentyl - 12 - ethoxy - 27 - [(1R)-1 - methoxyethyl]-8 - [2 - [3 - methoxy - 4 - (trifluoromethyl)phenyl]ethyl]-N, N, 4, 19, 22, 26, 32, 35 - octamethyl - 30 - [(1S)-1 - methylpropyl]-3, 6, 9, 15, 18, 21, 25, 28, 31, 34, 42 - undecaooxo - 2 - [[4 - (trifluoromethyl)phenyl]methyl]spiro[16 - oxa - 1, 4, 7, 10, 19, 22, 26, 29, 32, 35 - decaazatricyclo[34.5.1.0 10，14 tetratetracont - 38 - ene - 17, 1′ - cyclobutane]-23 - carboxamide,

[0494] PP3382: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-12-ethoxy-27-isobutyl-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-(p-tolylmethyl)spiro[16-oxa-1,4,7,10,19,22,26,29,32,35-decaazatricyclo[34.5.1.0 10 , 14 42-Carbene-38-ene-17,1'-cyclobutane]-23-carboxamide, and

[0495] PP3394: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-(p-tolylmethyl)spiro[16-oxa-1,4,7,10,19,22,26,29,32,35-decaazatricyclo[34.5.1.0 10,14 42-Carbene-38-ene-17,1'-cyclobutane]-23-carboxamide.

[0496] [C4-1]A cyclic compound which is PP3376: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[16-oxa-1,4,7,10,19,22,26,29,32,35-decaazatricyclo[34.5.1.0 10,14 42-Carbene-38-ene-17,1'-cyclobutane]-23-carboxamide, or a salt or a solvate thereof.

[0497] [C4-2]A cyclic compound, which is PP3382: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-27-isobutyl-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-2-(p-tolylmethyl)spiro[16-oxa-1,4,7,10,19,22,26,29,32,35-decaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1'-cyclobutane]-23-carboxamide, or a salt or solvate thereof.

[0498] [C4-3]A cyclic compound, which is PP3394: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-2-(p-tolylmethyl)spiro[16-oxa-1,4,7,10,19,22,26,29,32,35-decaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1'-cyclobutane]-23-carboxamide, or a salt or solvate thereof.

[0499] [C5]The cyclic compound or a salt thereof according to any one of [C1] to [C4-3].

[0500] [C6]The cyclic compound or a solvate thereof according to any one of [C1] to [C4-3].

[0501] [C7]The cyclic compound according to any one of [C1] to [C4-3], or a solvate of a salt thereof.

[0502] [C8]The cyclic compound according to any one of [C1] to [C4-3].

[0503] [D1]The cyclic compound or a salt or solvate thereof according to any one of [A1] to [A7], [B1] to [B92] and [C1] to [C8], which binds to KRAS.

[0504] [D2]The cyclic compound or a salt thereof or a solvate thereof according to any one of [A1] to [A7], [B1] to [B92] and [C1] to [C8] inhibits KRAS.

[0505] [D3]The cyclic compound or a salt thereof or a solvate thereof according to any one of [A1] to [A7], [B1] to [B92] and [C1] to [C8] has high selectivity for KRAS.

[0506] [D4]The cyclic compound or a salt thereof or a solvate thereof according to any one of [A1] to [A7], [B1] to [B92] and [C1] to [C8] has a KRAS selectivity (KRAS selectivity for NRAS and / or KRAS selectivity for HRAS) higher than that of PP1820: (3S,9S,12S,17S,20S,23S,27S,30S,36S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-30-cyclopentyl-23-isobutyl-9-(isopentyloxymethyl)-N,N,7,17,18,24,28,31-octamethyl-20-[(1S)-1-methylpropyl]-2,5,8,11,16,19,22,25,29,32,35-undecaooxo-10-propyl-spiro[1,4,7,10,15,18,21,24,28,31,34-undecaazatricyclo[34.3.0.0 12，15 nonatriacontane-33,1′-cyclobutane]-27-carboxamide.

[0507] [D5]The cyclic compound or a salt thereof or a solvate thereof according to any one of [A1] to [A7], [B1] to [B94] and [C1] to [C8] binds selectively to KRAS.

[0508] [D6]The cyclic compound or a salt thereof or a solvate thereof according to any one of [A1] to [A7], [B1] to [B92] and [C1] to [C8] selectively inhibits KRAS.

[0509] [D7]The cyclic compound or a salt thereof or a solvate thereof according to any one of [A1] to [A7], [B1] to [B92] and [C1] to [C8] has a KRAS binding activity that is 3 times or more the NRAS binding activity and the HRAS binding activity.

[0510] [D8]The cyclic compound or a salt thereof or a solvate thereof according to [D7] has a KRAS binding activity that is 5 times, 7 times, 10 times, 15 times or 20 times or more the NRAS binding activity and the HRAS binding activity.

[0511] [D9]The cyclic compound, or a salt thereof, or a solvate thereof according to any one of [A1] to [A7], [B1] to [B92], and [C1] to [C8], which has a KRAS inhibitory activity that is 3 times or more the NRAS inhibitory activity and the HRAS inhibitory activity.

[0512] [D10]The cyclic compound, or a salt thereof, or a solvate thereof according to [D9], which has a KRAS inhibitory activity that is 5 times, 7 times, 10 times, 15 times, 20 times or more the NRAS inhibitory activity and the HRAS inhibitory activity.

[0513] [D11]A pharmaceutical composition comprising the cyclic compound, or a salt thereof, or a solvate thereof according to any one of [A1] to [A7], [B1] to [B92], and [C1] to [C8].

[0514] [D12]A pharmaceutical composition for selectively inhibiting KRAS in a subject, the composition comprising the cyclic compound, or a salt thereof, or a solvate thereof according to any one of [A1] to [A7], [B1] to [B92], and [C1] to [C8].

[0515] [D13]The pharmaceutical composition according to [D12], wherein the KRAS inhibitory activity of the compound is 3 times or more the NRAS inhibitory activity and the HRAS inhibitory activity of the compound.

[0516] [D14]The pharmaceutical composition according to [D13], wherein the KRAS inhibitory activity of the compound is 5 times, 7 times, 10 times, 15 times, 20 times or more the NRAS inhibitory activity and the HRAS inhibitory activity of the compound.

[0517] [D15]A pharmaceutical composition for treating or preventing cancer in a subject, the composition comprising an effective amount of the cyclic compound, or a salt thereof, or a solvate thereof according to any one of [A1] to [A7], [B1] to [B92], and [C1] to [C8].

[0518] [D16]The pharmaceutical composition according to [D15], wherein the cancer is lung cancer.

[0519] [D17]The pharmaceutical composition according to [D15] or [D16], wherein the subject is a human.

[0520] [D18]The cyclic compound, or a salt thereof, or a solvate thereof according to any one of [A1] to [A7], [B1] to [B92], and [C1] to [C8], which is used for treating or preventing cancer in a subject.

[0521] [D19]The cyclic compound or a salt thereof, or a solvate thereof according to [D18], wherein the cancer is lung cancer.

[0522] [D20]The cyclic compound or a salt thereof, or a solvate thereof according to any one of [A1] to [A7], [B1] to [B92] and [C1] to [C8], which is used for selectively inhibiting KRAS in a subject.

[0523] [D21]The cyclic compound or a salt thereof, or a solvate thereof according to any one of [D18] to [D20], wherein the subject is a human.

[0524] [D22]Use of the cyclic compound or a salt thereof, or a solvate thereof according to any one of [A1] to [A7], [B1] to [B92] and [C1] to [C8] in the manufacture of a medicament for treating or preventing cancer in a subject.

[0525] [D23]The use according to [D22], wherein the cancer is lung cancer.

[0526] [D24]Use of the cyclic compound or a salt thereof, or a solvate thereof according to any one of [A1] to [A7], [B1] to [B92] and [C1] to [C8] in the manufacture of a medicament for selectively inhibiting KRAS in a subject.

[0527] [D25]The use according to any one of [D22] to [D24], wherein the subject is a human.

[0528] [D26]A method for treating or preventing cancer in a subject, the method comprising administering to a subject in need thereof an effective amount of the cyclic compound or a salt thereof, or a solvate thereof according to any one of [A1] to [A7], [B1] to [B92] and [C1] to [C8].

[0529] [D27]The method according to [D26], wherein the cancer is lung cancer.

[0530] [D28]A method for selectively inhibiting KRAS in a subject, the method comprising administering to a subject in need thereof an effective amount of the cyclic compound or a salt thereof, or a solvate thereof according to any one of [A1] to [A7], [B1] to [B92] and [C1] to [C8]

[0531] [D29]The method according to any one of [D26] to [D28], wherein the subject is a human.

[0532] [E1]An amino acid selected from aa511 and aa512 listed in Table 4, or a salt or solvate thereof.

[0533] [E2]An oligopeptide compound selected from tp025, tp026 and tp027 listed in Table 9, or a salt or solvate thereof.

[0534] [Advantages of the Invention]

[0535] The present invention can provide a novel cyclic compound having selective KRAS inhibitory activity. Detailed Description of the Invention

[0536] (Abbreviations)

[0537] The abbreviations used herein are as follows.

[0538] AA: Ammonium acetate

[0539] Boc: tert-Butyloxycarbonyl

[0540] CSA: (+)-10-Camphorsulfonic acid

[0541] CPME: Cyclopentyl methyl ether

[0542] DAST: (Diethylamino)sulfur trifluoride

[0543] DBU: 1,8-Diazabicyclo[5.4.0]-7-undecene

[0544] DCM: Dichloromethane

[0545] DCE: 1,2-Dichloroethane

[0546] DEAD: Diethyl azodicarboxylate

[0547] DEPBT: 3-(Diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one

[0548] DIAD: Diisopropyl azodicarboxylate

[0549] DIC: N,N′-Diisopropylcarbodiimide

[0550] DIPEA: N,N-Diisopropylethylamine

[0551] DHP: 3,4-Dihydro-2H-pyran

[0552] DMA: N,N-Dimethylacetamide

[0553] DMAP: N,N-Dimethyl-4-aminopyridine

[0554] DMF: N,N-Dimethylformamide

[0555] dtbbpy: 4,4'-Di-tert-butyl-2,2'-bipyridine

[0556] EDTA: Ethylenediaminetetraacetic acid

[0557] FA: Formic acid

[0558] Fmoc: 9-Fluorenylmethyloxycarbonyl

[0559] NMP: N-Methyl-2-pyrrolidone

[0560] TBME: tert-Butyl methyl ether

[0561] TES: Triethylsilane

[0562] TFA: Trifluoroacetic acid

[0563] TFE: 2,2,2-Trifluoroethanol

[0564] THF: Tetrahydrofuran

[0565] THP: Tetrahydropyranyl

[0566] TMSCl: Trimethylchlorosilane

[0567] HFIP: 1,1,1,3,3,3-Hexafluoroisopropanol

[0568] HOAt: 1-Hydroxy-7-azabenzotriazole

[0569] HOBt: 1-Hydroxybenzotriazole

[0570] HOOBt: 3,4-Dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine

[0571] IPAC: Isopropyl acetate

[0572] oxyma: Ethyl cyano(oximino)acetate

[0573] PPTS: Pyridinium p-toluenesulfonate

[0574] Pis: 2-Phenylisopropyl

[0575] WSCI·HCl, WSCDI: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride

[0576] TIPS: Triisopropylsilane

[0577] TfOH: Trifluoromethanesulfonic acid

[0578] HATU: O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate

[0579] DMSO: Dimethyl sulfoxide

[0580] Fmoc-Cl: (9H-Fluoren-9-yl)methyl chloroformate

[0581] Fmoc-OSu: N-Succinimidyl 9-fluorenylmethyl carbonate

[0582] Ns: o-Nitrobenzenesulfonyl

[0583] Trt: Triphenylmethyl

[0584] 9-BBN: 9-Borabicyclo[3.3.1]nonane

[0585] HMDS: 1,1,1,3,3,3-Hexamethyldisilazane

[0586] LDA: Lithium diisopropylamide

[0587] TMSOTf: Trimethylsilyl trifluoromethanesulfonate

[0588] PPA: Polyphosphoric acid

[0589] In this document, when used in combination with a numerical value, the term "about" means a numerical range of +10% and -10% of that numerical value.

[0590] In this document, the "-" indicating a range includes the values at both ends of the range. For example, "A - B" means a range of A or more and B or less.

[0591] In this document, the molecular weight unit is "g / mol" (hereinafter, the unit of molecular weight may be omitted).

[0592] The articles "a", "an", and "the" used in both the specification and the claims shall be construed to cover both the singular and the plural, unless otherwise specified herein or in obvious contradiction to the context. (Definition of functional groups, etc.)

[0593] In this document, examples of "halogen atom" include F, Cl, Br, and I.

[0594] In this document, "alkyl" means a monovalent group derived by removing any one hydrogen atom from an aliphatic hydrocarbon and having a hydrocarbon group or a subset of the hydrocarbon group structure that does not contain heteroatoms (atoms other than carbon and hydrogen atoms) or unsaturated carbon-carbon bonds in its backbone but contains hydrogen and carbon atoms. Alkyl includes straight-chain and branched-chain alkyls. Specifically, alkyl has 1 to 20 carbon atoms (C1 - C 20 , hereinafter "C p - C q " means that the number of carbon atoms is p to q), and is preferably C1 - C 10alkyl, and more preferably a C1-C6 alkyl. Specific examples of the alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, isobutyl (2-methylpropyl), n-pentyl, sec-pentyl (1-methylbutyl), tert-pentyl (1,1-dimethylpropyl), neopentyl (2,2-dimethylpropyl), isopentyl (3-methylbutyl), 3-pentyl (1-ethylpropyl), 1,2-dimethylpropyl, 2-methylbutyl, n-hexyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1,1,2,2-tetramethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, and 2-ethylbutyl.

[0595] As used herein, "alkenyl" means a monovalent group having at least one double bond (two adjacent SP 2 carbon atoms). Depending on the configuration of the double bond and substituents (if any), the geometric form of the double bond can be trans (E) or cis (Z) and cis or trans configurations. Alkenyl includes straight-chain and branched-chain alkenyl. Alkenyl is preferably a C2-C 10 alkenyl, and more preferably a C2-C7 alkenyl or a C2-C6 alkenyl, and specific examples include vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl (including cis and trans forms), 3-butenyl, pentenyl, 3-methyl-2-butenyl, hexenyl, and 6-heptenyl.

[0596] As used herein, "alkynyl" means a monovalent group having at least one triple bond (two adjacent SP carbon atoms). Alkynyl includes straight-chain and branched-chain alkynyl. Alkynyl is preferably a C2-C 10 alkynyl, and more preferably a C2-C6 alkynyl, and specific examples include ethynyl, 1-propynyl, propargyl, 3-butynyl, pentynyl, hexynyl, 3-phenyl-2-propynyl, 3-(2'-fluorophenyl)-2-propynyl, 2-hydroxy-2-propynyl, 3-(3-fluorophenyl)-2-propynyl, and 3-methyl-(5-phenyl)-4-pentynyl.

[0597] As used herein, "cycloalkyl" means a saturated or partially saturated cyclic monovalent aliphatic hydrocarbon group and includes monocyclic, bicyclic, and spiro rings. Cycloalkyl is preferably a C3-C8 cycloalkyl, and specific examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[1.1.1]heptyl, bicyclo[2.2.1]heptyl, and spiro[3.3]heptyl.

[0598] As used herein, "aryl" means a monovalent aromatic hydrocarbon ring, and is preferably a C6-C 10Aryl. Specific examples of aryl include phenyl and naphthyl (e.g., 1-naphthyl and 2-naphthyl). In the present context, aryl includes bicyclic aryl in which an aromatic hydrocarbon ring is fused to another saturated or unsaturated ring, and for example includes aryl having a fused ring structure in which the aromatic hydrocarbon ring is a benzene ring and the saturated ring is a 5-, 6- or 7-membered saturated hydrocarbon ring or saturated heterocyclic ring. Specific examples include indanyl, 1,2,3,4-tetrahydronaphthyl and 2,3-dihydrobenzofuranyl.

[0599] In the present context, "heterocyclic group" means a non-aromatic cyclic monovalent group containing 1 to 5 heteroatoms in addition to carbon atoms. The heterocyclic group may have double bonds and / or triple bonds within the ring, the carbon atoms within the ring may be oxidized to form carbonyl groups, and the heterocyclic group may be a monocyclic or fused ring. The number of atoms constituting the ring is preferably 3 to 10 (3-membered to 10-membered heterocyclic group) or 4 to 10 (4-membered to 10-membered heterocyclic group), and more preferably 3 to 7 (3-membered to 7-membered heterocyclic group) or 4 to 7 (4-membered to 7-membered heterocyclic group). Specific examples of the heterocyclic group include azetidinyl, oxiranyl, oxetanyl, azetidinyl, dihydrofuranyl, tetrahydrofuranyl, dihydropyranyl, tetrahydropyranyl, tetrahydropyridyl, tetrahydropyrimidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrazolidinyl, imidolinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, 1,2-thiazinane, thiadiazolidinyl, azetidinyl, oxazolidinone, benzodioxolyl, benzoxazolyl, dioxolanyl, dioxanyl, tetrahydropyrrolo[1,2-c]imidazole, thietanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, sultam and 2-oxaspiro[3.3]heptyl.

[0600] In the present context, "protected heterocyclic group" means a group in which one or more functional groups (such as amino groups) contained in the above-defined "heterocyclic group" are protected by a protecting group, and is preferably a 4- to 7-membered protected heterocyclic group. Specific examples of the protecting group include Boc, Fmoc, Cbz, Troc and Alloc, and specific examples of the protected heterocyclic group include Boc-protected azetidine.

[0601] In the present context, "heterocycloalkylene" means a divalent group obtained by removing two hydrogen atoms from one carbon atom of the above-defined "heterocyclic group", wherein the free valence forms part of a double bond. The heterocycloalkylene is preferably a 4- to 7-membered heterocycloalkylene, and specific examples include tetrahydropyran-4-ylidene and azetidine-3-ylidene.

[0602] As used herein, "protected heterocycloalkyl" means a group in which one or more functional groups (such as amino groups) contained in the above-defined "heterocycloalkyl" are protected by a protecting group, and is preferably a 4- to 7-membered protected heterocycloalkyl. Specific examples of the protecting group include Boc, Fmoc, Cbz, Troc, and Alloc, and specific examples of the protected heterocycloalkyl include Boc-protected azetidin-3-ylidene.

[0603] As used herein, "heteroaryl" means an aromatic cyclic monovalent group containing 1 to 5 heteroatoms in addition to carbon atoms. The ring can be a monocyclic ring, a fused ring formed with other rings, or can be partially saturated. The number of atoms constituting the ring is preferably 5 to 10 (5- to 10-membered heteroaryl), and more preferably 5 to 7 (5- to 7-membered heteroaryl). Specific examples of the heteroaryl include furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, benzofuryl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, indolyl, isoindolyl, indazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, benzodioxolyl, indazinyl, and imidazopyridyl.

[0604] As used herein, "alkoxy" means an oxy group bonded to the above-defined "alkyl", and is preferably C1-C6 alkoxy. Specific examples of the alkoxy include methoxy, ethoxy, 1-propoxy, 2-propoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, and 3-methylbutoxy.

[0605] As used herein, "alkylthio" means a mercapto group bonded to the above-defined "alkyl", and is preferably C1-C6 alkylthio. Specific examples of the alkylthio include methylthio, ethylthio, 1-propylthio, 2-propylthio, n-butylthio, isobutylthio, sec-butylthio, and tert-butylthio.

[0606] As used herein, "alkenyloxy" means an oxy group bonded to the above-defined "alkenyl", and is preferably C2-C6 alkenyloxy. Specific examples of the alkenyloxy include vinyloxy, allyloxy, 1-propenyloxy, 2-propenyloxy, 1-butenyloxy, 2-butenyloxy (including cis and trans forms), 3-butenyloxy, pentyloxy, and hexyloxy.

[0607] As used herein, "cycloalkoxy" means an oxy group bonded to the above-defined "cycloalkyl", and is preferably C3-C8 cycloalkoxy. Specific examples of the cycloalkoxy include cyclopropoxy, cyclobutoxy, and cyclopentyloxy.

[0608] As used herein, "aryloxy" means an oxy group bonded to an "aryl" as defined above, and is preferably C6-C 10 aryloxy. Specific examples of aryloxy include phenoxy, 1-naphthyloxy, and 2-naphthyloxy.

[0609] As used herein, "amino" means -NH2 in the narrow sense and -NRR' in the broad sense, where R and R' are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic group, aryl, or heteroaryl, or R and R' together with the nitrogen atom to which they are attached form a ring. Amino is preferably -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, 4- to 8-membered cyclic amino, etc.

[0610] As used herein, "monoalkylamino" means a group corresponding to "amino" as defined above, where R is hydrogen and R' is "alkyl" as defined above, and is preferably mono-C1-C6 alkylamino. Specific examples of monoalkylamino include methylamino, ethylamino, n-propylamino, isopropylamino, n-butylamino, sec-butylamino, and tert-butylamino.

[0611] As used herein, "dialkylamino" means a group corresponding to "amino" as defined above, where R and R' are independently "alkyl" as defined above, and is preferably di-C1-C6 alkylamino. Specific examples of dialkylamino include dimethylamino and diethylamino.

[0612] As used herein, "cyclic amino" means a group corresponding to "amino" as defined above, where R and R' together with the nitrogen atom to which they are attached form a ring, and is preferably 4- to 8-membered cyclic amino. Specific examples of cyclic amino include 1-azetidinyl, 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 4-morpholinyl, 3-oxazolidinyl, 1,1-dioxosulfomorpholin-4-yl, and 3-oxa-8-azabicyclo[3.2.1]octan-8-yl.

[0613] As used herein, "protected amino" means an amino group protected by any protecting group. Specific examples of protected amino include amino protected by a protecting group such as Boc, Fmoc, Cbz, Troc, or Alloc.

[0614] As used herein, "alkylcarbonyl" means a carbonyl group bonded to "alkyl" as defined above, and is preferably C1-C6 alkylcarbonyl. Specific examples of alkylcarbonyl include acetyl, propionyl, and butyryl. The number of carbon atoms listed in the above definition indicates the number of carbon atoms in the alkyl moiety. For example, "C1-C6" in "C1-C6 alkylcarbonyl" indicates that the alkyl moiety has 1 to 6 carbon atoms.

[0615] As used herein, "aminocarbonyl" means a carbonyl group bonded to the "amino" as defined above, and is preferably -CONH2, mono-C1-C6 alkylaminocarbonyl, di-C1-C6 alkylaminocarbonyl, and 4- to 8-membered cyclic aminocarbonyl. Specific examples of aminocarbonyl include -CONH2, dimethylaminocarbonyl, 1-azetidinylcarbonyl, 1-pyrrolidinylcarbonyl, 1-piperidinylcarbonyl, 1-piperazinylcarbonyl, 4-morpholinylcarbonyl, 3-oxazolidinylcarbonyl, 1,1-dioxosulfomorpholin-4-ylcarbonyl, and 3-oxa-8-azabicyclo[3.2.1]oct-8-ylcarbonyl.

[0616] As used herein, "alkenyloxycarbonyl" means a carbonyl group bonded to the "alkenyloxy" as defined above, and is preferably C2-C6 alkenyloxycarbonyl. Specific examples of alkenyloxycarbonyl include vinyloxycarbonyl, allyloxycarbonyl, 1-propenyloxycarbonyl, 2-propenyloxycarbonyl, 1-butenyloxycarbonyl, 2-butenyloxycarbonyl (including cis and trans forms), 3-butenyloxycarbonyl, pentyenyloxycarbonyl, and hexyenyloxycarbonyl.

[0617] As used herein, "alkylsulfonyl" means a sulfonyl group bonded to the "alkyl" as defined above, and is preferably C1-C6 alkylsulfonyl. A specific example of alkylsulfonyl is methylsulfonyl.

[0618] As used herein, "hydroxyalkyl" means a group in which one or more hydrogens of the "alkyl" as defined above are replaced by a hydroxy group, and is preferably C1-C6 hydroxyalkyl. Specific examples of hydroxyalkyl include hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl, and 5-hydroxypentyl.

[0619] As used herein, "haloalkyl" means a group in which one or more hydrogens of the "alkyl" as defined above are replaced by a halogen, and is preferably C1-C6 haloalkyl, and more preferably C1-C6 fluoroalkyl. Specific examples of haloalkyl include difluoromethyl, trifluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3-difluoropropyl, 4,4-difluorobutyl, 5,5-difluoropentyl, and 1,1-difluoroethyl.

[0620] As used herein, "cyanoalkyl" means a group in which one or more hydrogens of the "alkyl" as defined above are replaced by a cyano group, and is preferably C1-C6 cyanoalkyl. Specific examples of cyanoalkyl include cyanomethyl and 2-cyanoethyl.

[0621] As used herein, "aminoalkyl" means a group in which one or more hydrogens of "alkyl" as defined above are replaced by "amino" as defined above, and is preferably C1-C6 aminoalkyl. Specific examples of aminoalkyl include 1-pyridylmethyl, 2-(1-piperidyl)ethyl, 3-(1-piperidyl)propyl, 4-aminobutyl, and 2-aminoethyl.

[0622] As used herein, "carboxyalkyl" means a group in which one or more hydrogens of "alkyl" as defined above are replaced by carboxy, and is preferably C1-C6 carboxyalkyl or C2-C6 carboxyalkyl. A specific example of carboxyalkyl includes carboxymethyl. The number of carbon atoms listed in the above definition indicates the number of carbon atoms in the alkyl moiety. For example, "C1-C6 carboxyalkyl" 1- "C6" indicates that the alkyl moiety has 1 to 6 carbon atoms.

[0623] As used herein, "alkenyloxycarbonylalkyl" means a group in which one or more hydrogens of "alkyl" as defined above are replaced by "alkenyloxycarbonyl" as defined above, and is preferably C2-C6 alkenyloxycarbonyl C1-C6 alkyl, and more preferably C2-C6 alkenyloxycarbonyl C1-C2 alkyl. Specific examples of alkenyloxycarbonylalkyl include allyloxycarbonylmethyl and 2-(allyloxycarbonyl)ethyl.

[0624] As used herein, "alkoxyalkyl" means a group in which one or more hydrogens of "alkyl" as defined above are replaced by "alkoxy" as defined above, and is preferably C1-C6 alkoxy C1-C6 alkyl, and more preferably C1-C6 alkoxy C 1- C2 alkyl. Specific examples of alkoxyalkyl include methoxymethyl, ethoxymethyl, 1-propoxymethyl, 2-propoxymethyl, n-butoxymethyl, isobutoxymethyl, sec-butoxymethyl, tert-butoxymethyl, pentyloxymethyl, 3-methylbutoxymethyl, 1-methoxyethyl, 2-methoxyethyl, 2-ethoxyethyl, 1-ethoxyethyl, and 1-n-propoxyethyl.

[0625] As used herein, "alkylthioalkyl" means a group in which one or more hydrogens of "alkyl" as defined above are replaced by "alkylthio" as defined above, and is preferably C1-C6 alkylthio C1-C6 alkyl, and more preferably C1-C6 alkylthio C1-C2 alkyl. Specific examples of alkylthioalkyl include methylthiomethyl, ethylthiomethyl, 1-propylthiomethyl, 2-propylthiomethyl, n-butylthiomethyl, isobutylthiomethyl, sec-butylthiomethyl, and tert-butylthiomethyl.

[0626] As used herein, "alkenyloxyalkyl" means a group in which one or more hydrogens of the above-defined "alkyl" are replaced by the above-defined "alkenyloxy", and is preferably C2-C6 alkenyloxy C1-C6 alkyl, and more preferably C1-C6 alkenyloxy C1-C2 alkyl. Specific examples of alkenyloxyalkyl include vinyloxymethyl and allyloxymethyl.

[0627] As used herein, "cycloalkylalkyl" means a group in which one or more hydrogens of the above-defined "alkyl" are replaced by the above-defined "cycloalkyl", and is preferably C3-C8 cycloalkyl C1-C6 alkyl, and more preferably C3-C6 cycloalkyl C1-C2 alkyl. Specific examples of cycloalkylalkyl include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, and cyclohexylmethyl.

[0628] As used herein, "cycloalkyloxyalkyl" means a group in which one or more hydrogens of the above-defined "alkyl" are replaced by the above-defined "cycloalkyloxy", and is preferably C3-C8 cycloalkyloxy C1-C6 alkyl, and more preferably C3-C6 cycloalkyloxy C1-C2 alkyl. Specific examples of cycloalkyloxyalkyl include cyclopropoxymethyl and cyclobutoxymethyl.

[0629] As used herein, "heterocyclylalkyl" means a group in which one or more hydrogens of the above-defined "alkyl" are replaced by the above-defined "heterocyclyl", and is preferably 4- to 7-membered heterocyclyl C1-C6 alkyl, and more preferably 4- to 7-membered heterocyclyl C1-C2 alkyl. Specific examples of heterocyclylalkyl include 2-(tetrahydro-2H-pyran-4-yl)ethyl and 2-(azetidin-3-yl)ethyl.

[0630] As used herein, "alkylsulfonylalkyl" means a group in which one or more hydrogens of the above-defined "alkyl" are replaced by the above-defined "alkylsulfonyl", and is preferably C 1- C6 alkylsulfonyl C1-C6 alkyl, and more preferably C1-C6 alkylsulfonyl C1-C2 alkyl. Specific examples of alkylsulfonylalkyl include methanesulfonylmethyl and 2-(methanesulfonyl)ethyl.

[0631] As used herein, "aminocarbonylalkyl" means a group in which one or more hydrogens of the above-defined "alkyl" are replaced by the above-defined "aminocarbonyl", and is preferably aminocarbonyl C1-C6 alkyl, and more preferably aminocarbonyl C1-C4 alkyl. Specific examples of aminocarbonylalkyl include methylaminocarbonylmethyl, dimethylaminocarbonylmethyl, tert-butylaminocarbonylmethyl, 1-azetidinylcarbonylmethyl, 1-pyrrolidinylcarbonylmethyl, 1-piperidinylcarbonylmethyl, 4-morpholinylcarbonylmethyl, 2-(methylaminocarbonyl)ethyl, 2-(dimethylaminocarbonyl)ethyl, 2-(1-azetidinylcarbonyl)ethyl, 2-(1-pyrrolidinylcarbonyl)ethyl, 2-(4-morpholinylcarbonyl)ethyl, 3-(dimethylaminocarbonyl)propyl, and 4-(dimethylaminocarbonyl)butyl.

[0632] As used herein, "aryloxyalkyl" means a group in which one or more hydrogens of the above-defined "alkyl" are replaced by the above-defined "aryloxy", and is preferably C6-C 10 aryloxy C1-C6 alkyl, and more preferably C6-C 10 aryloxy C1-C2 alkyl. Specific examples of aryloxyalkyl include phenoxymethyl and 2-phenoxyethyl.

[0633] As used herein, "aralkyl (arylalkyl)" means a group in which one or more hydrogen atoms of the above-defined "alkyl" are replaced by the above-defined "aryl", and is preferably C7-C 14 aralkyl, and more preferably C7-C 10 aralkyl. Specific examples of aralkyl include benzyl, phenethyl, and 3-phenylpropyl.

[0634] As used herein, "aralkyloxy" means an oxy group bonded to the above-defined "aralkyl", and is preferably C7-C 14 aralkyloxy, and more preferably C7-C 10 aralkyloxy. Specific examples of aralkyloxy include benzyloxy, phenethyloxy, and 3-phenylpropoxy.

[0635] As used herein, "aralkyloxyalkyl" means a group in which one or more hydrogens of the above-defined "alkyl" are replaced by the above-defined "aralkyloxy", and is preferably C7-C 14 aralkyloxy C1-C6 alkyl, and more preferably C7-C 14 aralkyloxy C1-C2 alkyl. Specific examples of aralkyloxyalkyl include benzyloxymethyl and 1-(benzyloxy)ethyl.

[0636] As used herein, "heteroarylalkyl" means a group in which one or more hydrogen atoms of "alkyl" as defined above are replaced by "heteroaryl" as defined above, and is preferably a 5- to 10-membered heteroaryl C1-C6 alkyl, and more preferably a 5- to 10-membered heteroaryl C1-C2 alkyl. Specific examples of heteroarylalkyl include 3-thienylmethyl, 4-thiazolylmethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-(2-pyridyl)ethyl, 2-(3-pyridyl)ethyl, 2-(4-pyridyl)ethyl, 2-(6-quinolyl)ethyl, 2-(7-quinolyl)ethyl, 2-(6-indolyl)ethyl, 2-(5-indolyl)ethyl, and 2-(5-benzofuranyl)ethyl.

[0637] As used herein, "heteroarylalkoxy" means an oxy group bonded to "heteroarylalkyl" as defined above, and is preferably a 5- to 10-membered heteroaryl C1-C6 alkoxy, and more preferably a 5- to 10-membered heteroaryl C1-C2 alkoxy. Specific examples of heteroarylalkoxy include 3-thienylmethoxy and 3-pyridylmethoxy.

[0638] As used herein, "heteroarylalkoxyalkyl" means a group in which one or more hydrogens of "alkyl" as defined above are replaced by "heteroarylalkoxy" as defined above, and is preferably a 5- to 10-membered heteroaryl C1-C6 alkoxy C1-C6 alkyl, and more preferably a 5- to 10-membered heteroaryl C1-C2 alkoxy C1-C2 alkyl. Specific examples of heteroarylalkoxyalkyl include 3-pyridylmethoxymethyl.

[0639] As used herein, "heterocycloalkylalkyl" means a group in which one or more hydrogens of "alkyl" as defined above are replaced by "heterocycloalkyl" as defined above, and is preferably a 4- to 7-membered heterocycloalkyl C1-C6 alkyl, and more preferably a 4- to 7-membered heterocycloalkyl C1-C2 alkyl. Specific examples of heterocycloalkylalkyl include tetrahydro-4H-pyran-4-ylidene methyl and azetidine-3-ylidene methyl.

[0640] As used herein, "alkoxyalkenyl" means a group in which one or more hydrogens of "alkenyl" as defined above are replaced by "alkoxy" as defined above, and is preferably a C1-C6 alkoxy C2-C6 alkenyl. Specific examples of alkoxyalkenyl include (E)-4-methoxybut-2-en-1-yl.

[0641] As used herein, "aminocarbonylalkenyl" means a group in which one or more hydrogens of "alkenyl" as defined above are replaced by "aminocarbonyl" as defined above, and is preferably an aminocarbonyl C2-C6 alkenyl. Specific examples of aminocarbonylalkenyl include (E)-3-(dimethylaminocarbonylcarbonyl)-prop-2-en-1-yl.

[0642] As used herein, "haloalkoxy" means a group in which one or more hydrogens of the above-defined "alkoxy" are replaced by halogen, and is preferably C 1- C6 haloalkoxy. Specific examples of haloalkoxy include difluoromethoxy, trifluoromethoxy, 2,2-difluoroethoxy, and 2,2,2-trifluoroethoxy.

[0643] As used herein, "alkylene" means a divalent group derived by further removing any one hydrogen atom from the above-defined "alkyl", and is preferably C4-C8 alkylene. Specific examples of alkylene include -CH2-, -(CH2)2-, -(CH2)3-, -CH(CH3)CH2-, -C(CH3)2-, -(CH2)4-, -CH(CH3)CH2CH2-, -C(CH3)2CH2-, -CH2CH(CH3)CH2-, -CH2C(CH3)2-, -CH2CH2CH(CH3)-, -(CH2)5-, -(CH2)6-, -(CH2)7-, and -(CH2)8-.

[0644] As used herein, "cycloalkylene" means a divalent group derived by further removing any one hydrogen atom from the above-defined "cycloalkyl", and is preferably C3-C8 cycloalkylene. Specific examples of cycloalkylene include cyclopropane-1,2-diyl, cyclobutane-1,2-diyl, cyclopentane-1,2-diyl, and cyclohexane-1,2-diyl.

[0645] As used herein, "heteroalkylene" means a divalent group derived by removing any one hydrogen atom from the above-defined "heteroalkyl", and is preferably a 3- to 7-membered heteroalkylene. Specific examples of heteroalkylene include oxolane-2,3-diyl, oxetane-2,3-diyl, tetrahydrofuran-2,5-diyl, and tetrahydropyran-2,6-diyl.

[0646] As used herein, "alkenylene" means a divalent group derived by further removing any one hydrogen atom from the above-defined "alkenyl". Depending on the configuration of the double bond and substituents (if any), the geometric form of the double bond can be trans (E) or cis (Z) and cis or trans configurations. Alkenylene can be straight-chain or branched, and is preferably C2-C 10 alkenylene, and more preferably C2-C6 alkenylene.

[0647] As used herein, "alkynylene" means a divalent group derived by further removing any one hydrogen atom from the above-defined "alkynyl". Alkynylene can be straight-chain or branched, and is preferably C2-C 10 alkynylene, and more preferably C2-C6 alkynylene.

[0648] As used herein, "arylene" means a divalent group derived by further removing any one hydrogen atom from the above-mentioned "aryl". The arylene may be monocyclic or fused-ring. The number of atoms constituting the ring is not particularly limited, and is preferably 6 to 10 (C 6-10 arylene). Specific examples of the arylene include 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 1,2-naphthylene, 1,3-naphthylene, and 1,4-naphthylene.

[0649] As used herein, "spiroalkyl" means a group formed by sharing one carbon atom constituting a cycloalkane ring with a carbon atom present in a bonding group. The spiroalkyl is preferably a C3-C8 spiroalkyl, and specific examples thereof include spiropropyl, spirobutyl, spiropentyl, spirohexyl, spiroheptyl, and spirooctyl.

[0650] As used herein, "spiroheterocyclic group" means a group obtained by replacing one or more carbon atoms in the above-mentioned "spiroalkyl" with a heteroatom. The spiroheterocyclic group is preferably a 4- to 10-membered spiroheterocyclic group.

[0651] As used herein, "alicyclic ring" means a non-aromatic hydrocarbon ring. The alicyclic ring may have an unsaturated bond in the ring and may be a polycyclic ring having two or more rings. The carbon atoms constituting the ring may be oxidized to form a carbonyl group. The alicyclic ring is preferably a 3- to 8-membered alicyclic ring, and specific examples thereof include a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, a cycloheptane ring, a cyclooctane ring, and a bicyclo[2.2.1]heptane ring.

[0652] As used herein, "saturated heterocycle" means a non-aromatic heterocycle containing 1 to 5 heteroatoms in addition to carbon atoms and having no double bond and / or triple bond in the ring. The saturated heterocycle may be monocyclic or may form a fused ring with another ring (for example, an aromatic ring such as a benzene ring). The saturated heterocycle is preferably a 4- to 7-membered saturated heterocycle, and specific examples thereof include an azetidine ring, an oxetane ring, a tetrahydrofuran ring, a tetrahydropyran ring, a morpholine ring, a thiomorpholine ring, a pyrrolidine ring, a 4-oxopyrrolidine ring, a piperidine ring, a 4-oxopiperidine ring, a piperazine ring, a pyrazolidine ring, an imidazolidine ring, an oxazolidine ring, an isoxazolidine ring, a thiazolidine ring, an isothiazolidine ring, a thiadiazolidine ring, an oxazolidinone ring, a dioxolane ring, a dioxane ring, a thiacyclobutane ring, an octahydroindole ring, a dihydroindole ring, and an azepane ring.

[0653] As used herein, "peptide chain" means a peptide chain in which 1, 2, 3, 4 or more natural amino acids and / or unnatural amino acids are linked by an amide bond and / or an ester bond. The peptide chain is preferably a peptide chain containing 1 to 4 amino acid residues, and more preferably a peptide chain composed of 1 to 4 amino acid residues.

[0654] As used herein, "optionally substituted" means that the group may be substituted with any substituent.

[0655] As used herein, "optionally protected" means that the group may be protected by any protecting group.

[0656] As used herein, "one or more" means one or two or more. When used in the context of substituents of a group, the phrase means a number ranging from one to the maximum number of substituents allowed for the group. Specific examples of "one or more" include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and / or more.

[0657] The wavy lines in the structural formulas herein may mean that any stereochemistry is allowed. For example, when an asymmetric center is provided with a wavy line, the stereochemistry of the asymmetric center may be in the S configuration or the R configuration. When a double bond is provided with a wavy line, the stereochemistry of the double bond may be in the E configuration or the Z configuration.

[0658] As used herein, the symbol represented by "PPn 1 n 2 n 3 n 4 , where n 1 , n 2 , n 3 and n 4 each independently represents an integer from 0 to 9", such as PP1574 and PP1640, represents the compound number.

[0659] The compounds of the present invention may be salts thereof, and preferably chemical or pharmaceutical salts. Additionally, the compounds or salts thereof of the present invention may be solvates thereof, and preferably chemical or pharmaceutical solvates. Examples of salts of the compounds of the present invention include hydrochloride salts; hydrobromide salts; hydroiodide salts; phosphate salts; phosphonate salts; sulfate salts; sulfonate salts, such as mesylate and tosylate; carboxylate salts, such as acetate, citrate, malate, tartrate, succinate and salicylate; alkali metal salts, such as sodium salts and potassium salts; alkaline earth metal salts, such as magnesium salts and calcium salts; and ammonium salts, such as ammonium salts, alkylammonium salts, dialkylammonium salts, trialkylammonium salts and tetraalkylammonium salts. These salts are prepared, for example, by contacting the compound with an acid or base useful in the production of pharmaceuticals. In the present invention, a solvate of a compound refers to a molecular aggregate formed by the compound with a solvent, and when the solvent is water, it is called a hydrate. The solvate of the compound of the present invention is preferably a hydrate, and specific examples of such hydrates include monohydrates to decahydrates, preferably monohydrates to pentahydrates, and more preferably monohydrates to trihydrates. The solvates of the compounds of the present invention include not only solvates formed by a single solvent (such as water, an alcohol (e.g., methanol, ethanol, 1-propanol or 2-propanol) or dimethylformamide), but also solvates formed by multiple solvents.

[0660] As used herein, the term "amino acid" includes natural and unnatural amino acids. As used herein, the term "natural amino acid" refers to Gly, Ala, Ser, Thr, Val, Leu, Ile, Phe, Tyr, Trp, His, Glu, Asp, Gln, Asn, Cys, Met, Lys, Arg or Pro. Examples of unnatural amino acids include, but are not particularly limited to, β - amino acids, γ - amino acids, D - amino acids, N - substituted amino acids, α,α - disubstituted amino acids, amino acids with side chains different from those of natural amino acids, and hydroxycarboxylic acids. The amino acids herein can have any conformation. The choice of amino acid side chains is not particularly limited and can freely be selected from, for example, alkyl groups, alkenyl groups, alkynyl groups, aryl groups, heteroaryl groups, aralkyl groups and cycloalkyl groups, in addition to a hydrogen atom. One or two non - adjacent methylene groups in such groups are optionally substituted with an oxygen atom, a carbonyl group (-CO-), or a sulfonyl group (-SO2-). Each group can have substituents and there is no limitation on the substituents. For example, one or more substituents can freely and independently be selected from any substituents including halogen atoms, O atoms, S atoms, N atoms, B atoms, Si atoms or P atoms. Examples include optionally substituted alkyl groups, alkenyl groups, alkynyl groups, aryl groups, heteroaryl groups, aralkyl groups and cycloalkyl groups. In non - limiting embodiments, the amino acids herein can be compounds having a carboxyl group and an amino group in the same molecule (even in such cases, amino acids such as proline, hydroxyproline, azetidine - 2 - carboxylic acid, etc., in which the nitrogen atom of the amino acid in each of them is connected to any atom of the side chain to form a ring, are also included in the amino acids).

[0661] The backbone amino group of the amino acid can be unsubstituted (NH2 group) or substituted (i.e., -NHR group, where R represents an alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl or cycloalkyl that can have substituents, one or two non - adjacent methylene groups in such groups can be replaced by an oxygen atom, a carbonyl group (-CO-), or a sulfonyl group (-SO2-), and the carbon chain bonded to the N atom and the carbon atom at the α - position can form a ring, such as proline). The R substituent is selected in the same manner as the substituents for the above - mentioned amino acid side chains. When the backbone amino group is substituted, R is included in the "amino acid side chain" as used herein. Such amino acids in which the backbone amino group is substituted are referred to herein as "N - substituted amino acids". As used herein, preferred examples of "N - substituted amino acids" include, but are not limited to, N - alkyl amino acids, N - C1 - C6 alkyl amino acids, N - C1 - C4 alkyl amino acids and N - methyl amino acids.

[0662] As used herein, "amino acids" that make up a peptide compound include all isotopes corresponding to each amino acid. Isotopes of "amino acids" refer to cases where at least one atom is replaced by an atom having the same atomic number (number of protons) but a different mass number (total number of protons and neutrons). Examples of isotopes contained in the "amino acids" that make up the peptide compounds of the present invention include hydrogen atoms, carbon atoms, nitrogen atoms, oxygen atoms, phosphorus atoms, sulfur atoms, fluorine atoms, and chlorine atoms, which respectively include 2 H and 3 H; 13 C and 14 C; 15 N; 17 O and 18 O; 31 P and 32 P; 35 S; 18 F; and 36 Cl.

[0663] As used herein, substituents containing a halogen atom include halogen-substituted alkyl groups, cycloalkyl groups, alkenyl groups, alkynyl groups, aryl groups, heteroaryl groups, or aralkyl groups. More specific examples include fluoroalkyl, difluoroalkyl, and trifluoroalkyl.

[0664] Substituents containing an O atom include groups such as hydroxy (-OH), oxy (-OR), carbonyl (-C(=O)-R), carboxy (-CO2H), oxycarbonyl (-C(=O)-OR), carbonyloxy (-O-C(=O)-R), thiocarbonyl (-C(=O)-SR), carbonylthio (-S-C(=O)-R), aminocarbonyl (-C(=O)-NHR), carbonylamino (-NH-C(=O)-R), oxycarbonylamino (-NH-C(=O)-OR), sulfonylamino (-NH-SO2-R), aminosulfonyl (-SO2-NHR), amidosulfonylamino (-NH-SO2-NHR), thiocarboxy (-C(=O)-SH), and carboxycarbonyl (-C(=O)-CO2H).

[0665] Examples of oxy (-OR) include alkoxy, cycloalkoxy, alkenoxy, alkynoxy, aryloxy, heteroaryloxy, and aralkyloxy. The alkoxy is preferably C1-C4 alkoxy or C1-C2 alkoxy, and particularly preferably methoxy or ethoxy.

[0666] Examples of carbonyl (-C(=O)-R) include formyl (-C(=O)-H), alkylcarbonyl, cycloalkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, arylcarbonyl, heteroarylcarbonyl, and aralkylcarbonyl.

[0667] Examples of oxycarbonyl (-C(=O)-OR) include alkoxycarbonyl, cycloalkoxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, and aralkyloxycarbonyl.

[0668] Examples of carbonyloxy (-O-C(=O)-R) include alkylcarbonyloxy, cycloalkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, and aralkylcarbonyloxy.

[0669] Examples of thiocarbonyl (-C(=O)-SR) include alkylthiocarbonyl, cycloalkylthiocarbonyl, alkenylthiocarbonyl, alkynylthiocarbonyl, arylthiocarbonyl, heteroarylthiocarbonyl, and aralkylthiocarbonyl.

[0670] Examples of carbonothioyl (-S-C(=O)-R) include alkylcarbonothioyl, cycloalkylcarbonothioyl, alkenylcarbonothioyl, alkynylcarbonothioyl, arylcarbonothioyl, heteroarylcarbonothioyl, and aralkylcarbonothioyl.

[0671] Examples of aminocarbonyl (-C(=O)-NHR) include alkylaminocarbonyl (such as C1-C6 or C1-C4 alkylaminocarbonyl, and especially ethylaminocarbonyl and methylaminocarbonyl), cycloalkylaminocarbonyl, alkenylaminocarbonyl, alkynylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, and aralkylaminocarbonyl. Additionally, examples further include compounds obtained by replacing the H atom bonded to the N atom in -C(=O)-NHR with an alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl group.

[0672] Examples of carbonylamino (-NH-C(=O)-R) include alkylcarbonylamino, cycloalkylcarbonylamino, alkenylcarbonylamino, alkynylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, and aralkylcarbonylamino. Additionally, examples further include compounds obtained by replacing the H atom bonded to the N atom in -NH-C(=O)-R with an alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl group.

[0673] Examples of oxycarbonylamino (-NH-C(=O)-OR) include alkoxycarbonylamino, cycloalkoxycarbonylamino, alkenyloxycarbonylamino, alkynyloxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, and aralkyloxycarbonylamino. Additionally, examples further include compounds obtained by replacing the H atom bonded to the N atom in -NH-C(=O)-OR with an alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl group.

[0674] Examples of sulfonylamino (-NH-SO2-R) include alkylsulfonylamino, cycloalkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, and aralkylsulfonylamino. In addition, examples further include compounds obtained by replacing the H atom bonded to the N atom in -NH-SO2-R with alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl.

[0675] Examples of aminosulfonyl (-SO2-NHR) include alkylaminosulfonyl, cycloalkylaminosulfonyl, alkenylaminosulfonyl, alkynylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl, and aralkylaminosulfonyl. In addition, examples further include compounds obtained by replacing the H atom bonded to the N atom in -SO2-NHR with alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl.

[0676] Examples of amidosulfonylamino (-NH-SO2-NHR) include alkylamid sulfonylamino, cycloalkylamid sulfonylamino, alkenylamid sulfonylamino, alkynylamid sulfonylamino, arylamid sulfonylamino, heteroaryl amid sulfonylamino, and aralkylamid sulfonylamino. In addition, the two H atoms bonded to the N atom in -NH-SO2-NHR can be independently replaced by substituents selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl, and the two substituents can form a ring.

[0677] Substituents containing an S atom include groups such as mercapto (-SH), thio (-S-R), sulfinyl (-S(=O)-R), sulfonyl (-SO2-R), and sulfo (-SO3H).

[0678] Examples of thio (-S-R) are selected from alkylthio, cycloalkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio, aralkylthio, and the like.

[0679] Examples of sulfonyl (-SO2-R) include alkylsulfonyl, cycloalkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heteroarylsulfonyl, and aralkylsulfonyl.

[0680] Substituents containing an N atom include groups such as azide (-N3, also referred to as "azido group"), cyano (-CN), primary amino group (-NH2), secondary amino group (-NH-R; also referred to as monosubstituted amino), tertiary amino group (-NR(R′); also referred to as disubstituted amino), amidino group (-C(=NH)-NH2), substituted amidino group (-C(=NR)-NR′R″), guanidino group (-NH-C(=NH)-NH2), substituted guanidino group (-NR-C(=NR″′)-NR′R″), aminocarbonylamino group (-NR-CO-NR′R″), pyridyl, piperidino, morpholino, and azetidinyl.

[0681] Examples of secondary amino groups (-NH-R; monosubstituted amino) include alkylamino, cycloalkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, and aralkylamino.

[0682] Examples of tertiary amino groups (-NR(R′); disubstituted amino) include amino groups having any two substituents each independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl, such as alkyl(aralkyl)amino, and the two substituents may form a ring. Specific examples include dialkylamino, especially C1-C6 dialkylamino, C1-C4 dialkylamino, dimethylamino, and diethylamino. As used herein, "C p -C q dialkylamino group" refers to an amino group substituted with two C p -C q alkyl groups, and the C p -C q alkyl groups may be the same or different.

[0683] Examples of substituted amidino groups (-C(=NR)-NR′R″) include groups in which the three substituents R, R′, and R″ on the N atom are each independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl, such as alkyl(aralkyl)(aryl)amidino.

[0684] Examples of substituted guanidino groups (-NR-C(=NR″′)-NR′R″) include groups in which R, R′, R″, and R″′ are each independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl, and groups in which these substituents form a ring.

[0685] Examples of aminocarbonylamino groups (-NR-CO-NR′R″) include groups in which R, R′, and R″ are each independently selected from a hydrogen atom, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl, or groups in which these substituents form a ring.

[0686] Here, the "peptide residue" or "amino acid residue" constituting the peptide compound may be abbreviated as "peptide" or "amino acid", respectively.

[0687] In the present invention, the meaning of the term "and / or" includes any combination obtained by appropriately combining "and" and "or". Specifically, for example, "A, B and / or C" includes the following seven variations:

[0688] (i) A, (ii) B, (iii) C, (iv) A and B, (v) A and C, (vi) B and C, (vii) A, B and C.

[0689] In one embodiment, the present invention relates to a cyclic compound represented by the following formula (1), or a salt thereof, or a solvate thereof.

[0690] [Formula 22]

[0691]

[0692] In the cyclic compound of formula (1), the ring is composed of 11 amino acid residues. Herein, the amino acid residue having P1, Q1, R1 and L1 in formula (1) may be referred to as core 1, the amino acid residue having P2, Q2 and R2 may be referred to as core 2, the amino acid residue having P3, Q3 and R3 may be referred to as core 3, the amino acid residue having P4, Q4 and R4 may be referred to as core 4, the amino acid residue having P5, Q5 and R5 may be referred to as core 5, the amino acid residue having P6, Q6 and R6 may be referred to as core 6, the amino acid residue having P7, Q7 and R7 may be referred to as core 7, the amino acid residue having P8, Q8 and R8 may be referred to as core 8, the amino acid residue having P9, Q9 and R9 may be referred to as core 9, the amino acid residue having P 10 , Q 10 and R 10 may be referred to as core 10, and the amino acid residue having P 11 , Q 11 , R 11 and L 11 may be referred to as core 11.

[0693] In one embodiment, in formula (1), L1 is a single bond.

[0694] In one embodiment, in formula (1), R1 is a C1-C6 alkyl group, a C2-C6 alkynyl group or a C3-C8 cycloalkyl group which is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a C3-C6 cycloalkyl group and a C1-C6 alkoxy group, and is preferably 2-methylpropyl, n-butyl, 2,2,2-trifluoroethyl, 1-methoxyethyl, bicyclo[1.1.1]pentyl or n-propyl.

[0695] In one embodiment, P1 is a hydrogen atom or a C1-C6 alkyl group, and is preferably a hydrogen atom or a methyl group.

[0696] In one embodiment, Q1 is a hydrogen atom.

[0697] In one embodiment, in formula (1), R2 is a C1-C6 alkyl group or a C3-C6 cycloalkyl group, and is preferably an isopropyl group, a cyclopropyl group or a 1-methylpropyl group.

[0698] In one embodiment, P2 is a hydrogen atom.

[0699] In one embodiment, Q2 is a hydrogen atom.

[0700] The amino acid residue of core 2 is, for example, Val, Gly(cPent) or Ile.

[0701] In one embodiment, in formula (1), R3 is a hydrogen atom.

[0702] In one embodiment, R3 is connected to P3, the carbon atom to which P3 is attached, and the nitrogen atom to which P3 is attached to form a 4- to 7-membered saturated heterocyclic ring. The 4- to 7-membered saturated heterocyclic ring is, for example, an azetidine ring or a pyrrolidine ring.

[0703] In one embodiment, P3 is a C1-C6 alkyl group or a C2-C6 alkynyl group, and is preferably a methyl group or a propynyl group.

[0704] In one embodiment, Q3 is a hydrogen atom.

[0705] The amino acid residue of core 3 is, for example, MeGly, Pro, PraGly or Aze(2).

[0706] In one embodiment, R4 is connected to P5 to form a divalent group, and a partial structure of the cyclic compound represented by formula (1): *-CR4Q4-CO-NP5-* is represented by the following formula:

[0707] [Formula 23]

[0708]

[0709] wherein T is a hydrogen atom or a halogen atom.

[0710] In one embodiment, R4 is a C1-C6 alkyl group, and is preferably a methyl group.

[0711] In one embodiment, Q4 is a hydrogen atom.

[0712] If the side chain of core 4 (R4) and the N-substituent of core 5 (P5) are linked together to form a divalent group, then preferably, the group at the position corresponding to R4 of MeAlgly and the group at the position corresponding to the N-substituent of core 5 (P5) can be linked by using the method described, for example, in the "General Method" described later.

[0713] In one embodiment, in formula (1), R5 is benzyl optionally substituted with one or more groups independently selected from the group consisting of C1-C6 alkyl and C1-C6 haloalkyl, and is preferably 4-(trifluoromethyl)benzyl, 4-methylbenzyl or 4-(1,1-difluoroethyl)benzyl.

[0714] In one embodiment, R5 is linked to R4 to form a divalent group. The details of this group are the same as those defined above.

[0715] In one embodiment, Q5 is a hydrogen atom.

[0716] In one embodiment, in formula (1), R6 is a hydrogen atom.

[0717] In one embodiment, R6 is C1-C6 alkyl, and is preferably methyl.

[0718] In one embodiment, Q6 is a hydrogen atom.

[0719] The amino acid residue of core 6 is, for example, MeGly.

[0720] In one embodiment, in formula (1), R7 is phenethyl optionally substituted with one or more groups independently selected from the group consisting of halogen, C1-C6 haloalkyl and C1-C6 alkoxy, and is preferably 3,5-difluoro-4-(trifluoromethyl)phenethyl, 3-chloro-4-(trifluoromethyl)phenethyl or 3-methoxy-4-(trifluoromethyl)phenethyl.

[0721] In one embodiment, P7 is a hydrogen atom.

[0722] In one embodiment, Q7 is a hydrogen atom.

[0723] The amino acid residue of core 7 is, for example, Hph(4-CF3-35-F2), Hph(4-CF3-3-C1) or Hph(4-CF3-3-OMe).

[0724] In one embodiment, in formula (1), R8 is connected to P8, the carbon atom to which R8 is attached, and the nitrogen atom to which P8 is attached to form a 4- to 7-membered saturated heterocycle. The 4- to 7-membered saturated heterocycle is optionally substituted with one or more groups independently selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl, and C1-C6 alkoxy, and is preferably optionally substituted with ethoxy, cyclopropyl, or isopropoxy. The 4- to 7-membered saturated heterocycle is, for example, a pyrrolidine ring or an azetidine ring.

[0725] In one embodiment, Q8 is a hydrogen atom.

[0726] The amino acid residue of core 8 is, for example, Hyp(Et), Hyp(iPr), Pro(4-cPr), or Aze(2).

[0727] In one embodiment, in formula (1), R9 is C1-C6 alkyl, or is connected to Q9 and the carbon atom to which R9 and Q9 are attached to form a 3- to 8-membered alicyclic ring. The 3- to 8-membered alicyclic ring is optionally substituted with one or more C1-C6 alkyl groups, such as two methyl groups. The 3- to 8-membered alicyclic ring is, for example, a cyclobutane ring or a cyclopentane ring.

[0728] In one embodiment, P9 is a hydrogen atom or C1-C6 alkyl, and is preferably a hydrogen atom or methyl.

[0729] The amino acid residue of core 9 is, for example, cLeu, cVal, cVal(3-Me2), or MecVal or Aib.

[0730] In one embodiment, in formula (1), R 10 is C1-C6 alkyl or C3-C8 cycloalkyl, and is preferably pentan-3-yl, cyclobutyl, 2,2-dimethylpropyl, 1-methylpropyl, or cyclopentyl.

[0731] In one embodiment, R 10 is C1-C6 alkyl, and is preferably methyl.

[0732] In one embodiment, Q 10 is a hydrogen atom.

[0733] The amino acid residue of core 10 is, for example, MeGly(cPent) or MeNva(3-Et).

[0734] In one embodiment, in formula (1), L 11 is -CH2-.

[0735] In one embodiment, in formula (1), R 11is di-C1 to C6 alkylaminocarbonyl or 4- to 8-membered cyclic aminocarbonyl, and is preferably dimethylaminocarbonyl, N-ethyl-N-methylaminocarbonyl, pyrrolidinylcarbonyl or piperidinylcarbonyl.

[0736] In one embodiment, P 11 is C1 to C6 alkyl, and is preferably methyl.

[0737] In one embodiment, Q 11 is a hydrogen atom.

[0738] In one embodiment, the compound of the present invention may be one or more compounds selected from the following, or a salt or a solvate thereof:

[0739] PP3169: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-[(1S)-1-methoxyethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0740] PP3194: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0741] PP3198: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoXO-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0742] PP3230: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoXO-27-prop-2-ynyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0743] PP3234: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoXO-27-prop-2-ynyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0744] PP3236: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1'-cyclobutane]-23-carboxamide,

[0745] PP3238: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1'-cyclobutane]-23-carboxamide,

[0746] PP3240: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1'-cyclobutane]-23-carboxamide,

[0747] PP3255: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-Cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,19,22,25,31,34,37,45-undecaooxo-13-prop-2-ynyl-38-(p-tolylmethyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4，8 .0 26，30 tetratetracont-42-ene-23,1′-cyclobutane]-17-carboxamide,

[0748] PP3290: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3-methoxy-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratriaconta hydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methano pyrrolo[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclooctatriacontene-39′,1″-cyclopropane]-9′-carboxamide,

[0749] PP3299: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-6′,16′-bis((S)-sec-butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontene-39′,1″-cyclopropane]-9′-carboxamide,

[0750] PP3327: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-butyl)-6′-cyclopentyl-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontene-39′,1″-cyclopropane]-9′-carboxamide,

[0751] PP3328: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-16′-cyclopentyl-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontene-39′,1″-cyclopropane]-9′-carboxamide,

[0752] PP3356: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-butyl)-6′-cyclopentyl-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontene-39′,1″-cyclopropane]-9′-carboxamide,

[0753] PP3406: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracont-39′,1″-cyclopropane]-9′-carboxamide,

[0754] PP3418: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracont-39′,1″-cyclopropane]-9′-carboxamide,

[0755] PP3438: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3-methoxy-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecazacyclotetracontacene-39′,1″-cyclopropane]-9′-carboxamide,

[0756] PP3440: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-6′-cyclopentyl-N,N,5′,8′,12′,18′,21′,31′-octamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecazacyclotetracontacene-39′,1″-cyclopropane]-9′-carboxamide,

[0757] PP3456: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-27-butyl-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3′,3′,4,19,22,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoXO-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0758] PP3457: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3′,3′,4,19,22,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoXO-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0759] PP3484: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-isobutyl-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoXO-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0760] PP3496: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-2-[[4-(difluoromethyl)phenyl]methyl]-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-20-(1-ethylpropyl)-12-isopropoxy-30-isopropyl-N,N,4,16,19,22,26,35-octamethyl-3,6,9,15,18,21,25,28,31,34,42-undecaoXO-32-prop-2-ynyl-27-(2,2,2-trifluoroethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0761] PP3516: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38E)-20-cyclobutyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-38-fluoro-27-isobutyl-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoXO-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclopentane]-23-carboxamide,

[0762] PP3517: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38E)-20-cyclobutyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-38-fluoro-27-isobutyl-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoXO-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclopentane]-23-carboxamide,

[0763] PP3521: (2S,8S,13S,19S,22S,26S,29S,35S,37E)-19-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-37-fluoro-26-isobutyl-N,N,4,18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-3,6,9,14,17,20,24,27,30,33,41-undecaooxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,15,18,21,25,28,31,34-undecaazatricyclo[33.5.1.0 10，13 hentetracont-37-ene-16,1′-cyclopentane]-22-carboxamide,

[0764] PP3522: (2S,8S,13S,19S,22S,26S,29S,35S,37E)-19-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-37-fluoro-26-isobutyl-N,N,4,18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-3,6,9,14,17,20,24,27,30,33,41-undecaooxo-2-(p-tolylmethyl)spiro[1,4,7,10,15,18,21,25,28,31,34-undecaazatricyclo[33.5.1.0 10,13 hentetracont-37-ene-16,1′-cyclopentane]-22-carboxamide,

[0765] PP3523: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38E)-20-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-38-fluoro-27-isobutyl-N,N,4,17,17,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-2-(p-tolylmethyl)-1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 dotetracont-38-ene-23-carboxamide, and

[0766] PP3529: (1S,4S,9S,12S,16S,19S,25S,27R,31S,37S,41E)-19-Cyclopentyl-27-ethoxy-42-fluoro-31-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,13,17,20,23,35-octamethyl-9-[(1S)-1-methylpropyl]-3,8,11,14,18,21,24,30,33,36,44-undecaooxo-12-propyl-37-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,7,10,13,17,20,23,29,32,35,38-undecaazatetracyclo[36.5.1.0 4 ,7 .0 25,29 tetratetracont-41-ene-22,1′-cyclobutane]-16-carboxamide. These compounds are included in the formula represented by formula (1).

[0767] In one embodiment, the compounds of the present invention are preferably compounds represented by formula (2):

[0768] [Formula 24]

[0769]

[0770] wherein

[0771] R1, P1, R2, R3, P3, P4, R5, P6, R7, R8, P8, R9, P9, Q9, R 10 , P 10 , R 11 , P 11 and T are the same as defined in formula (1).

[0772] For example, the following compounds may be included in formula (2).

[0773] PP3169: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-[(1S)-1-methoxyethyl]-N,N,3′,3′,4,19,22,26,32,35-decarmethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0774] PP3194: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0775] PP3198: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0776] PP3230: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-prop-2-ynyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0777] PP3234: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-prop-2-ynyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0778] PP3236: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 ′0，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0779] PP3238: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0780] PP3240: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0781] PP3255: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,19,22,25,31,34,37,45-undecaoxo-13-prop-2-ynyl-38-(p-tolylmethyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4，8 .0 26，30 pentatetracont-42-ene-23,1′-cyclobutane]-17-carboxamide,

[0782] PP3290: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3-methoxy-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopteropyrrolo[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide,

[0783] PP3299: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-6′,16′-bis((S)-sec-Butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopteropyrrolo[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide,

[0784] PP3327: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontene-39′,1″-cyclopropane]-9′-carboxamide,

[0785] PP3328: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-16′-cyclopentyl-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontene-39′,1″-cyclopropane]-9′-carboxamide,

[0786] PP3356: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontene-39′,1″-cyclopropane]-9′-carboxamide,

[0787] PP3406: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontene-39′,1″-cyclopropane]-9′-carboxamide,

[0788] PP3418: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontacene-39′,1″-cyclopropane]-9′-carboxamide,

[0789] PP3438: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3-methoxy-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontacene-39′,1″-cyclopropane]-9′-carboxamide,

[0790] PP3440: (6′S, 9′S, 13′S, 16′S, 22′S, 29′S, 35′S, 40a′S, Z)-16′-((S)-sec-Butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-6′-cyclopentyl-N,N,5′,8′,12′,18′,21′,31′-octamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopyrrolo[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontene-39′,1″-cyclopropane]-9′-carboxamide,

[0791] PP3456: (2S, 8S, 12R, 14S, 20S, 23S, 27S, 30S, 36S, 38Z)-27-butyl-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3′,3′,4,19,22,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10 ,1 4 tetracos-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0792] PP3457: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3′,3′,4,19,22,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,

[0793] PP3484: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-isobutyl-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, and

[0794] PP3496: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-2-[[4-(difluoromethyl)phenyl]methyl]-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-20-(1-ethylpropyl)-12-isopropoxy-30-isopropyl-N,N,4,16,19,22,26,35-octamethyl-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-32-prop-2-ynyl-27-(2,2,2-trifluoroethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide

[0795] In one embodiment, the present invention relates to a cyclic compound represented by the following formula (3) or a salt thereof or a solvate thereof.

[0796] [Formula 25]

[0797]

[0798] In the cyclic compound of formula (3), the ring is composed of 11 amino acid residues. In the present text, the amino acid residues having P1, Q1, R1, and L1 in formula (3) may be referred to as core 1, the amino acid residues having P2, Q2, and R2 may be referred to as core 2, the amino acid residues having P3, Q3, and R3 may be referred to as core 3, the amino acid residues having P4, Q4, and R4 may be referred to as core 4, the amino acid residues having P5, Q5, and R5 may be referred to as core 5, the amino acid residues having P6, Q6, and R6 may be referred to as core 6, the amino acid residues having P7, Q7, and R7 may be referred to as core 7, the amino acid residues having P8, Q8, and R8 may be referred to as core 8, the amino acid residues having P9 and R9 may be referred to as core 9 (however, core 9 is also referred to as hydroxycarboxylic acid), and the amino acid residues having P 10 , Q 10 and R 10 may be referred to as core 10, and the amino acid residues having P 11 , Q 11 , R 11 and L 11 may be referred to as core 11.

[0799] In one embodiment, in formula (1), L1 is a single bond or -CHM1-, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m -. M1 is a hydrogen atom, except when R1 and M1 form a 3- to 8-membered alicyclic ring. n and m are each independently 1 or 2. L1 is preferably a single bond or -CH2- or -CH2-S-CH2-.

[0800] In the case where L1 is -(CH2) n S(CH2) m -, specific examples of this group include -CH2SCH2-, -CH2CH2SCH2-, -CH2SCH2CH2-, and -CH2CH2SCH2CH2-.

[0801] In the case where L1 is -(CH2) n S(O)(CH2) mIn the case of, specific examples of the group include -CH2S(O)CH2-, -CH2CH2S(O)CH2-, -CH2S(O)CH2CH2-, and -CH2CH2S(O)CH2CH2-.

[0802] wherein L1 is -(CH2) n S(O)2(CH2) m -, specific examples of the group include -CH2S(O)2CH2-, -CH2CH2S(O)2CH2-, -CH2S(O)2CH2CH2-, and -CH2CH2S(O)2CH2CH2-.

[0803] In one embodiment, in formula (1), R1 is a hydrogen atom, a C1-C7 alkyl group, a C2-C7 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C2-C6 alkenyloxy C1-C6 alkyl group, a C1-C6 alkylthio C1-C6 alkyl group, a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl C1-C6 alkyl group, a C3-C8 cycloalkoxy C1-C6 alkyl group, a C7-C 14 aralkyl group or a 5- to 10-membered heteroaryl C1-C6 alkyl group, and each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, a C1-C6 alkyl group, an aminocarbonyl group (the amino group is -NH2, a mono-C1-C6 alkylamino group, a di-C1-C6 alkylamino group or a 4- to 8-membered cyclic amino group), and a C1-C6 alkylsulfonyl group.

[0804] In this embodiment, R1 is preferably a C1-C7 alkyl group optionally substituted by a di-C1-C6 alkylaminocarbonyl group; a C1-C6 haloalkyl group; a C1-C6 hydroxyalkyl group; a C2-C7 alkenyl group; a C2-C6 alkynyl group; a C1-C6 alkoxy C1-C6 alkyl group optionally substituted by one or more halogen atoms; a C2-C6 alkenyloxy C1-C6 alkyl group; a C1-C6 alkylthio C1-C6 alkyl group; a C7-C 14 aralkyl group; a 5- to 10-membered heteroaryl C1-C6 alkyl group; a C3-C8 cycloalkyl group; a C3-C8 cycloalkyl C1-C6 alkyl group; or a C3-C8 cycloalkoxy C1-C6 alkyl group.

[0805] In this embodiment, R1 is specifically, for example, methyl, 2-methylpropyl, isopropyl, ethyl, n-propyl, n-butyl, n-hexyl, n-pentyl, n-heptyl, neopentyl, 3-(dimethylamino)-3-oxopropyl, cyclohexylmethyl, cyclopentylmethyl, cyclobutylmethyl, cyclopropylmethyl, 3,3-difluoropropyl, 2,2,2-trifluoroethyl, 2,2-difluoroethyl, 3,3-dichloropropyl, cyclopropoxymethyl, hydroxymethyl, n-propoxymethyl, methoxymethyl, 1-methoxyethyl, 2-methoxyethyl, ethoxymethyl, (2,2,2-trifluoroethoxy)methyl, allyloxymethyl, methylthiomethyl, allyl, hex-5-en-1-yl, pent-4-en-1-yl, but-3-en-1-yl, propargyl, cyclobutyl, benzyl, phenethyl, 2-cyanobenzyl, 3-cyanobenzyl, 4-cyanobenzyl, 4-chlorobenzyl, 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 2-chlorobenzyl, 3-chlorobenzyl, 3,4-difluorobenzyl, 3,4-dichlorobenzyl, 2-methylbenzyl, 3-methylbenzyl, 4-methylbenzyl, pyridin-3-ylmethyl, thiazol-4-ylmethyl, (thiophen-3-yl)methyl, (thiophen-2-yl)methyl, cyclopropyl, bicyclo[1.1.1]pentyl or hept-6-en-1-yl.

[0806] In one embodiment, R1 is connected to P1, the carbon atom to which R1 is attached, and the nitrogen atom to which P1 is attached to form a 4- to 7-membered saturated heterocycle. In this case, the 4- to 7-membered saturated heterocycle is preferably an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring, a morpholine ring or a homopiperidine ring.

[0807] In one embodiment, R1 is connected to Q1 and the carbon atoms to which R1 and Q1 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle. In this case, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring or a cyclohexane ring, and the 4- to 7-membered saturated heterocycle is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[0808] In one embodiment, R1 is connected to M1, the carbon atom to which R1 is attached, and the carbon atom to which M1 is attached to form a 3- to 8-membered alicyclic ring. In this case, the 3- to 8-membered alicyclic ring is preferably a cyclopentane ring or a cyclohexane ring.

[0809] In one embodiment, R1 is connected to R5 to form a group selected from C1 to C 10 alkylene, C2 to C 10 alkenylene, C2 to C 10 alkynylene, C3 to C8 cycloalkylene, C6 to C 10 arylene, -CO-NR A -, -NR AA divalent group selected from the group consisting of -CO- and combinations of two or more of them. In this text, in cases where three or more groups are combined, two or more groups of the same type can be used. One or more carbon atoms constituting the divalent group may be replaced by one or more heteroatoms independently selected from N, O, and S. The divalent group is optionally substituted by one or more groups independently selected from the group consisting of halogen atoms and C1-C6 alkyl groups. Wherein the divalent group contains -CO-NR A - or -NR A -CO-, R A is a hydrogen atom or a C1-C6 alkyl group, and preferably a hydrogen atom or a methyl group.

[0810] The divalent group formed by connecting R1 and R5 together is preferably *-C1-C8 alkylene-C6-C 10 arylene-C1-C3 alkylene-#, *-C1-C8 alkylene-O-C6-C 10 arylene-C1-C3 alkylene-#, *-C2-C8 alkenylene-O-C6-C 10 arylene-C1-C3 alkylene-# or *-C2-C8 alkenylene-C6-C 10 arylene-C1-C3 alkylene-#, and each of them is optionally substituted by one or more groups independently selected from the group consisting of halogen atoms and C1-C6 alkyl groups. * represents the connection point of the carbon atom connected to R1, and # represents the connection point of the carbon atom connected to R5.

[0811] In one embodiment, R1 and R5 are connected together to form a divalent group, and the partial structure in the cyclic compound represented by formula (3): *-CR1Q1-L1-CO-NP2-CR2Q2-CO-NP3-CR3Q3-CO-NP4-CR4Q4-CO-NP5-CR5Q5-* can be represented by the following formula:

[0812] [Formula 26]

[0813]

[0814] wherein

[0815] X2 is -L1-CO-NP2-CR2Q2-CO-NP3-CR3Q3-CO-NP4-CR4Q4-CO-NP5-,

[0816] Y 31 、Y 32 、Y 33 、Y 34 、Y 35 、Y 36 、Y37 and Y 38 each independently represents a hydrogen atom or a C1-C6 alkyl group, and preferably represents a hydrogen atom or a methyl group,

[0817] n is 0, 1 or 2,

[0818] m is 0, 1, 2, 3 or 4; and

[0819] * represents a connection point to an adjacent atom.

[0820] In one embodiment, R1 and R5 are connected together to form a divalent group, and the partial structure in the cyclic compound represented by formula (3): *-CR1Q1-L1-CO-NP2-CR2Q2-CO-NP3-CR3Q3-CO-NP4-CR4Q4-CO-NP5-CR5Q5-* can be represented by the following formula:

[0821] [Formula 27]

[0822]

[0823] wherein

[0824] X2 is -L1-CO-NP2-CR2Q2-CO-NP3-CR3Q3-CO-NP4-CR4Q4-CO-NP5-,

[0825] n is 1, 2, 3 or 4; and

[0826] * represents a connection point to an adjacent atom.

[0827] In one embodiment, R4 and P5 are connected together to form a divalent group, and the partial structure *-CR4Q4-CO-NP5-* in the cyclic compound represented by formula (3) is represented by the following formula:

[0828] [Formula 28]

[0829]

[0830] and

[0831] R1 and R5 are connected together to form a divalent group, and the partial structure in the cyclic compound represented by formula (3): The partial structure in the cyclic compound represented by formula (3): *-CR1Q1-L1-CO-NP2-CR2Q2-CO-NP3-CR3Q3-CO-NP4-CR4Q4-CO-NP5-CR5Q5-* is represented by the following formula:

[0832] [Formula 29]

[0833]

[0834] wherein

[0835] X2 is -L1-CO-NP2-CR2Q2-CO-NP3-CR3Q3-CO-NP4-CR4Q4-CO-NP5-

[0836] n is 1, 2, 3 or 4; and

[0837] * represents a connection point to an adjacent atom.

[0838] This partial structure: *-CR1Q1-L 1- CO-NP2-CR2Q2-CO-NP3-CR3Q3-CO-NP4-CR4Q4-CO-NP5-CR5Q5-* is preferably:

[0839] [Formula 30]

[0840]

[0841] In one embodiment, R1 and R9 are connected together to form a divalent group selected from the group consisting of C1 to C 10 alkylene, C2 to C 10 alkenylene, C2 to C 10 alkynylene, C3 to C8 cycloalkylene, C6 to C 10 arylene, -CO-NR B -, -NR B -CO- and combinations of two or more of them. One or more carbon atoms constituting the divalent group may be replaced by one or more heteroatoms independently selected from N, O and S. The divalent group is optionally substituted by one or more groups independently selected from the group consisting of halogen atoms and C1 to C6 alkyl groups. Wherein the divalent group contains -CO-NR B - or -NR B -CO-, R B is a hydrogen atom or C1 to C6 alkyl, and preferably a hydrogen atom or methyl.

[0842] The divalent group formed by connecting R1 and R9 together is preferably *-C3 to C8 alkylene-#, *-C3 to C8 alkenylene-# or *-C1 to C3 alkylene-O-C1 to C8 alkylene-#, and each of them is optionally substituted by one or more groups independently selected from the group consisting of halogen atoms and C1 to C6 alkyl groups. * represents the connection point of the carbon atom connected to R1, and # represents the connection point of the carbon atom connected to R9.

[0843] In one embodiment, the partial structure in the cyclic compound represented by formula (3): *-CR1Q1-NP1-CO-L 11 -CR 11 Q 11 -NP 11- CO-CR 10 Q 10 -NP 10 -CO-CR9Q9-* can be represented by the following formula:

[0844] [Formula 31]

[0845]

[0846] wherein

[0847] X3 is -NP1-CO-L 11 -CR 11 Q 11 -NP 11 -CO-CR 10 Q 10 -NP 10 -CO-

[0848] Y 41 、Y 42 、Y 43 、Y 44 、Y 45 and Y 46 each independently is a hydrogen atom or a C1 to C6 alkyl group, and preferably is a hydrogen atom or a methyl group,

[0849] n is an integer from 0 to 3,

[0850] m is an integer from 0 to 5, and

[0851] * represents a connection point to an adjacent atom.

[0852] The partial structure: *-CR1Q1-NP1-CO-L 11 -CR 11 Q 11 -NP 11 -CO-CR 10 Q 10 -NP 10 -CO-CR9Q9-* is preferably:

[0853] [Formula 32]

[0854]

[0855] In one embodiment, P1 is a hydrogen atom or a C1-C6 alkyl group, and the C1-C6 alkyl group is optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group, and an aminocarbonyl group (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or a 4- to 8-membered cyclic amino group).

[0856] P1 is preferably a hydrogen atom or a C1-C6 alkyl group, and more preferably a hydrogen atom, a methyl group, or a n-propyl group.

[0857] In one embodiment, Q1 is a hydrogen atom or a C1-C6 alkyl group, and is preferably a hydrogen atom or a methyl group.

[0858] In one embodiment, M1 is a hydrogen atom or a C1-C6 alkyl group, and is preferably a hydrogen atom or a methyl group.

[0859] The amino acid residues of Core 1 are, for example, Azp(2), D-MeLeu, EtLeu, Leu, MeAbu, MeAbu(4-F2), MeAbu(4-F3), MeAhxe(2), MeAib, MeAla, MeAla(2-Thie), MeAla(3-Pyr), MeAla(3-Thie), MeAla(4-Thz), MeAla(cBu), MeAla(cPent), MeAla(cPr), MeAla(tBu), MeAlgly, MeAnon(2), MeAOC(2), MeAocte(2), MeCha, MeCys(Me), MeGln(Me2), MeGly(cBu), MeHnl, MeHph, MeHse(Me), MeLeu, MeNle, MeNva, MeNva(5-Cl2), MeNva(5-F2), MePhe, MePhe(2-Cl), MePhe(2-CN), MePhe(2-F), MePhe(2-Me), MePhe(34-Cl2), MePhe(34-F2), MePhe(3-Cl), MePhe(3-CN), MePhe(3-F), MePhe(3-Me), MePhe(4-Cl), MePhe(4-CN), MePhe(4-F), MePhe(4-Me), MePRA, MeSer, MeSer(Al), MeSer(cPr), MeSer(Et), MeSer(Me), MeSer(nPr), MeSer(Tfe), MeVal, R-MeAMPA, MeGly(cPr), nPrLeu or MeAnone(2), except when the side chain (R1) of Core 1 and the side chain (R5) of Core 5, or the side chain (R1) of Core 1 and the side chain (R9) of Core 9 are linked together to form a divalent group.

[0860] If the side chain (R1) of Core 1 and the side chain (R5) of Core 5, or the side chain (R1) of Core 1 and the side chain (R9) of Core 9 are linked together to form a divalent group, the group at the position of R1 corresponding to any one of the listed amino acid residues (preferably MeAhpe(2), MeAlgly, MeAnon(2), MeAOC(2), MeAocte(2), MeHnl, MeSer(Al) or MeAnone(2)) and the group at the position corresponding to the side chain (R5) of Core 5 or the side chain (R9) of Core 9 can be linked by using, for example, the method described in the "General Method" described later.

[0861] In one embodiment, in formula (3), R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, C3-C8 cycloalkoxy C1-C6 alkyl or a 4- to 7-membered heterocyclic group, and each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group and a C1-C6 alkylsulfonyl group.

[0862] In this embodiment, R2 is preferably C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C8 cycloalkyl optionally substituted by one or more halogen atoms, C1-C6 alkoxy C1-C6 alkyl, a 4- to 7-membered heterocyclic group or C3-C8 cycloalkyl.

[0863] In this embodiment, R2 is specifically, for example, ethyl, isopropyl, 1-methylpropyl, pentan-3-yl, 2,2,2-trifluoroethyl, hydroxymethyl, allyl, cyclopentyl, cyclobutyl, 3,3-difluorocyclobutyl, 1-methoxyethyl, 1-ethoxyethyl, 1-n-propoxyethyl, tetrahydropyran-4-yl, cyclopropyl, 2-methylpropyl or cyclohexyl.

[0864] In one embodiment, R2 is linked to P2, the carbon atom to which R2 is attached and the nitrogen atom to which P2 is attached to form a 4- to 7-membered saturated heterocycle. In this case, the 4- to 7-membered saturated heterocycle is preferably an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring or a morpholine ring.

[0865] In one embodiment, R2 is linked to Q2 and the carbon atoms to which R2 and Q2 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle. In this case, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring or a cyclohexane ring, and the 4- to 7-membered saturated heterocycle is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[0866] In one embodiment, R2 is linked to R 11 to form a group selected from C1-C 10 alkylene, C2-C 10 alkenylene, C2-C 10 alkynylene, C3-C8 cycloalkylene, C6-C 10 arylene, -CO-NR C -, -NR C -CO-, -C3-C8 alkylene-NR C -, -C3-C8 alkenylene-NR C- and a divalent group of the group consisting of two or more of them. One or more carbon atoms constituting the divalent group may be replaced by one or more heteroatoms independently selected from N, O, and S. The divalent group is optionally substituted by one or more groups independently selected from the group consisting of halogen atoms and C1-C6 alkyl groups. Wherein the divalent group contains -CO-NR C -, -NR C -CO-, -C3-C8 alkylene-NR C - or -C3-C8 alkenylene-NR C -, in the case of R C is a hydrogen atom or a C1-C6 alkyl group, and preferably a hydrogen atom or a methyl group.

[0867] The divalent group formed by connecting R2 and R 11 together is preferably *-C3-C8 alkylene-NR C -# or *-C3-C8 alkenylene-NR C -#,

[0868] and each of them is optionally substituted by one or more groups independently selected from halogen atoms and C1-C6 alkyl groups. * represents the connection point of the carbon atom connected to R2, and # represents the connection point of the carbon atom connected to R 11 connected.

[0869] In one embodiment, the partial structure in the cyclic compound represented by formula (3): *-CR2Q2-NP2-CO-L1-CR1Q1-NP1-CO-L 11 -CR 11 Q 11 -* can be represented by the following formula:

[0870] [Formula 33]

[0871]

[0872] where

[0873] X4 is -NP2-CO-L1-CR1Q1-NP1-CO-L 11 -,

[0874] Y 51 、Y 52 、Y 53 、Y 54 、Y 55 and Y 56 are each independently a hydrogen atom or a C1-C6 alkyl group, and preferably a hydrogen atom or a methyl group,

[0875] R Cis a hydrogen atom or a C1-C6 alkyl group, and is preferably a methyl group,

[0876] n is an integer from 1 to 6, and

[0877] * represents a point of attachment to an adjacent atom.

[0878] This partial structure: *-CR2Q2-NP2-CO-L1-CR1Q1-NP1-CO-L 11 -CR 11 Q 11 -* is preferably:

[0879] [Formula 34]

[0880]

[0881] In one embodiment, P2 is a hydrogen atom or a C1-C6 alkyl group, and the C1-C6 alkyl group is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group, and an aminocarbonyl group (the amino group is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or a 4- to 8-membered cyclic amino group).

[0882] P2 is preferably a hydrogen atom or a C1-C6 alkyl group, and more preferably hydrogen.

[0883] In one embodiment, Q2 is a hydrogen atom or a C1-C6 alkyl group, and is preferably a hydrogen atom.

[0884] The amino acid residue of core 2 is, for example, Algly, Ile, Val, Gly(cBu), Gly(cBu-3-F2), aIle, Nva(3-Et), Gly(cPent), Abu(4-F3), Abu, Thr(Me), Thr(Et), Thr(nPr), Gly(4-THP), Gly(cPr), Leu, or Chg, except when the side chain (R2) of core 2 and the side chain (R 11 ) of core 11 are linked together to form a divalent group.

[0885] If the side chain (R2) of core 2 and the side chain (R 11 ) of core 11 are linked together to form a divalent group, then the group at the position corresponding to R2 of any one of the listed amino acid residues (preferably Algly) and the group at the position corresponding to the side chain (R 11 ) of core 11 can be linked by using, for example, the method described in the "General Method" described later.

[0886] In one embodiment, in formula (3), R3 is a hydrogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl C1-C6 alkyl group, a C3-C8 cycloalkoxy C1-C6 alkyl group, or a C7-C 14 arylalkyl group, and each of them is optionally substituted by one or more groups independently selected from the group consisting of a hydroxyl group and an aminocarbonyl group (the amino group is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or a 4- to 8-membered cyclic amino group).

[0887] In this embodiment, R3 is preferably a hydrogen atom, a C1-C6 alkyl group, or a C7-C 14 arylalkyl group.

[0888] In this embodiment, R3 is specifically, for example, a hydrogen atom, a methyl group, an ethyl group, or a benzyl group.

[0889] In one embodiment, R3 is connected to P3, the carbon atom to which R3 is attached, and the nitrogen atom to which P3 is attached to form a 4- to 7-membered saturated heterocycle. The 4- to 7-membered saturated heterocycle is optionally substituted by one or more groups selected from the group consisting of a C1-C6 alkyl group and a C1-C6 alkoxy group. The C1-C6 alkyl group is preferably a methyl group, and the C1-C6 alkoxy group is preferably a methoxy group or an ethoxy group. The 4- to 7-membered saturated heterocycle is specifically, for example, a piperidine ring, a pyrrolidine ring, an azetidine ring, a morpholine ring, or a thiomorpholine ring. The 4- to 7-membered saturated heterocycle substituted by an alkyl group is specifically, for example, a 3-methylazetidine ring or a 3,3-dimethylazetidine ring, and the 4- to 7-membered saturated heterocycle substituted by an alkoxy group is specifically, for example, a 3-ethoxypyrrolidine ring.

[0890] In one embodiment, R3 is connected to Q3 and the carbon atom to which R3 and Q3 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle. In this case, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, or a cyclohexane ring, and the 4- to 7-membered saturated heterocycle is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[0891] In one embodiment, P3 is a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy C1-C6 alkyl group, or a C3-C8 cycloalkyl group, and each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, a C1-C6 alkoxy group, and a C1-C6 aminoalkyl group (the amino group is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or a 4- to 8-membered cyclic amino group, and the 4- to 8-membered cyclic amino group is optionally substituted by one or more halogen atoms).

[0892] P3 is preferably a hydrogen atom, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 cyanoalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C3-C8 cycloalkyl group or a C1-C6 alkoxy C1-C6 alkyl group. Specifically, P3 is, for example, a hydrogen atom, a methyl group, an ethyl group, a n-propyl group, a cyanomethyl group, a 2-fluoroethyl group, a 2,2-difluoroethyl group, an allyl group, a propargyl group, a cyclopropyl group or a 2-methoxyethyl group.

[0893] In one embodiment, Q3 is a hydrogen atom or a C1-C6 alkyl group, and is preferably a hydrogen atom or a methyl group.

[0894] The amino acid residues of core 3 are, for example, MeGly, Gly, Aze(2), Ala, D-Aze(2), (Me)Pro, Tmo(2), Mor(3), Pic(2), Hyp(Et), Pro, MeAla, nPrGly, EtGly, DfeGly, MfeGly, PraGly, allyl Gly, MeAbu, Aze(2)(3S-Me), Aze(2)(3R-Me), Aze(2)(3-Me2), 1-ACPrC, NCMeGly, cPrGly, MePhe, EtAla, Pro(4S-Me), cisHyp(Me) or (MeOEt)Gly.

[0895] In one embodiment, in formula (3), R4 is a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C2-C6 alkenoxy C1-C6 alkyl group or a C1-C6 carboxyalkyl group, and each of them is optionally substituted with one or more hydroxyl groups.

[0896] In this embodiment, R4 is preferably a hydrogen atom, a C1-C6 alkyl group, a C1-C6 hydroxyalkyl group, a C2-C6 alkenyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C2-C6 alkenoxy C1-C6 alkyl group or a C1-C6 carboxyalkyl group.

[0897] In this embodiment, R4 is specifically, for example, hydrogen, a methyl group, an ethyl group, an allyl group, a 2-methylallyl group, a but-3-en-1-yl group, a hydroxymethyl group, a n-propoxymethyl group, an allyloxymethyl group or a carboxymethyl group.

[0898] In one embodiment, in formula (3), R4 is linked to P4, the carbon atom to which R4 is attached, and the nitrogen atom to which P4 is attached to form a 4- to 7-membered saturated heterocycle. The 4- to 7-membered saturated heterocycle is optionally substituted with one or more C1-C6 alkyl groups. The C1-C6 alkyl group is preferably methyl. Specific examples of the 4- to 7-membered saturated heterocycle include an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring, and a morpholine ring, and specific examples of the alkyl-substituted 4- to 7-membered saturated heterocycle include a 3-methylazetidine ring.

[0899] In one embodiment, R4 is linked to Q4 and the carbon atoms to which R4 and Q4 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle. In this case, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, or a cyclohexane ring, and the 4- to 7-membered saturated heterocycle is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[0900] In one embodiment, R4 is linked to P5 to form a divalent group selected from the group consisting of C1-C 10 alkylene, C2-C 10 alkenylene, C2-C 10 alkynylene, C3-C8 cycloalkylene, 3- to 7-membered heteroalkylene, C6-C 10 arylene, -CO-NR D -, -NR D -CO-, and combinations of two or more thereof. One or more carbon atoms constituting the divalent group may be replaced with one or more heteroatoms independently selected from N, O, and S. The divalent group is optionally substituted with one or more groups independently selected from the group consisting of halogen atoms and C1-C6 alkyl groups. Wherein the divalent group contains -CO-NR D - or -NR D -CO-, R D is a hydrogen atom or a C1-C6 alkyl group, and is preferably a hydrogen atom or a methyl group.

[0901] The divalent group formed by linking R4 and P5 is preferably *-C3-C8 alkylene-#, *-C3-C8 alkenylene-#, *-C1-C3 alkylene-C3-C8 cycloalkylene-C1-C3 alkylene-#, *-C1-C3 alkylene-O-C3-C6 alkenylene-#, *-C1-C3 alkylene-CO-NR D-C1 to C3 alkylene-#, *-C1 to C3 alkylene-NRD-CO-C1 to C3 alkylene-# or *-C1 to C3 alkylene-3- to 7-membered heteroalkylene-C1 to C3 alkylene-#, and each of them is optionally substituted with one or more groups independently selected from the group consisting of halogen atoms and C1 to C6 alkyl groups. * represents the connection point of the carbon atom connected to R4, and # represents the connection point of the nitrogen atom connected to P5.

[0902] The divalent group formed by connecting R4 and P5 together is more preferably *-C4 to C5 alkylene-# or *-C4 to C5 alkenylene-#, and even more preferably *-C4 to C5 alkenylene-#.

[0903] In one embodiment, the partial structure of the cyclic compound represented by formula (3): *-CR4Q4-CO-NP5-* can be represented by the following formula:

[0904] [Formula 35]

[0905]

[0906] wherein

[0907] Y 11 is a hydrogen atom, a C1 to C6 alkyl group or a halogen atom, and is preferably a hydrogen atom, a methyl group or a fluorine atom,

[0908] Y 12 is a hydrogen atom, a C1 to C6 alkyl group or a halogen atom, and is preferably a hydrogen atom, a methyl group or a fluorine atom,

[0909] Y 13 is a hydrogen atom, a C1 to C6 alkyl group or a halogen atom, and is preferably a hydrogen atom, a methyl group or a fluorine atom, or

[0910] Y 13 is connected to Y 15 to form a C3 to C8 alkylene or -O-, preferably methylene or -O-,

[0911] Y 14 is a hydrogen atom or a C1 to C6 alkyl group, and is preferably a hydrogen atom,

[0912] Y 15 is a hydrogen atom, a C1 to C6 alkyl group or a halogen atom, and is preferably a hydrogen atom, a methyl group or a fluorine atom, provided that Y 13 and Y 15 in the case of forming a C3 to C8 alkylene or -O- is excluded,

[0913] Y 16 is a hydrogen atom or a C1 to C6 alkyl group, and is preferably a hydrogen atom or a methyl group,

[0914] Y 17 is a hydrogen atom or a C1-C6 alkyl group, and is preferably a hydrogen atom or a methyl group,

[0915] Y 18 is a hydrogen atom or a C1-C6 alkyl group, and is preferably a hydrogen atom or a methyl group,

[0916] R D is a hydrogen atom or a C1-C6 alkyl group, and is preferably a hydrogen atom or a methyl group,

[0917] n is 0, 1 or 2,

[0918] m is 0, 1 or 2; and

[0919] * represents a connection point to an adjacent atom.

[0920] This partial structure: *-CR4Q4-CO-NP5-* is preferably of the following formula:

[0921] [Formula 36]

[0922]

[0923] Furthermore, this partial structure: *-CR4Q4-CO-NP5-* is more preferably of the following formula:

[0924] [Formula 37]

[0925]

[0926] In one embodiment, P4 is a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group or a C1-C6 alkoxy C1-C6 alkyl group, or P4 and P5 are linked together to form a divalent group.

[0927] In the case where P4 is a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group or a C 1- C6 alkoxy C1-C6 alkyl group, each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group and an aminocarbonyl group (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino or a 4- to 8-membered cyclic amino group). In this case, P4 is preferably a C1-C6 alkyl group or a C1-C6 alkenyl group. Such P4 is specifically, for example, a methyl group, an ethyl group, a n-propyl group, a n-butyl group or a 3-butenyl group.

[0928] In the case where P4 and P5 are linked together to form a divalent group, the divalent group is selected from C1-C 10 alkylene, C2-C 10 alkenylene, C2-C10 An alkynylene group, a C3 to C8 cycloalkylene group, a C6 to C 10 arylene group, -CO-NR E -, -NR E -CO- and combinations of two or more thereof. One or more carbon atoms constituting the divalent group are optionally replaced by one or more heteroatoms selected from N, O, and S, and the divalent group is optionally substituted by one or more groups independently selected from the group consisting of halogen atoms and C1 to C6 alkyl groups. In the case where the divalent group contains -CO-NR E- or -NR E- CO-, RE is a hydrogen atom or a C1 to C6 alkyl group, and preferably is a hydrogen atom or a methyl group.

[0929] The divalent group formed by connecting P4 and P5 together is preferably a C3 to C8 alkylene group or a C3 to C8 alkenylene group, and each of them is optionally substituted by one or more groups independently selected from the group consisting of halogen atoms and C1 to C6 alkyl groups.

[0930] In one embodiment, the partial structure of the cyclic compound represented by formula (3): *-NP4-CR4Q4-CO-NP5-* can be represented by the following formula:

[0931] [Formula 38]

[0932]

[0933] Wherein

[0934] Y 21 、Y 22 、Y 23 、Y 24 、Y 25 and Y 26 are each independently a hydrogen atom or a C1 to C6 alkyl group, and preferably are a hydrogen atom or a methyl group,

[0935] n is 0, 1, or 2,

[0936] m is 0, 1, or 2; and

[0937] * represents the connection point to the adjacent atom.

[0938] The partial structure: *-NP4-CR4Q4-CO-NP5-* is preferably:

[0939] [Formula 39]

[0940]

[0941] In one embodiment, Q4 is a hydrogen atom or a C1-C6 alkyl group, and is preferably a hydrogen atom.

[0942] The amino acid residue of core 4 is, for example, Aze(2), Aze(2)(3S-Me), butenyl Gly, D-MeSer(Al), EtGly, MeAhxe(2), MeAlgly, MeGly, MeMethagly, MeSer, MeSer(Al), nBuGly, nPrGly, Algly or Asp, except when the side chain (R4) of core 4 and the N-substituent (P5) of core 5, or the N-substituent (P4) of core 4 and the N-substituent (P5) of core 5 are linked together to form a divalent group.

[0943] If the side chain (R4) of core 4 and the N-substituent (P5) of core 5 or the N-substituent (P4) of core 4 and the N-substituent (P5) of core 5 are linked together to form a divalent group, the group at the position corresponding to R4 or P4 in any one of the listed amino acid residues (preferably butenyl Gly, D-MeSer(Al), MeAhxe(2), MeAlgly, MeMethagly, MeSer(Al), Algly or MeAsp) and the group at the position corresponding to the N-substituent (P5) of core 5 can be linked by using, for example, the method described in the "General Method" described later.

[0944] In one embodiment, in formula (3), R5 is a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkenyloxycarbonyl C1-C6 alkyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl C1-C6 alkyl group, a C3-C8 cycloalkoxy C1-C6 alkyl group, a C7-C 14 aralkyl group, a C6-C 10 aryloxy C1-C6 alkyl group, a C7-C 14 aralkyloxy C1-C6 alkyl group or a 5- to 10-membered heteroaryl C1-C6 alkyl group, and each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 alkoxy group, a C2-C6 alkenyloxy group, a C1-C6 haloalkoxy group, a cyano group, a C1-C6 alkylsulfonyl group, a C2-C6 alkenyl group, a C3-C8 cycloalkyl group and a C1-C6 alkylcarbonyl group.

[0945] In this embodiment, R5 is preferably C2-C6 alkynyl; C2-C6 alkenyloxycarbonyl C1-C6 alkyl; C3-C8 cycloalkyl; C3-C8 cycloalkyl C1-C6 alkyl optionally substituted with one or more halogen atoms; C7-C 14 arylalkyl; or 5- to 10-membered heteroaryl C1-C6 alkyl; C3-C8 cycloalkyloxy C1-C6 alkyl; or C1-C6 alkoxy C1-C6 alkyl.

[0946] In this embodiment, R5 is specifically, for example, benzyl, 4-fluorobenzyl, 4-chlorobenzyl, 4-fluoro-2-methylbenzyl, 4-fluoro-3-methylbenzyl, 2-chloro-4-fluorobenzyl, 3-chloro-4-fluorobenzyl, 2,4-difluorobenzyl, 3,4-difluorobenzyl, 4-fluoro-2-methoxybenzyl, 4-fluoro-3-methoxybenzyl, 4-bromobenzyl, 4-iodobenzyl, allyloxycarbonylmethyl, 4-methylbenzyl, 4-methoxybenzyl, 4-allyloxybenzyl, 4-(trifluoromethyl)benzyl, 4-(trifluoromethoxy)benzyl, propargyl, cyclopentyl, cyclohexylmethyl, 4,4-difluorocyclohexylmethyl, thiazol-2-ylmethyl, benzothiazol-6-ylmethyl, or benzothiazol-5-ylmethyl, cyclobutoxymethyl, 3-methylbutoxymethyl, 4-vinylbenzyl, 4-chloro-2-fluorobenzyl, 4-(difluoromethyl)benzyl, 4-(trifluoromethyl)benzyl, 4-ethylbenzyl, 2-fluoro-4-methylbenzyl, 3-fluoro-4-methylbenzyl, 4-(1,1-difluoroethyl)benzyl, 4-cyclopropylbenzyl, 4-isopropylbenzyl, 4-methoxybenzyl, 4-acetylbenzyl or 1,1-difluoroindol-5-ylmethyl.

[0947] In one embodiment, R5 and R8 are linked together to form a C4-C8 alkylene group. The C4-C8 alkylene group is preferably -(CH2)8-.

[0948] In one embodiment, in formula (3), R5 is linked to P5, the carbon atom to which R5 is attached, and the nitrogen atom to which P5 is attached to form a 4- to 7-membered saturated heterocycle. In this case, the 4- to 7-membered saturated heterocycle is preferably an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring or a morpholine ring.

[0949] In one embodiment, in formula (3), R5 and R1 are linked together to form a divalent group. The details of this group are the same as those defined above.

[0950] In one embodiment, in formula (3), R5 is connected to Q5 and the carbon atom to which R5 and Q5 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring. In this case, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring or a cyclohexane ring, and the 4- to 7-membered saturated heterocyclic ring is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[0951] In one embodiment, P5 is a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy C1-C6 alkyl group or a C3-C8 cycloalkyl C1-C6 alkyl group, and the C1-C6 alkyl group is optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group, an aminocarbonyl group (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino or a 4- to 8-membered cyclic amino group) and an amino group.

[0952] P5 is preferably a C1-C6 alkyl group, a C3-C6 alkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C3-C8 cycloalkyl C1-C6 alkyl group or a C1-C6 aminoalkyl group. Specific examples of such P5 are, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, isopentyl, neohexyl, 3-fluoropropyl, 3,3,3-trifluoropropyl, allyl, 2-methylallyl, propargyl, 3-butenyl, 2-methoxyethyl, 3-methoxypropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl or 2-aminoethyl.

[0953] In one embodiment, in formula (3), P5 is connected to R4 to form a divalent group. The details of this group are the same as those defined above.

[0954] In one embodiment, in formula (3), P5 is connected to P4 to form a divalent group. The details of this group are the same as those defined above.

[0955] In one embodiment, Q5 is a hydrogen atom or a C1-C6 alkyl group, and is preferably a hydrogen atom.

[0956] The amino acid residues of core 5 are, for example, allyl Phe, allyl Phe(4-CF3), allyl Phe(4-Cl), allyl Phe(4-F), allyl Phe(4-Me), allyl Phe(4-OCF3), allyl Phe(4-OMe), allyl PRA, butenyl Ala(2-Thz), butenyl Ala(5-Bzt), butenyl Ala(6-Bzt), butenyl Cha, butenyl Cha(4-F2), butenyl Phe(24-F2), butenyl Phe(2-Cl-4-F), butenyl Phe(34-F2), butenyl Phe(3-Cl-4-F), butenyl Phe(4-Br), butenyl Phe(4-CF3), butenyl Phe(4-F), butenyl Phe(4-F-2-Me), butenyl Phe(4-F-2-OMe), butenyl Phe(4-F-3-Me), butenyl Phe(4-F-3-OMe), butenyl Phe(4-Me), cBuMePhe(4-CF3), cBuMePhe(4-Me), cHexMePhe(4-Me), cPentMePhe(4-CF3), cPentMePhe(4-Me), cPrMePhe(4-CF3), cPrMePhe(4-Me), EtGly(cPent), EtPhe, EtPhe(4-CF3), EtPhe(4-F), EtPhe(4-Me), iBuPhe(4-CF3), iBuPhe(4-Me), iPenPhe(4-CF3), iPenPhe(4-Me), iPrPhe(4-Me), MeOEtPhe(4-CF3), MeOEtPhe(4-Me), MeOnPrPhe(4-CF3), MeOnPrPhe(4-Me), MePhe, MePhe(4-CF3), MePhe(4-F), MePhe(4-Me), MethaPhe(4-CF3), MfpPhe(4-CF3), nBuPhe(4-CF3), nBuPhe(4-Me), neoHexPhe(4-CF3), neoHexPhe(4-Me), nPrCha(4-F2), nPrGly(cPent), nPrPhe, nPrPhe(4-CF3), nPrPhe(4-F), nPrPhe(4-Me), nPrPhe(4-OCF3), nPrTyr(Al), nPrTyr(Me), PraPhe(4-CF3), PraPhe(4-Me), TfpPhe(4-CF3), TfpPhe(4-Me), nPrSer(cBu), nPrSer(iPen), butenyl Phe(4-CH=CH2), butenyl Phe,Butenyl Phe(4-Cl-2-F), butenyl Phe(4-CHF2), NH2EtPhe(4-CF3), butenyl Phe(4-Et), butenyl Phe(2-F-4-Me), butenyl Phe(3-F-4-Me), butenyl Phe(4-CF2Me), butenyl Phe(4-cPr), butenyl Phe(4-iPr), butenyl Phe(4-OMe), butenyl Phe(4-Ac), butenyl Ala(5-Inda-1-F2) or allyl Phe(4-CF3), with the exception of the case where the side chain (R5) of core 5 and the side chain (R1) of core 1, or the N-substituent (P5) of core 5 and the side chain (R4) or N-substituent (P4) of core 4 are linked together to form a divalent group.

[0957] If the side chain (R5) of core 5 and the side chain (R1) of core 1, or the N-substituent (P5) of core 5 and the side chain (R4) or N-substituent (P4) of core 4 are linked together to form a divalent group, the group at the position of R5 corresponding to any one of the listed amino acid residues (preferably allyl Phe, allyl Phe(4-CF3), allyl Phe(4-Cl), allyl Phe(4-F), allyl Phe(4-Me), allyl Phe(4-OCF3), allyl Phe(4-OMe), butenyl Ala(2-Thz), butenyl Ala(5-Bzt), butenyl Ala(6-Bzt), butenyl Cha, butenyl Cha(4-F2), butenyl Phe(24-F2), butenyl Phe(2-Cl-4-F), butenyl Phe(34-F2), butenyl Phe(3-Cl-4-F), butenyl Phe(4-Br), butenyl Phe(4-CF3), butenyl Phe(4-F), butenyl Phe(4-F-2-Me), butenyl Phe(4-F-2-OMe), butenyl Phe(4-F-3-Me), butenyl Phe(4-F-3-OMe), butenyl Phe(4-Me), MethaPhe(4-CF3), nPrTyr(Al), butenyl Phe(4-CH=CH2), butenyl Phe, butenyl Phe(4-Cl-2-F), butenyl Phe(4-CHF2), NH2EtPhe(4-CF3), butenyl Phe(4-Et), butenyl Phe(2-F-4-Me), butenyl Phe(3-F-4-Me), butenyl Phe(4-CF2Me), butenyl Phe(4-cPr), butenyl Phe(4-iPr), butenyl Phe(4-OMe), butenyl Phe(4-Ac), butenyl Ala(5-Inda-1-F2) or allyl Phe(4-CF3)) and the group at the position corresponding to the side chain (R1) of core 1, or the group at the position of P5 corresponding to any one of those amino acid residues and the group at the position corresponding to the side chain (R4) or N-substituent (P4) of core 4 can be linked by using, for example, the method described in the "General Method" described later.

[0958] In one embodiment, in formula (3), R6 is a hydrogen atom or a C1-C6 alkyl group, and preferably a hydrogen atom or a C1-C3 alkyl group. Specific examples of R6 include a hydrogen atom and a methyl group.

[0959] In one embodiment, in formula (3), R6 is connected to P6, the carbon atom to which R6 is attached, and the nitrogen atom to which P6 is attached to form a 4- to 7-membered saturated heterocycle. In this case, the 4- to 7-membered saturated heterocycle is preferably an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring, or a morpholine ring.

[0960] In one embodiment, in formula (3), R6 is connected to Q6 and the carbon atoms to which R6 and Q6 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle. In this case, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, or a cyclohexane ring, and the 4- to 7-membered saturated heterocycle is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[0961] In one embodiment, P6 is a C1-C6 alkyl or a C3-C8 cycloalkyl, and each of them is optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group, and an aminocarbonyl group (the amino group is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or a 4- to 8-membered cyclic amino group).

[0962] P6 is preferably a C1-C6 alkyl. Such P6 is specifically, for example, methyl, ethyl, or n-propyl.

[0963] In one embodiment, Q6 is a hydrogen atom or a C1-C6 alkyl, and is preferably a hydrogen atom.

[0964] The amino acid residue of core 6 is, for example, MeGly, D-Pro, D-MeAla, EtGly, or nPrGly.

[0965] In one embodiment, in formula (3), R7 is a C6-C 10 aryloxy C1-C6 alkyl, a C7-C 14 arylalkyl, a C7-C 14 arylalkoxy C1-C6 alkyl, or a 5- to 10-membered heteroaryl C1-C6 alkyl, and each of them is optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a C1-C6 alkyl, a C1-C6 haloalkyl, a C2-C6 alkynyl, a C1-C6 alkoxy, a C1-C6 haloalkoxy, a cyano group, a C1-C6 alkylsulfonyl group, SF5, and a C3-C8 cycloalkyl.

[0966] In this embodiment, R7 is preferably a C7-C optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a C1-C6 alkyl, a C1-C6 haloalkyl, a C1-C6 haloalkoxy, a C1-C6 alkoxy, and a C3-C8 cycloalkyl. 14an aralkyl group; or a C1-C6 alkyl group of a 5- to 10-membered heteroaryl optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a C1-C6 alkoxy group, and a C3-C8 cycloalkyl group.

[0967] In this embodiment, R7 is more preferably a phenethyl group optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a C1-C6 alkoxy group, and a C3-C8 cycloalkyl group; or a C1-C6 alkyl group of a 5- to 10-membered heteroaryl optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 haloalkoxy group, a C1-C6 alkoxy group, and a C3-C8 cycloalkyl group.

[0968] In this embodiment, R7 is specifically, for example, 4-methylphenethyl, 2-fluoro-4-(trifluoromethyl)phenethyl, 3-fluoro-4-(trifluoromethyl)phenethyl, 3-fluoro-4-(difluoromethoxy)phenethyl, 3,5-difluoro-4-(trifluoromethyl)phenethyl, 3,4,5-trifluorophenethyl, 2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenethyl, 3-chloro-4-(trifluoromethyl)phenethyl, 4-chloro-3,5-difluorophenethyl, 3,4-dichlorophenethyl, 3,5-dichloro-4-(trifluoromethyl)phenethyl, 3,4,5-trichlorophenethyl, 3-methoxy-4-(trifluoromethyl)phenethyl, 3-methyl-4-(trifluoromethyl)phenethyl, benzothiazol-5-ylethyl, benzothiazol-6-ylethyl, 4-chloro-3,5-dimethylphenethyl, 4-(trifluoromethyl)phenethyl, 4-chlorophenethyl, 3-ethyl-4-trifluoromethylphenethyl, 3-methoxy-4-trifluoromethylphenethyl, 3-chloro-4-trifluoromethylphenethyl, 3,5-difluoro-4-trifluoromethylphenethyl, 4-chloro-3-fluoro-5-methoxyphenethyl, 4-ethyl-3-fluoro-5-methoxyphenethyl, 3,5-dimethyl-4-difluoromethylphenethyl, 3-methyl-5-fluoro-4-difluoromethylphenethyl, 3-methyl-5-chloro-4-difluoromethylphenethyl, 3-methoxy-5-fluoro-4-difluoromethylphenethyl, 2-(4-fluoro-2,3-dihydrobenzofuran-6-yl)ethyl, 3-cyclopropyl-4-trifluoromethylphenethyl, 2-(1,1-difluoroindan-6-yl)ethyl, 4-cyclopropyl-3-fluorophenethyl, 4-cyclopropyl-3-chlorophenethyl, 4-cyclopropyl-3-methylphenethyl, 4-ethyl-3-fluorophenethyl, 4-ethyl-3-chlorophenethyl, 3,5-difluoro-4-difluoromethylphenethyl, 4-chloro-3-trifluoromethylphenethyl, 4-chloro-3-methoxyphenethyl, 2-(7-fluoroindan-5-yl)ethyl, 3-methoxy-4-cyclopropylphenethyl, 3,5-dimethyl-4-cyclopropylphenethyl, 3,5-dichloro-4-difluoromethylphenethyl, 3-methoxy-4-difluoromethylphenethyl, 3-methoxy-4-ethylphenethyl, 2-(7-chlorobenzothiophen-5-yl)ethyl, 2-(2,3-dimethylbenzothiophen-5-yl)ethyl, 2-(2-fluoro-3-methylbenzothiophen-5-yl)ethyl, 2-(1,2,3-trimethylindol-5-yl)ethyl, 2-(7-chloro-1-methylindol-5-yl)ethyl, 2-(1,3-dimethylindol-6-yl)ethyl or 2-(1-methylindol-6-yl)ethyl.

[0969] In one embodiment, in formula (3), R7 is connected to P7, the carbon atom to which R7 is attached and the nitrogen atom to which P7 is attached together to form a 4- to 7-membered saturated heterocycle. In this case, the 4- to 7-membered saturated heterocycle is preferably an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring or a morpholine ring.

[0970] In one embodiment, in formula (3), R7 is joined to Q7 and the carbon atom to which R7 and Q7 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring. In this case, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring or a cyclohexane ring, and the 4- to 7-membered saturated heterocyclic ring is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[0971] In one embodiment, P7 is a hydrogen atom or a C1-C6 alkyl group, and the C1-C6 alkyl group is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group and an aminocarbonyl group (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino or a 4- to 8-membered cyclic amino group). P7 is preferably a hydrogen atom.

[0972] In one embodiment, Q7 is a hydrogen atom or a C1-C6 alkyl group, and is preferably a hydrogen atom.

[0973] The amino acid residues of core 7 are, for example, Hph(4-CF3-35-F2), Hph(34-C12), Hph(4-Cl-35-F2), Abu(5-Bzt), Hph(4-CF3-3-Cl), Hph(4-CF3-3-OMe), Hph(4-CF3-3-Me), Hph(4-CF3-35-C12), Hph(345-C13), Hph(3-F-4-OCHF2), Abu(6-Bzt), Hph(4-CF3-2356-F4), Hph(4-CF3-2-F), Hph(4-Me), Hph(4-CF3-3-F), Hph(345-F3), Hph(4-Cl-35-Me2), Hph(4-CF3), Hph(4-Cl), Hph(4-CF3-3-Et), Hph(4-Cl-3-F-5-OMe), Hph(4-Et-3-F-5-OMe), Hph(4-CHF2-35-Me2), Hph(4-CHF2-3-F-5-Me), Hph(4-CHF2-3-C1-5-Me), Hph(4-CHF2-3-F-5-OMe), Abu(6-DHBzfr-4-F), Hph(4-CF3-3-cPr), Abu(5-Inda-1-F2), Hph(4-cPr-3-F), Hph(4-cPr-3-Cl), Hph(4-cPr-3-Me), Hph(4-Et-3-F), Hph(3-Cl-4-Et), Hph(4-CHF2-35-F2), Hph(4-Cl-3-CF3), Hph(4-Cl-3-OMe), Abu(6-Inda-4-F), Hph(4-cPr-3-OMe), Hph(4-cPr-35-Me2), Hph(4-CHF2-35-C12), nph(4-CHF2-3-OMe), Hph(4-Et-3-OMe), Abu(5-Bzt-7-Cl), Abu(5-Bzt-23-Me2), Abu(5-Bzt-2-F-3-Me), Abu(123-Me3-6-Indo), Abu(1-Me-7-Cl-5-Indo), Abu(13-Me2-6-Indo), or Abu(1-Me-6-Indo).

[0974] In one embodiment, in formula (3), R8 is a hydrogen atom, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy C1-C6 alkyl, C2-C6 alkenyloxycarbonyl C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, C6-C 10Aryloxy C1-C6 alkyl, C7-C 14 Aralkyl, C7-C 14 Aralkyloxy C1-C6 alkyl, 5- to 10-membered heteroaryl C1-C6 alkyl or 5- to 10-membered heteroaryloxy C1-C6 alkyl, and each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a carboxyl group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkoxy group, a cyano group, an aminocarbonyl group (the amino group is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino or a 4- to 8-membered cyclic amino group, and each of them is optionally substituted by a halogen), a 4- to 7-membered heteroalkylidene group, a protected 4- to 7-membered heteroalkylidene group, a 4- to 7-membered heterocyclic group and a protected 4- to 7-membered heterocyclic group.

[0975] In this embodiment, R8 is preferably a hydrogen atom, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 alkoxy C1-C6 alkyl group or a C3-C8 cycloalkyl C1-C6 alkyl group.

[0976] In this embodiment, R8 is specifically, for example, a hydrogen atom, a methyl group, a n-butyl group, a 2,2-difluoroethyl group, a 3,3-difluoropropyl group, a cyclohexylmethyl group, a methoxymethyl group, a n-propoxymethyl group, a 3-methylbutoxymethyl group or an ethyl group.

[0977] In one embodiment, in formula (3), R8 is linked to R5 to form a C4-C8 alkylene group. The C4-C8 alkylene group is preferably -(CH2)8-.

[0978] In one embodiment, in formula (3), R8, the carbon atom to which R8 is attached and the nitrogen atom to which P8 is attached can be linked together to form a 4- to 7-membered saturated heterocycle. The 4- to 7-membered saturated heterocycle is optionally fused with a saturated carbocyclic ring or an aromatic ring. The 4- to 7-membered saturated heterocycle is optionally substituted by one or more halogen atoms, oxo, one or more C1-C6 alkyl groups, C1-C6 haloalkyl groups, C3-C8 spiroalkyl groups, C6-C 10 An aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered cyclic amino group (the cyclic amino group is optionally substituted by one or more halogen atoms) or OS8. S8 is a hydrogen atom, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 hydroxyalkyl group, a C3-C8 cycloalkyl C1-C6 alkyl group, a 4- to 7-membered heterocyclic group, C7-C 14 An aralkyl group (the aralkyl group is optionally substituted by one or more halogen atoms, C1-C6 alkyl groups, C1-C6 alkoxy groups or C1-C6 haloalkoxy groups), a 5- to 10-membered heteroaryl C1-C6 alkyl group or a C3-C8 cycloalkyl group.

[0979] In the case where R8 and P8 form a 4- to 7-membered saturated heterocycle, the 4- to 7-membered saturated heterocycle is preferably an azetidine ring, pyrrolidine ring, piperidine ring, piperazine ring, morpholine ring, thiomorpholine ring or azepane ring. Each of these saturated heterocycles is optionally fused to a 3- to 8-membered saturated carbocyclic ring (preferably a cyclopropane ring, cyclohexane ring) or a 6- to 10-membered aromatic ring (preferably a benzene ring). In the case where the 4- to 7-membered saturated heterocycle has one or more substituents, the 4- to 7-membered saturated heterocycle is preferably substituted with one or more halogen atoms; one or more C1-C6 alkyl groups; C1-C6 haloalkyl; hydroxy; 4- to 7-membered heteroepoxy; oxo; C1-C6 alkoxy; C3-C8 cycloalkyl C1-C6 alkoxy; C1-C6 haloalkoxy; a 4- to 8-membered cyclic amino group optionally substituted with one or more halogen atoms; C3-C8 spiroalkyl; or C3-C8 cycloalkoxy.

[0980] In one embodiment, in formula (3), R8 and Q8 may be joined together with the carbon atom to which they are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle. In this case, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, cyclobutane ring, cyclopentane ring or cyclohexane ring, and the 4- to 7-membered saturated heterocycle is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[0981] In one embodiment, P8 is a hydrogen atom, C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy C2-C6 alkenyl, C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, 4- to 7-membered heterocyclic group C1-C6 alkyl, C6-C 10 aryl, C7-C 14 aralkyl, 5- to 10-membered heteroaryl or 5- to 10-membered heteroaryl C1-C6 alkyl, and each of them is optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, hydroxy, C1-C6 alkoxy and aminocarbonyl (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino or 4- to 8-membered cyclic amino).

[0982] P8 is preferably a hydrogen atom or C1-C6 alkyl, and more preferably methyl, ethyl, n-propyl or n-butyl.

[0983] In one embodiment, Q8 is a hydrogen atom or C1-C6 alkyl, and is preferably a hydrogen atom or methyl.

[0984] The amino acid residues of the core 8 are, for example, Hyp(Et), Pro(4-F2), Pro(4S-Me), Hyp(3)(Et(2-F2)), Pro(4R-CF3), Pro(4R-F), Pro, MeAbu(4-F2), MeNva(5-F2), Hyp(iBu), Hyp(nPr), MeNle, MeCha, MeSer(iPen), D-MeSer(nPr), MeAla, MeSer(Me), MeSer(nPr), EtGly, nBuGly, nPrGly, Ala, Aze(2), Mor(3), Tmo(2), Pic(2), Pro(4S-F), Hyp(Me), cisHyp(Me), cisHyp(3)(Me), cisHyp(3)(nPr), cisHyp(3)(Et), Hyp(3)(nPr), Hyp(3)(Et), Hyp(3)(Me), Hyp(3)(Me-cPent), Hyp(3)(Me-cPr), Hyp(3)(nBu), Hyp(3)(Tfp), Hyp(Me-cPent), Hyp(Me-cPr), Hyp(nBu), Hyp(Et(2-F2)), Hyp(Tfp), cisHyp(3), Hyp(3), Hyp, cisHyp, Pro(3S4-Cl), (Me)Pro, cisPro(4-pip - 4-F2), Pro(4-pip - 4-F2), EtAla, Pro(4-keto), Pro(4-Me2), MeGly, Pic(2)(4-F2), Pro(4-cPr), cisHyp(Et(2-F2)), cisHyp(Et), Hyp(THP), Nle, Gly, Pro(4R-Me), MeAbu, Pro(4R-Et), Pro(4R-nPr), Hyp(iPr), Hyp(cBu), Hyp(cPent) or Azp(2).

[0985] In one embodiment, in formula (3), R9 is a hydrogen atom, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy C1-C6 alkyl, C2-C6 alkenyloxy C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, C7-C 14an aralkyl group or a 5- to 10-membered heteroaryl C1-C6 alkoxy C1-C6 alkyl group, and each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 alkoxy group, a C1-C6 haloalkoxy group, an aminocarbonyl group (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino or a 4- to 8-membered cyclic amino group), and a C1-C6 alkylsulfonyl group.

[0986] In this embodiment, R9 is preferably a C1-C6 alkyl group, a C2-C6 alkenyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C1-C6 alkenoxy C1-C6 alkyl group, a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl C1-C6 alkyl group or a C7-C 14 aralkyl.

[0987] In this embodiment, R9 is specifically, for example, a methyl group, an ethyl group, a n-propyl group, an isopropyl group, a 1-methylpropyl group, a 2-methylpropyl group, an allyl group, a cyclopropyl group, a cyclohexylmethyl group, a methoxymethyl group, a tert-butoxymethyl group, an allyloxymethyl group or a benzyl group.

[0988] In one embodiment, in formula (3), R9 is linked to Q9 and the carbon atom to which R9 and Q9 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring. The 3- to 8-membered alicyclic ring or the 4- to 7-membered saturated heterocyclic ring is optionally substituted by one or more halogen atoms or one or more C1-C6 alkyl groups. In this case, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclopentene ring or a cyclohexane ring, and the 4- to 7-membered saturated heterocyclic ring is preferably an oxetane ring, a tetrahydrofuran ring or a tetrahydropyran ring.

[0989] In one embodiment, in formula (3), R9 is linked to R1 to form a divalent group. The details of this group are the same as those defined above.

[0990] In one embodiment, Q9 is a hydrogen atom or a C1-C6 alkyl group, and is preferably a hydrogen atom or a methyl group.

[0991] The amino acid residues of core 9 are, for example, HO(Me)Abu, HO(Me)Cha, HO(Me)Gly(cPr), HO(Me)Ile, HO(Me)Leu, HO(Me)Nva, HO(Me)Phe, HO(Me)Ser(Al), HO(Me)Ser(Me), HO(Me)Ser(tBu), HO(Me)Val, HO1-ACPrC, HOAib, HOAoxeC, HOAthpc, HOcHex, HOcHex(4-F2), HOcLeu, HOcLeu(34-d), HOcVal, HOcVal(3-F2), HOcVal(3-Me2), D-HO(Me)Algly, D-HOAla or D-HOAlgly, and preferably HOcVal, provided that the side chain (R9) of core 9 and the side chain (R1) of core 1 are linked together to form a divalent group.

[0992] If the side chain (R9) of core 9 and the side chain (R1) of core 1 are linked together to form a divalent group, then the group at the position corresponding to R9 of any one of the listed amino acid residues (preferably D-HO(Me)Algly, HO(Me)Ser(Al) or D-HOAlgly) and the group at the position corresponding to the side chain (R1) of core 1 can be linked by using, for example, the method described in the "General Method" described later.

[0993] In one embodiment, in formula (3), R 10 is C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxy C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, C3-C8 cycloalkoxy C1-C6 alkyl or C7-C 14 arylalkyl, and each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group and a C1-C6 alkylsulfonyl group.

[0994] In this embodiment, R 10 is preferably C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy C1-C6 alkyl, C3-C8 cycloalkyl or C3-C8 cycloalkyl C1-C6 alkyl.

[0995] R 10 is specifically, for example, methyl, isopropyl, 1-methylpropyl, 2-methylpropyl, tert-butyl, pentan-3-yl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, n-propoxymethyl, cyclobutyl, cyclopentyl, cyclohexyl, 2,2-dimethylpropyl, cyclobutylmethyl or cyclopropylmethyl.

[0996] In one embodiment, in formula (3), R 10 and P 10 , R 10 the carbon atom to which it is attached and P 10 the nitrogen atom to which it is attached may be joined together to form a 4- to 7-membered saturated heterocyclic ring. In this case, the 4- to 7-membered saturated heterocyclic ring is preferably an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring or a morpholine ring.

[0997] In one embodiment, in formula (3), R 10 and Q 10 and also R 10 and Q 10 the carbon atoms to which they are attached may be joined together to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring. In this case, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring or a cyclohexane ring, and the 4- to 7-membered saturated heterocyclic ring is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[0998] In one embodiment, P 10 is a hydrogen atom or a C1-C6 alkyl group, and the C1-C6 alkyl group is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group and an aminocarbonyl group (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino or a 4- to 8-membered cyclic amino group). P 10 is preferably a hydrogen atom or a C1-C6 alkyl group, and more preferably a hydrogen atom, a methyl group or an ethyl group.

[0999] In one embodiment, Q 10 is a hydrogen atom or a C1-C6 alkyl group, and is preferably a hydrogen atom or a methyl group.

[1000] The amino acid residues of core 10 are for example MeGly(cPent), MeNva(3-Et), MeLeu, MeVal, MeIle, MeChg, MeTle, MeAbu(4-F2), MeaIle, MeAbu(4-F3), MeGly(cBu), Gly(cPent), EtGly(cPent), Leu, MeAla(tBu), MeAla(cBu) or MeAla(cPr).

[1001] In one embodiment, in formula (3), L 11 is a single bond or -CHM 11 -, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m-or -(CH2) n S(O)2(CH2) m -, and n and m are each independently 1 or 2. M 11 is a hydrogen atom, provided that R 11 and M 11 form a 3- to 8-membered alicyclic ring. L 11 is preferably -CH2- or -CH2-S-CH2-.

[1002] In the case where L 11 is -(CH2) n S(CH2) m -, specific examples of the group include -CH2SCH2-, -CH2CH2SCH2-, -CH2SCH2CH2-, and -CH2CH2SCH2CH2-.

[1003] In the case where L 11 is -(CH2) n S(O)(CH2) m -, specific examples of the group include -CH2S(O)CH2-, -CH2CH2S(O)CH2-, -CH2S(O)CH2CH2-, and -CH2CH2S(O)CH2CH2-.

[1004] In the case where L 11 is -(CH2) n S(O)2(CH2) m -, specific examples of the group include -CH2S(O)2CH2-, -CH2CH2S(O)2CH2-, -CH2S(O)2CH2CH2-, and -CH2CH2S(O)2CH2CH2-.

[1005] In one embodiment, in formula (3), R 11 is linked to R2 together to form a divalent group. Details of the group are the same as those defined above.

[1006] In one embodiment, in formula (3), R 11 is a hydrogen atom, C1 to C6 alkyl, C2 to C6 alkenyl, C2 to C6 alkynyl, C1 to C6 alkoxy C1 to C6 alkyl, C7 to C 14an aralkyl or an aminocarbonyl (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, N-C1-C6 alkyl-N-C2-C6 alkenylamino or a 4- to 8-membered cyclic amino group) or a C3-C8 cycloalkyl, and each of them is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, oxo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, a 4- to 7-membered heterocyclic group, aminocarbonyl (the amino group being -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino or a 4- to 8-membered cyclic amino group) and C1-C6 alkylsulfonyl.

[1007] In this embodiment, R 11 is preferably C1-C6 alkyl; di-C1-C6 alkylaminocarbonyl; N-C1-C6 alkyl-N-C2-C6 alkenylaminocarbonyl; N-C1-C6 alkyl-N-C1-C6 alkoxy C1-C6 alkylaminocarbonyl; a cyclic aminocarbonyl optionally substituted by one or more C1-C6 alkyl groups or a 4- to 7-membered heterocyclic group; or C3-C8 cycloalkyl.

[1008] In this embodiment, R 11 is specifically, for example, methyl, dimethylaminocarbonyl, diethylaminocarbonyl, N-ethyl-N-methylaminocarbonyl, N-allyl-N-methylaminocarbonyl, N-propyl-N-methylaminocarbonyl, N-butenyl-N-methylaminocarbonyl, N-pentenyl-N-methylaminocarbonyl, N-hexenyl-N-methylaminocarbonyl, N-methoxyethyl-N-methylaminocarbonyl, azetidinylcarbonyl, pyrrolidinylcarbonyl, 3,3-dimethylpyrrolidinylcarbonyl, piperidinylcarbonyl, 4-methylpiperidinylcarbonyl, morpholinylcarbonyl, morpholino carbonyl, oxazolidin-3-ylcarbonyl, 1-(oxetane-3-yl)-piperazin-4-ylcarbonyl, 3-oxa-8-azabicyclo[3.2.1]octan-8-ylcarbonyl, cyclopropyl or 2-methylpropyl.

[1009] In one embodiment, in formula (3), R 11 is a peptide chain containing 1 to 4 amino acid residues. In this case, the 1 to 4 amino acid residues constituting the peptide chain may each be a natural amino acid residue or a non-natural amino acid residue, and may be the same or different.

[1010] In which the L of the core 11 11 is -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m or r-(CH2) n S(O)2(CH2) mIn the case of -, R 11 is preferably aminocarbonyl (the amino group being -NH2, mono-C1 to C6 alkylamino, di-C1 to C6 alkylamino or 4- to 8-membered cyclic amino).

[1011] In one embodiment, in formula (3), R 11 and P 11 、R 11 The carbon atom to which it is attached and P 11 The nitrogen atom to which it is attached may be joined together to form a 4- to 7-membered saturated heterocyclic ring. In this case, the 4- to 7-membered saturated heterocyclic ring is preferably an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring or a morpholine ring.

[1012] In one embodiment, in formula (3), R 11 and Q 11 as well as R 11 and Q 11 The carbon atoms to which they are attached may be joined together to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring. In this case, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring or a cyclohexane ring, and the 4- to 7-membered saturated heterocyclic ring is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[1013] In one embodiment, in formula (3), R 11 may be joined to M 11 、R 11 The carbon atom to which it is attached and M 11 The carbon atoms to which they are attached are joined together to form a 3- to 8-membered alicyclic ring. In this case, the 3- to 8-membered alicyclic ring is preferably a cyclopentane ring or a cyclohexane ring.

[1014] In one embodiment, in formula (3), M 11 is a hydrogen atom.

[1015] In one embodiment, P 11 is a hydrogen atom, C1 to C6 alkyl, C3 to C8 cycloalkyl C1 to C6 alkyl or C7 to C 14 arylalkyl, and the C1 to C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1 to C6 alkoxy group and aminocarbonyl (the amino group being s-NH2, mono-C1 to C6 alkylamino, di-C1 to C6 alkylamino or 4- to 8-membered cyclic amino).

[1016] P 11 is preferably a hydrogen atom, C1 to C6 alkyl, C3 to C8 cycloalkyl C1 to C6 alkyl or C7 to C 14 arylalkyl. Such P 11Specifically, for example, a hydrogen atom, a methyl group, an ethyl group, a n-propyl group, a 2-cyclobutylethyl group, a 2-cyclopentylethyl group, or a phenethyl group.

[1017] In one embodiment, Q 11 is a hydrogen atom or a C1-C6 alkyl group, and preferably a hydrogen atom.

[1018] In one embodiment, R 11 is preferably -CONR 11A R 11B wherein R 11A and R 11B are each independently a hydrogen atom or a C1-C6 alkyl group (preferably a methyl group), or R 11A and R 11B are joined together with the nitrogen atom to which they are attached to form a 4- to 8-membered saturated heterocyclic ring. The 4- to 8-membered saturated heterocyclic ring is optionally substituted with one or more groups independently selected from the group consisting of one or more halogen atoms (preferably fluorine atoms), one or more oxo groups, one or more C1-C6 alkyl groups (preferably C1-C4 alkyl groups), and 4- to 7-membered heterocyclic groups (preferably oxetan-3-yl).

[1019] The amino acid residues of core 11 are, for example, MeAsp-MeN allyl, MeAsp-MeN butenyl, MeAsp-MeN pentenyl, MeAsp - MeN hexenyl, MeAsp-MeNEt, MeAsp-NMe2, MeAsp-mor, D-3-MeAbu, MeAsp - pyrro, MeAsp-age, MeAsp-MeNnPr, MeAsp-MeNEtOMe, MeAsp-mor(35-bicyc), MeAsp-NEt2, MeAsp-pip, D-MeAsp-NMe2, MeAsp-mor(35-diMe), EtAsp-NMe2, D-3-Abu, D-Pro-(C#CH2), Asp-NMe2, MeAsp-mor(26-bicyc), cPentEtAsp-NMe2, cPentEtAsp - mor, EtAsp-mor, phenethyl Asp -mor, cBuEtAsp-mor, nPrAsp-mor, phenethyl Asp-NMe2, cBuEtAsp-NMe2, nPrAsp-NMe2, Asp-mor, MeAsp-pyrro(3-Me2), MeAsp-pip(4-Me), MeAsp-piz(oxe), MeAsp-oxz, MeGly(cPr) or nPrLeu, provided that the side chain (R 11 ) of core 11 and the side chain (R2) of core 2 are linked together to form a divalent group.

[1020] If the side chain (R 11 ) of core 11 and the side chain (R2) of core 2 are linked together to form a divalent group, then the group at the position of R11 corresponding to any one of the listed amino acid residues (preferably MeAsp-MeN allyl, MeAsp-MeN butenyl, MeAsp-MeN pentenyl or MeAsp-MeN hexenyl) and the group at the position corresponding to the side chain (R2) of core 2 can be linked by using the method described, for example, in the "General Method" described later.

[1021] In the case where L 11 is -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m or -(CH2) n S(O)2(CH2) m -, the amino acid residue of core 11 is specifically, for example, MeCys(AcOH)-NMe2.

[1022] In one embodiment, in formula (3), at least three, at least four, at least five or at least six of P1 to P 11 are not hydrogen atoms.

[1023] In one embodiment, in formula (3), at least three, at least four, at least five or at least six of P1 to P 11 are preferably C1-C6 alkyl groups, and each of the C1-C6 alkyl groups is preferably methyl or ethyl.

[1024] In one embodiment, the present invention may be a compound of formula (3), wherein one of -CO-L1- and -CO-L 11 - is -(CH2) n C≡CCH2S(CH2) m -, -(CH2) n CH=CHCH2S(CH2) m-or -(CH2) n+3 S(CH2) m - substitution, n is 1, 2 or 3, and m is 1 or 2. -S- can be oxidized to -S(O)- or -S(O)2-. In which -CO-L1- is via -(CH2) n C≡CCH2S(CH2) m -, -(CH2) n CH=CHCH2S(CH2) m - or -(CH2) n+3 S(CH2) m - substitution, L 11 is a single bond; in which -CO-L 11 - is via -(CH2) n C≡CCH2S(CH2) m -, -(CH2) n CH=CHCH2S(CH2) m - or -(CH2) n+3 S(CH2) m - substitution, L1 is a single bond. In formula (1), other groups except L1 and L 11 are as described above.

[1025] In one embodiment, the present invention relates to a cyclic compound represented by the following formula (3) or a salt thereof or a solvate thereof.

[1026] [Formula 40]

[1027]

[1028] In the cyclic compound of formula (3), the ring is composed of 11 amino acid residues. Herein, the amino acid residue having P1, Q1, R1 and L1 in formula (3) can be called core 1, the amino acid residue having P2, Q2 and R2 can be called core 2, the amino acid residue having P3, Q3 and R3 can be called core 3, the amino acid residue having P4, Q4 and R4 can be called core 4, the amino acid residue having P5, Q5 and R5 can be called core 5, the amino acid residue having P6, Q6 and R6 can be called core 6, the amino acid residue having P7, Q7 and R7 can be called core 7, the amino acid residue having P8, Q8 and R8 can be called core 8, the amino acid residue having P9 and R9 can be called core 9 (but core 9 is also called hydroxycarboxylic acid), the amino acid residue having P 10 , Q 10 and R 10 can be called core 10, and the amino acid residue having P 11 , Q 11 , R 11 and L 11The amino acid residue of can be referred to as Core 11.

[1029] In one embodiment, in formula (1), L1 is a single bond.

[1030] In one embodiment, in formula (1), R1 is a C1-C6 alkyl group, a C2-C6 alkynyl group or a C3-C8 cycloalkyl group optionally substituted with one or more groups independently selected from the group consisting of halogen atoms, C3-C6 cycloalkyl groups and C1-C6 alkoxy groups, and is preferably 2-methylpropyl, n-butyl, 2,2,2-trifluoroethyl, bicyclo[1.1.1]pentyl or n-propyl.

[1031] In one embodiment, P1 is a hydrogen atom or a C1-C6 alkyl group, and is preferably a hydrogen atom or a methyl group.

[1032] In one embodiment, Q1 is a hydrogen atom.

[1033] In one embodiment, in formula (1), R2 is a C1-C6 alkyl group or a C3-C6 cycloalkyl group, and is preferably isopropyl, cyclopropyl or 1-methylpropyl.

[1034] In one embodiment, P2 is a hydrogen atom.

[1035] In one embodiment, Q2 is a hydrogen atom.

[1036] The amino acid residues of Core 2 are, for example, Val, Gly(cPent) or Ile.

[1037] In one embodiment, in formula (1), R3 is a hydrogen atom.

[1038] In one embodiment, R3 is connected to P3, the carbon atom to which R3 is attached and the nitrogen atom to which P3 is attached to form a 4- to 7-membered saturated heterocycle. The 4- to 7-membered saturated heterocycle is specifically, for example, an azetidine ring or a pyrrolidine ring.

[1039] In one embodiment, P3 is a C1-C6 alkyl group or a C2-C6 alkynyl group, and is preferably a methyl group or a propargyl group.

[1040] In one embodiment, Q3 is a hydrogen atom.

[1041] The amino acid residues of Core 3 are, for example, MeGly, Pro, PraGly or Aze(2).

[1042] In one embodiment, R4 is connected to P5 to form a divalent group, and in this case, the partial structure *-CR4Q4-CO-NP5-* in the cyclic compound represented by formula (1) is represented by the following formula:

[1043] [Formula 41]

[1044]

[1045] wherein

[1046] T is a hydrogen atom or a halogen atom.

[1047] In one embodiment, R4 is a C1-C6 alkyl group, and preferably is a methyl group.

[1048] In one embodiment, Q4 is a hydrogen atom.

[1049] In the case where the side chain (R4) of core 4 and the N-substituent (P5) of core 5 are linked together to form a divalent group, preferably, the group at the position corresponding to R4 of MeAlgly and the group at the position corresponding to the N-substituent (P5) of core 5 can be linked by using a method described, for example, in the "general method" described later.

[1050] In one embodiment, in formula (1), R5 is a benzyl group optionally substituted with one or more groups independently selected from the group consisting of a C1-C6 alkyl group and a C1-C6 haloalkyl group, and preferably is 4-(trifluoromethyl)benzyl, 4-methylbenzyl or 4-(1,1-difluoroethyl)benzyl.

[1051] In one embodiment, P5 is linked with R4 to form a divalent group. Details of this group are the same as those defined above.

[1052] In one embodiment, Q5 is a hydrogen atom.

[1053] In one embodiment, in formula (1), R6 is a hydrogen atom.

[1054] In one embodiment, R6 is a C1-C6 alkyl group, and preferably is a methyl group.

[1055] In one embodiment, Q6 is a hydrogen atom.

[1056] The amino acid residue of core 6 is, for example, MeGly.

[1057] In one embodiment, in formula (1), R7 is a phenethyl group optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a C1-C6 haloalkyl group and a C1-C6 alkoxy group, and preferably is 3,5-difluoro-4-(trifluoromethyl)phenethyl, 3-chloro-4-(trifluoromethyl)phenethyl or 3-methoxy-4-(trifluoromethyl)phenethyl.

[1058] In one embodiment, P7 is a hydrogen atom.

[1059] In one embodiment, Q7 is a hydrogen atom.

[1060] The amino acid residue of core 7 is, for example, Hph(4-CF3-35-F2), Hph(4-CF3-3-Cl), or Hph(4-CF3-3-OMe).

[1061] In one embodiment, in formula (1), R8 is linked to P8, the carbon atom to which R8 is attached, and the nitrogen atom to which P8 is attached to form a 4- to 7-membered saturated heterocyclic ring. The 4- to 7-membered saturated heterocyclic ring is optionally substituted by one or more groups independently selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl, and C1-C6 alkoxy, and is preferably optionally substituted by ethoxy, cyclopropyl, or isopropoxy. The 4- to 7-membered saturated heterocyclic ring is specifically, for example, a pyrrolidine ring or an azetidine ring.

[1062] In one embodiment, Q8 is a hydrogen atom.

[1063] The amino acid residue of core 8 is, for example, Hyp(Et), Hyp(iPr), Pro(4-cPr), or Aze(2).

[1064] In one embodiment, in formula (1), R9 is C1-C6 alkyl, or is linked to Q9 and the carbon atom to which R9 and Q9 are attached to form a 3- to 8-membered alicyclic ring. The 3- to 8-membered alicyclic ring is optionally substituted by one or more C1-C6 alkyl groups, such as two methyl groups. Specific examples of the 3- to 8-membered alicyclic ring include a cyclobutane ring and a cyclopentane ring.

[1065] The amino acid residue of core 9 is, for example, HOcLeu, HOcVal, HOcVal(3-Me2), or HOAib.

[1066] In one embodiment, in formula (1), R 10 is C1-C6 alkyl or C3-C8 cycloalkyl, and is preferably pentan-3-yl, cyclobutyl, 2,2-dimethylpropyl, 1-methylpropyl, or cyclopentyl.

[1067] In one embodiment, R 10 is C1-C6 alkyl, and is preferably methyl.

[1068] In one embodiment, Q 10 is a hydrogen atom.

[1069] The amino acid residue of core 10 is, for example, MeGly(cPent), MeNva(3-Et), MeAla(tBu), MeIle, or MeGly(cBu).

[1070] In one embodiment, in formula (1), L 11 is -CH2-.

[1071] In one embodiment, in formula (1), R 11 is di-C1-C6 alkylaminocarbonyl or 4- to 8-membered cyclic aminocarbonyl, and is preferably dimethylaminocarbonyl.

[1072] In one embodiment, R 11 is C1-C6 alkyl, and is preferably methyl.

[1073] In one embodiment, Q 11 is a hydrogen atom.

[1074] In one embodiment, the compound of the present invention is a compound represented by formula (4):

[1075] [Formula 42]

[1076]

[1077] wherein

[1078] R1, P1, R2, R3, P3, P4, R5, P6, R7, R8, P8, R9, Q9, R 10 , P 10 , R 11 , P 11 and T are the same as those defined in formula (3).

[1079] For example, the following compounds may be included in formula (4).

[1080] PP3376: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[16-oxa-1,4,7,10,19,22,26,29,32,35-decaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1'-cyclobutane]-23-carboxamide,

[1081] PP3382: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-27-isobutyl-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-2-(p-tolylmethyl)spiro[16-oxa-1,4,7,10,19,22,26,29,32,35-decaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, and

[1082] PP3394: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-2-(p-tolylmethyl)spiro[16-oxa-1,4,7,10,19,22,26,29,32,35-decaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide

[1083] In one embodiment, the cyclic compounds of the invention have high selectivity for KRAS. In one embodiment, the cyclic compounds of the invention selectively inhibit KRAS. Without wishing to be bound by a particular theory, the divalent group formed by R4 and P5 interacts with His95 of KRAS, and thereby high selectivity for KRAS can be achieved. Although three isoforms of the RAS protein are known, namely HRAS, KRAS, and NRAS, His95 is only present in KRAS. Thus, a compound that specifically interacts with His95 of KRAS can inhibit KRAS with high selectivity relative to NRAS and / or HRAS.

[1084] In the present invention, the sources of NRAS, HRAS, and KRAS are not particularly limited and may include those derived from various animals such as humans, mice, rats, rabbits, dogs, cats, cows, horses, pigs, goats, rhesus monkeys, cynomolgus monkeys, chimpanzees, and chickens, but preferably HRAS, KRAS, and NRAS of human origin. The amino acid sequence of human-derived NRAS is shown in SEQ ID NO: 1, the amino acid sequence of human-derived HRAS is shown in SEQ ID NO: 2, and the amino acid sequence of human-derived KRAS is shown in SEQ ID NO: 3.

[1085] In one embodiment, the cyclic compound of the present invention has a KRAS inhibitory activity that is 3 times or more the NRAS inhibitory activity and / or the HRAS inhibitory activity. In one embodiment, the cyclic compound of the present invention has a KRAS binding activity that is 3 times or more the NRAS binding activity and / or the HRAS binding activity.

[1086] In one embodiment, the cyclic compound of the present invention has a KRAS inhibitory activity that is 5 times, 7 times, 10 times, 15 times, or 20 times or more the NRAS inhibitory activity and / or the HRAS inhibitory activity. In one embodiment, the cyclic compound of the present invention has a KRAS binding activity that is 5 times, 7 times, 10 times, 15 times, or 20 times or more the NRAS binding activity and / or the HRAS binding activity.

[1087] In the present invention, the KRAS inhibitory activity relative to the NRAS inhibitory activity and / or the HRAS inhibitory activity can be determined by the ratio of the KRAS inhibitory activity of the cyclic compound of the present invention to the NRAS inhibitory activity and / or the HRAS inhibitory activity of the cyclic compound of the present invention. For example, when the ratio is defined as [IC 50 value of the cyclic compound of the present invention relative to NRAS and / or HRAS] divided by [IC 50 value of the cyclic compound of the present invention relative to KRAS], a larger value of this ratio means that the KRAS inhibitory activity is higher than the NRAS inhibitory activity and / or the HRAS inhibitory activity, or in other words, the cyclic compound of the present invention has a high KRAS selective inhibitory activity. On the other hand, a smaller value of this ratio means that the KRAS inhibitory activity is lower than the NRAS inhibitory activity and / or the HRAS inhibitory activity, or in other words, the cyclic compound of the present invention has a low KRAS selective inhibitory activity.

[1088] In the present invention, the KRAS binding activity relative to the NRAS binding activity and / or the HRAS binding activity can be determined by the ratio of the KRAS binding activity of the cyclic compound of the present invention to the NRAS binding activity and / or the HRAS binding activity of the cyclic compound of the present invention. For example, when the ratio is defined as [KD value relative to NRAS and HRAS] divided by [KD relative to KRAS], a larger value means that the KRAS binding activity is higher than the NRAS binding activity and / or the HRAS binding activity, or in other words, the binding selectivity for KRAS is higher than that for NRAS and / or HRAS. On the other hand, a smaller value means that the KRAS binding activity is lower than the NRAS binding activity and / or the HRAS binding activity, or in other words, the binding selectivity for KRAS is lower than that for NRAS and / or HRAS.

[1089] In the present invention, "interaction" means non-covalent interactions such as electrostatic interactions (including ionic bonds, hydrogen bonds, and dipole interactions), van der Waals interactions (including hydrophobic interactions), and the like. For example, it means CH-π interaction, NH-π interaction, S-π interaction, cation-π interaction, or halogen-π interaction. The interaction in the present invention may or may not be mediated by another molecule such as a water molecule, but is preferably not mediated by another molecule such as a water molecule.

[1090] In the present invention, whether the 95th amino acid residue histidine (denoted as His95 or H95) in the human KRAS wild-type protein interacts with the cyclic compound can be determined by the interatomic distance of its non-hydrogen atoms (in the case of bonding via another molecule such as a water molecule, the interatomic distance between their non-hydrogen atoms does not consider such another molecule). When the interatomic distance is 5.1 angstroms or less, it can be determined that their non-hydrogen atoms interact with each other. In some embodiments, the interatomic distance between two interacting non-hydrogen atoms can be, for example, or less, or less, or less, or less, or less, or less, or less, or less, or or less. Additionally, the interatomic distance can be or greater, or greater, or or greater.

[1091] In the present invention, the interatomic distance can be measured, for example, by analyzing the three-dimensional structure of a complex of human KRAS wild-type protein and the cyclic compound of the present invention. Specifically, a crystal of a complex of human KRAS wild-type protein and the cyclic compound of the present invention is prepared. X-ray diffraction measurement is performed on the crystal to obtain X-ray diffraction intensity data of the space group, unit cell, etc. The obtained X-ray diffraction intensity data is applied to programs well-known to those skilled in the art for initial structure or refined structure determination, such as Coot (Emsley, P. et al., 2010), Phenix (Adams, P.D. et al., 2010), Phaser (J. Appl. Cryst. 40: 658-674 (2007)), Refmac5 (Acta Cryst. D67: 355-467 (2011)) and ARP / wARP (Cohen, S.X. et al., 2008), and thereby the three-dimensional structure of the complex of human KRAS wild-type protein and the cyclic compound of the present invention can be determined.

[1092] Once the three-dimensional structure of the complex of human KRAS wild-type protein and the cyclic compound of the present invention is determined, the interatomic distance can be measured by methods well-known to those skilled in the art. For example, by allowing a software program (such as Discovery Studio 2020 Client, MOE (Molecular Operating Environment) or Maestro) used in molecular modeling or molecular simulation to read the structural information of the complex of the cyclic compound of the present invention and human KRAS wild-type protein, and using functions incorporated in the software program (such as the distance monitor function in the case of Discovery Studio 2020 Client) to measure the interatomic distance. Details of the conditions and criteria used by the software to determine the presence or absence of interactions can be viewed in the manuals, specifications, etc. attached to the software (for example, in the case of Discovery Studio 2020 Client, details of the conditions and criteria used to determine the presence or absence of interactions can be viewed by opening the web page of the manual from the help button, selecting "Receptor-Ligand Interaction Tools", then selecting "Theory - Receptor-Ligand Interaction", and further selecting "Non-bonded Interactions").

[1093] Crystals of the complex of the human KRAS wild-type protein and the cyclic compound of the present invention can also be obtained by methods well known to those skilled in the art. For example, a solution containing the cyclic compound of the present invention is mixed with a solution containing the human KRAS wild-type protein to obtain a complex of the human KRAS wild-type protein and the cyclic compound of the present invention. Crystals of the complex of the human KRAS wild-type protein and the cyclic compound of the present invention can be prepared by crystallization methods well known to those skilled in the art (such as vapor diffusion methods, batch methods (batch or microbatch methods), dialysis methods, or reverse diffusion methods). Known vapor diffusion methods are the sitting drop method, the hanging drop method, and the sandwich drop method.

[1094] The human wild-type KRAS protein can also be obtained by methods known to those skilled in the art. For example, the human wild-type KRAS protein can be prepared by using recombinant polypeptide expression methods of cells, but this method is not limited thereto. In one embodiment, the nucleic acid encoding the human wild-type KRAS protein of the present invention is inserted into a suitable expression vector, the vector is introduced into a suitable cell, the transformed cell is cultured, and the expressed protein is isolated and purified. Such proteins can also be expressed as a fusion protein with another protein to facilitate purification. For example, methods for preparing a fusion protein with maltose-binding protein (vector pMAL series sold by New England BioLabs, USA) using Escherichia coli as a host, methods for preparing a fusion protein with glutathione-S-transferase (GST) (vector pGEX series sold by Amersham Pharmacia Biotech), methods for preparing a protein with a histidine tag added (pET series of Novagen), and methods for preparing a protein with a HAT tag added can be used. The host cell is not particularly limited as long as it is suitable for expressing recombinant proteins, and in addition to the above-mentioned Escherichia coli, yeast, various animal and plant cells, insect cells, etc. can also be used. Various methods known to those skilled in the art can be used to introduce the vector into the host cell. For example, for introducing into Escherichia coli, a method involving calcium ion introduction (Mandel, M., Higa, A. (1970) Journal of Molecular Biology, 53, 158-162 and Hanahan, D. (1983) Journal of Molecular Biology, 166, 557-580) can be used. The protein expressed in the host cell can be purified and recovered from the host cell or its cell culture or culture supernatant by methods known to those skilled in the art. When the protein is expressed as a fusion protein together with the above-mentioned maltose-binding protein, HAT tag, etc., affinity purification and gel filtration chromatography (size exclusion chromatography, SEC) purification can be easily performed. In affinity chromatography purification and SEC purification, AKTAxpress TM equipment (GE Healthcare), NGC TM chromatography system (Bio-Rad), BioLogic DuoFlow TM chromatography system (Bio-Rad), etc.

[1095] The energy between atoms can also be measured by methods well known to those skilled in the art. For example, the energy between atoms can be easily calculated by allowing molecular simulation programs well known to those skilled in the art (such as Discovery Studio 2020 Client, MOE (Molecular Operating Environment), or Maestro) to read the three-dimensional structure of the substance to be measured and select the force field to be used for calculation (such as Amber or CHARM) and the atoms for energy calculation according to the instructions of the program. For example, in the case of the Discovery Studio 2020 Client, the interaction energy calculation function can be used to calculate the energy between atoms.

[1096] In a non-limiting embodiment, in the complex of the cyclic compound of the present invention with the human KRAS wild-type protein, the cyclic compound of the present invention interacts with His95 in the human KRAS wild-type protein.

[1097] Without wishing to be bound by a particular theory, it is believed that the formation of a complex between the cyclic compound of the present invention and the human KRAS wild-type protein in this way is associated with the contribution to the high binding activity of the cyclic compound to the human KRAS wild-type protein, and furthermore, has binding selectivity with respect to HRAS and NRAS.

[1098] The present invention also relates to unnatural amino acids for use in the production of the cyclic compounds of the present invention. In one embodiment, the unnatural amino acids of the present invention are N-protected unnatural amino acids, which are used in the production of peptide compounds using solid-phase synthesis methods, and in another embodiment, the unnatural amino acids of the present invention are unnatural amino acids having a free amino group obtained by removing the protecting group from the N-protected unnatural amino acids. Examples of protecting groups for N-protected unnatural amino acids include Fmoc group, Boc group, Cbz group, Alloc group, p-nitrobenzenesulfonyl group, dinitrophenylsulfonyl group, t-Bu group, trityl group, and cumyl group. Among them, Fmoc group, Boc group, Cbz group, and Alloc group are preferred, and Fmoc group is more preferred.

[1099] In one embodiment, examples of the N-protected unnatural amino acids having an Fmoc group as a protecting group in the present invention include the following amino acids or their salts, or their solvates listed in Table 4.

[1100] aa004: (2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]octanoic acid,

[1101] aa013: (2R)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-methylthiopropanoic acid,

[1102] aa019: (2S)-2-[9H-Fluoren-9-ylmethoxycarbonyl(methyl)amino]-4,4-difluoro-butyric acid,

[1103] aa023: (2S)-2-[9H-Fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-(3-thienyl)propanoic acid,

[1104] aa028: (2S)-3-(3,4-Dichlorophenyl)-2-[9H-Fluoren-9-ylmethoxycarbonyl(methyl)amino]propanoic acid,

[1105] aa043: (2S)-5,5-Dichloro-2-[9H-Fluoren-9-ylmethoxycarbonyl(methyl)amino]pentanoic acid,

[1106] aa056: (2R)-3-[9H-Fluoren-9-ylmethoxycarbonyl(methyl)amino]-2-methyl-propanoic acid,

[1107] aa098: (2S,3S)-1-(9H-Fluoren-9-ylmethoxycarbonyl)-3-methyl-azetidine-2-carboxylic acid,

[1108] aa099: (2S,3R)-1-(9H-Fluoren-9-ylmethoxycarbonyl)-3-methyl-azetidine-2-carboxylic acid,

[1109] aa100: (2S)-1-(9H-Fluoren-9-ylmethoxycarbonyl)-3,3-dimethyl-azetidine-2-carboxylic acid,

[1110] aa111: (2R)-3-Allyloxy-2-[9H-Fluoren-9-ylmethoxycarbonyl(methyl)amino]propanoic acid,

[1111] aa136: (2S)-2-[9H-Fluoren-9-ylmethoxycarbonyl(propyl)amino]-3-[4-(trifluoromethyl)phenyl]propanoic acid,

[1112] aa174: (2S)-2-[9H-Fluoren-9-ylmethoxycarbonyl(propyl)amino]-3-(p-tolyl)propanoic acid,

[1113] aa210: (2S)-2-Cyclopentyl-2-[ethyl(9H-Fluoren-9-ylmethoxycarbonyl)amino]acetic acid,

[1114] aa220: (2S)-4-(4-Chloro-3,5-difluoro-phenyl)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)butyric acid,

[1115] aa229: (2S)-4-(Benzothiophen-5-yl)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)butyric acid,

[1116] aa233: (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-[3-methyl-4-(trifluoromethyl)phenyl]butanoic acid,

[1117] aa235: (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-[3-methoxy-4-(trifluoromethyl)phenyl]butanoic acid,

[1118] aa239: (2S,4S)-1-(9H-fluoren-9-ylmethoxycarbonyl)-4-methyl-pyrrolidine-2-carboxylic acid,

[1119] aa244: (2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-5,5-difluoro-pentanoic acid,

[1120] aa246: (2S,4R)-1-(9H-fluoren-9-ylmethoxycarbonyl)-4-propoxy-pyrrolidine-2-carboxylic acid,

[1121] aa250: (2R)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-propoxy-propanoic acid,

[1122] aa264: (2S,3R)-1-(9H-fluoren-9-ylmethoxycarbonyl)-3-tetrahydropyran-2-yloxy-pyrrolidine-2-carboxylic acid,

[1123] aa265: (2S,3S)-1-(9H-fluoren-9-ylmethoxycarbonyl)-3-tetrahydropyran-2-yloxy-pyrrolidine-2-carboxylic acid,

[1124] aa268: (1S,2S,5R)-3-(9H-fluoren-9-ylmethoxycarbonyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid,

[1125] aa279: (2S,4R)-1-(9H-fluoren-9-ylmethoxycarbonyl)-4-tetrahydropyran-2-yloxy-pyrrolidine-2-carboxylic acid,

[1126] aa281: (2S,4R)-1-(9H-fluoren-9-ylmethoxycarbonyl)-4-methoxy-pyrrolidine-2-carboxylic acid,

[1127] aa331: (2S)-3-ethyl-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]pentanoic acid,

[1128] aa389: (2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(propyl)amino]-4-methyl-pentanoic acid,

[1129] aa391: (2S,3R)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-propoxy-butyric acid,

[1130] aa397: (2S)-2-[9H-Fluoren-9-ylmethoxycarbonyl(propyl)amino]-3-isopentyloxy-propanoic acid,

[1131] aa398: (2S)-3-(Cyclobutyloxy)-2-[9H-Fluoren-9-ylmethoxycarbonyl(propyl)amino]propanoic acid,

[1132] aa399: (2S)-4-(7-Chloro-1-methyl-indol-5-yl)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)butyric acid,

[1133] aa400: (2S)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-(2-Fluoro-3-methyl-benzo[b]thiophen-5-yl)butyric acid,

[1134] aa401: (2S)-4-(7-Chlorobenzo[b]thiophen-5-yl)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)butyric acid,

[1135] aa402: (2S)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-(1-Methylindol-6-yl)butyric acid,

[1136] aa403: (2S)-4-(1,3-Dimethylindol-6-yl)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)butyric acid,

[1137] aa404: (2S)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-(1,2,3-Trimethylindol-6-yl)butyric acid,

[1138] aa405: (2S)-4-(2,3-Dimethylbenzo[b]thiophen-5-yl)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)butyric acid,

[1139] aa406: (2S)-4-(3-Chloro-4-ethyl-phenyl)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)butyric acid,

[1140] aa407: (2S)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4.[4-(Methoxymethyl)-3,5-dimethyl-phenyl]butyric acid,

[1141] aa408: (2S)-4-(4-Chloro-3-methoxy-phenyl)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)butyric acid,

[1142] aa409: (2S)-4-[4-chloro-3-(trifluoromethyl)phenyl]-2-(9H-fluoren-9-ylmethoxycarbonylamino)butyric acid,

[1143] aa410: (2S)-4-[4-(difluoromethyl)-3,5-difluoro-phenyl]-2-(9H-fluoren-9-ylmethoxycarbonylamino)butyric acid,

[1144] aa411: (2S)-4-(4-chloro-3,5-dimethyl-phenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)butyric acid,

[1145] aa414: (2S,4R)-4-(cyclopentyloxy)-1-(9H-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid,

[1146] aa415: (2S,4R)-4-(cyclobutyloxy)-1-(9H-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid,

[1147] aa423: (3S)-3-cyclobutyl-3-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]propanoic acid,

[1148] aa424: (3R)-3-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]pentanoic acid,

[1149] aa425: (3S)-3-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-4-methyl-pentanoic acid,

[1150] aa426: (3S)-3-cyclohexyl-3-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]propanoic acid,

[1151] aa443: (2S)-2-[but-3-enyl(9H-fluoren-9-ylmethoxycarbonyl)amino]-3-(p-tolyl)propanoic acid,

[1152] aa511: (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-[3-fluoro-5-methoxy-4-(trifluoromethyl)phenyl]butyric acid, and

[1153] aa512: (2S)-4-[3-ethyl-4-(trifluoromethyl)phenyl]-2-(9H-fluoren-9-ylmethoxycarbonylamino)butyric acid.

[1154] (General production method)

[1155] The cyclic compounds for use in the present invention, as well as general production methods for oligopeptide compounds and unnatural amino acids used in the production of these compounds, will be described below. In this document, the cyclic compounds may sometimes be referred to as "cyclic peptide compounds". In this document, the "cyclic portion" of a peptide compound means the cyclic portion formed by linking two or more amino acid residues.

[1156] Chemical synthesis method for peptide compounds

[1157] In the present text, examples of chemical synthesis methods for peptide compounds or cyclic compounds include liquid-phase synthesis methods, solid-phase synthesis methods using Fmoc synthesis, Boc synthesis, etc., and combinations thereof. In Fmoc synthesis, the basic unit is an amino acid with the main-chain amino group protected by an Fmoc group, and the side-chain functional groups are protected, as needed, by protecting groups (such as t-Bu group, THP group, or Trt group) that are not cleaved by piperidine or such bases, and the amino acid with the main-chain carboxylic acid unprotected. The basic unit is not particularly limited as long as it has a combination of an Fmoc-protected amino group and a carboxyl group. Hydroxycarboxylic acids can be used as the basic unit, and in this case, the hydroxyl group can be protected or unprotected. For example, a dipeptide or a tripeptide can be the basic unit, and a cyclic structure can be formed between the nitrogen atom and / or substituents on the side chain contained in the dipeptide or tripeptide. The basic unit provided at the N-terminus can be a unit other than an Fmoc amino acid. For example, it can be a Boc amino acid or a Tfa group or an Ns group, or a carboxylic acid analogue without an amino group. The main-chain carboxyl group or the side-chain carboxyl group of an amino acid having a carboxyl group in the side chain and the main-chain carboxyl group protected by a suitable protecting group is loaded onto the solid phase by a chemical reaction with the functional group of the solid-phase support. Subsequently, the Fmoc group is deprotected by a base (such as piperidine or DBU), and a condensation reaction is carried out on the newly produced amino group and the amino acid or hydroxycarboxylic acid protected by the basic unit having a carboxyl group added subsequently to produce a peptide bond. In the condensation reaction, various combinations (such as the combination of DIC and HOBt, the combination of DIC and HOAt, the combination of HATU and DIPEA, and the combination of HATU and HOAt and DIPEA) can be used as the activator for the carboxyl group. By repeating the Fmoc group deprotection and the subsequent peptide bond formation reaction, the desired peptide sequence can be produced. In the case where a hydroxycarboxyl group is used as the basic unit, the hydroxyl group can be unprotected, and the hydroxyl group and the amino acid protected by the basic unit having a carboxyl group added subsequently undergo a condensation reaction to produce a peptide bond. In this case, in the condensation reaction between the hydroxyl group and the carboxyl group, various combinations (such as the combination of DIC and DMAP, the combination of EDC and DMAP, and the combination of DCC and HOBt and DMAP) may be used as the activator for the carboxyl group. After obtaining the desired sequence, cleavage from the solid phase and deprotection of the protecting groups of the optionally introduced side-chain functional groups are carried out. In addition, conformational conversion and cyclization of the peptide can be carried out before cleavage from the solid phase. Cleavage from the solid phase and deprotection can be carried out under the same conditions, for example, in 90:10 TFA / H2O, or deprotection can be carried out under different conditions as needed. In some cases, a weak acid (such as 1% TFA) can be used to achieve cleavage from the solid phase, and a protecting group that can be deprotected with a Pd-containing catalyst, etc., can be used to utilize the orthogonality of the two chemical reactions.During or at the end of these steps, additional steps (such as cyclization) can also be carried out. For example, the side-chain carboxylic acid can be condensed with the N-terminal main-chain amino group, and the side-chain amino group can be condensed with the C-terminal main-chain carboxylic acid. Additionally, olefins can be introduced at two or more sites of the side-chain and / or nitrogen atom substituents and cyclized by a metathesis reaction. Furthermore, the double bond produced by cyclization can be reduced to a single bond. Additionally, the double bond produced by cyclization can be converted to a cyclopropane ring under conditions involving, for example, diiodomethane-diethylzinc. These steps of cyclization, reduction, conversion to a cyclopropane ring, etc. can be carried out during the synthesis of basic units such as dipeptides or tripeptides. At the same time, orthogonality of the reaction is required between the carboxylic acid on the C-terminal side and the side-chain carboxylic acid to be cyclized, between the main-chain amino group or hydroxyl group on the N-terminal side and the side-chain amino group to be cyclized, or between the olefins of the side-chain and / or the substituents of the nitrogen atom and the olefins to be cyclized. As described above, protecting groups are selected considering the orthogonality of the protecting groups. Additionally, by placing a chloroacetyl group at the N-terminal, cyclization can also be carried out between the thiol groups of the cysteine residue side-chains. The reaction products thus obtained can be purified by, for example, a reverse-phase column, a molecular sieve column, etc. Details of these procedures are described, for example, in the Solid-Phase Synthesis Handbook published by Merck on May 1, 2002. Commercially available resins for solid-phase synthesis are applicable, and examples include CTC resin, Wang resin, and SASRIN resin.

[1158] A general method for synthesizing an amino acid-loaded resin for use in peptide synthesis by a peptide synthesizer will be described below.

[1159] Fmoc amino acids can be loaded onto the resin by the method described in WO2013 / 100132 or WO2018 / 225864. Specifically, for example, 2-chlorotrityl chloride resin and a solvent (e.g., dehydrated dichloromethane) are introduced into a reaction vessel equipped with a filter to swell the resin. Next, the solvent and the resin are separated, and then a mixture of the resin, the C-terminal free Fmoc amino acid dissolved in a solvent (e.g., dehydrated dichloromethane), a solvent (e.g., dehydrated methanol), and a base (e.g., diisopropylethylamine) is added to the reaction vessel and mixed to load the Fmoc amino acid onto the resin. After separating the resin and the reaction solution, the resin is mixed with a mixture of one or more solvents and a base (e.g., a mixture of dehydrated dichloromethane, dehydrated methanol, and diisopropylethylamine) to wash the resin. After washing the resin several times with a solvent (e.g., dichloromethane) as needed, the resin and the reaction solution are separated. By drying the resulting resin under reduced pressure overnight, an Fmoc amino acid-loaded resin can be obtained.

[1160] [Formula 43]

[1161]

[1162] (where n represents an integer from 1 to 11; P1 to P 11、 Q1 to Q 11 and R1 to R 11 mean P1 to P as defined herein respectively 11 、Q1 to Q 11 and R1 to R 11 ; L1 and L 11 mean L1 and L as described herein respectively 11 ; L2 to L 10 are single bonds; and ○ (circle) means a resin part.)

[1163] The above structure shows that in Fmoc - amino acid, the 2 - chlorotrityl group on the resin is bonded to the carboxylic acid of the Fmoc amino acid via an ester bond.

[1164] In the production of the compounds described herein, when the defined groups undergo an undesired chemical transformation under the conditions of the method being carried out, the compound can be produced by, for example, protection and de - protection of functional groups. The selection of the protecting group and the introduction / removal procedures can be carried out according to the methods described in, for example, Greene's "Protective Groups in Organic Synthesis" (5th Edition, John Wiley & Sons, 2014), which can be appropriately used according to the reaction conditions. Additionally, the order of reaction steps such as the introduction of substituents can be varied as needed. For example, the protecting groups for amino groups are Fmoc, Boc, Cbz, or Alloc groups. These carbamate groups can be introduced by reacting the amino group with a carbamoylating agent in the presence of a basic catalyst. Examples of carbamoylating agents include Boc2O, BocOPh, FmocOSu, FmocCl, CbzCl, and AllocCl. Examples of basic catalysts include lithium carbonate, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, cesium carbonate, cesium bicarbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, cesium hydroxide, sodium phosphate, potassium phosphate, N - methylmorpholine, triethylamine, diisopropylethylamine, and N,N - dimethylaminopyridine. The carbamate groups as protecting groups for amino groups can be removed under basic conditions, acidic conditions, hydrogenolysis reaction conditions, etc.

[1165] (Method for synthesizing cyclic compounds through cyclization of peptide compounds)

[1166] A method for converting a linear peptide compound into a cyclic peptide compound can be carried out by performing an intramolecular bonding reaction according to methods described, for example, in Compositional Organic Transformations, A Guide to Function Group Preparations, 3rd Edition, R.C. Larock, or March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7th Edition, M.B. Marc...

Claims

1. A cyclic compound represented by formula (1), or a salt or solvate thereof: In the formula, L1 is a single bond; R1 is a C1-C6 alkyl group, a C2-C6 alkynyl group, or a C3-C8 cycloalkyl group optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a C3-C6 cycloalkyl group, and a C1-C6 alkoxy group; P1 is a hydrogen atom or a C1-C6 alkyl group; Q1 is a hydrogen atom; R2 is a C1-C6 alkyl group or a C3-C6 cycloalkyl group; P2 is a hydrogen atom; Q2 is a hydrogen atom; R3 is a hydrogen atom, or R3, the carbon atom to which R3 is attached, and the nitrogen atom to which P3 is attached are joined together to form a 4- to 7-membered saturated heterocyclic ring; Except when R3 and P3 form a 4- to 7-membered saturated heterocyclic ring, P3 is a C1-C6 alkyl group or a C2-C6 alkynyl group; Q3 is a hydrogen atom; R4 and P5 are joined together to form a divalent group, and in this case, the partial structure *-CR4Q4-CO-NP5-* in the cyclic compound represented by formula (1) is represented by the following formula: In the formula, T is a hydrogen atom or a halogen atom; P4 is a C1-C6 alkyl group; Q4 is a hydrogen atom, R5 is a benzyl group optionally substituted with one or more groups selected from the group consisting of a C1-C6 alkyl group and a C1-C6 haloalkyl group; Q5 is a hydrogen atom, R6 is a hydrogen atom; P6 is a C1-C6 alkyl group, Q6 is a hydrogen atom, R7 is a phenethyl group optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a C1-C6 haloalkyl group, and a C1-C6 alkoxy group; P7 is a hydrogen atom, Q7 is a hydrogen atom, R8, the carbon atom to which R8 is attached, and the nitrogen atom to which P8 is attached are joined together to form a 4- to 7-membered saturated heterocyclic ring, wherein the 4- to 7-membered saturated heterocyclic ring is optionally substituted with one or more groups independently selected from the group consisting of a C1-C6 alkyl group, a C3-C6 cycloalkyl group, and a C1-C6 alkoxy group; Q8 is a hydrogen atom, R9 is a C1-C6 alkyl group, or is joined together with Q9 and the carbon atom to which R9 and Q9 are attached to form a 3- to 8-membered alicyclic ring, and the 3- to 8-membered alicyclic ring is optionally substituted with one or more C1-C6 alkyl groups; P9 is a hydrogen atom or a C1-C6 alkyl group, Except when Q9, R9, and the carbon atom to which R9 and Q9 are attached are joined together to form a 3- to 8-membered alicyclic ring, Q9 is a C1-C6 alkyl group, R 10 is a C1 to C6 alkyl group or a C3 to C8 cycloalkyl group; P 10 is a C1 to C6 alkyl group, Q 10 is a hydrogen atom, L 11 is -CH2- R 11 is di-C1 to C6 alkylaminocarbonyl or 4- to 8-membered cyclic aminocarbonyl; P 11 is a C1 to C6 alkyl group, and Q 11 is a hydrogen atom, Wherein, The cyclic compound represented by formula (1) is selected from the group consisting of the following items: PP3169: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-[(1S)-1-methoxyethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3194: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetracosa-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3198: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10 ,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3230: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-prop-2-ynyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3234: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-prop-2-ynyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3236: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3238: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-dodecaaza-tricyclo[34.5.1.0 10,14 tetracosa-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3240: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10，14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3255: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-Cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,19,22,25,31,34,37,45-undecaoxo-13-prop-2-ynyl-38-(p-tolylmethyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 tetracos-42-ene-23,1′-cyclobutane]-17-carboxamide, PP3290: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3-methoxy-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopteroporphyrin[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, PP3299: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-6′,16′-bis((S)-sec-Butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopteroporphyrin[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, PP3327: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopiperazino[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, PP3328: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-16′-cyclopentyl-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopiperazino[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, PP3356: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontene-39′,1″-cyclopropane]-9′-carboxamide, PP3406: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-16′-((S)-sec-Butyl)-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontene-39′,1″-cyclopropane]-9′-carboxamide, PP3418: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-16′-((S)-sec-Butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontacene-39′,1″-cyclopropane]-9′-carboxamide, PP3438: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3-methoxy-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontacene-39′,1″-cyclopropane]-9′-carboxamide, PP3440: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-16′-((S)-sec-Butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-6′-cyclopentyl-N,N,5′,8′,12′,18′,21′,31′-octamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, PP3456: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-27-butyl-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3′,3′,4,19,22,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3457: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3′,3′,4,19,22,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoXO-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3484: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-isobutyl-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-decaaza-tricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3496: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-2-[[4-(difluoromethyl)phenyl]methyl]-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-20-(1-ethylpropyl)-12-isopropoxy-30-isopropyl-N,N,4,16,19,22,26,35-octamethyl-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-32-prop-2-ynyl-27-(2,2,2-trifluoroethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3516: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38E)-20-Cyclobutyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-38-fluoro-27-isobutyl-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclopentane]-23-carboxamide, PP3517: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38E)-20-Cyclobutyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-38-fluoro-27-isobutyl-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclopentane]-23-carboxamide, PP3521: (2S,8S,13S,19S,22S,26S,29S,35S,37E)-19-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-37-fluoro-26-isobutyl-N,N,4,18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-3,6,9,14,17,20,24,27,30,33,41-undecaoXO-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,15,18,21,25,28,31,34-undecaazatricyclo[33.5.1.0 10,13 hentetracont-37-ene-16,1′-cyclopentane]-22-carboxamide, PP3522: (2S,8S,13S,19S,22S,26S,29S,35S,37E)-19-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-37-fluoro-26-isobutyl-N,N,4,18,21,25,31,34-octamethyl-29-[(1S)-1-methylpropyl]-3,6,9,14,17,20,24,27,30,33,41-undecaoXO-2-(p-tolylmethyl)spiro[1,4,7,10,15,18,21,25,28,31,34-undecaazatricyclo[33.5.1.0 10,13 hentetracont-37-ene-16,1′-cyclopentane]-22-carboxamide, PP3523: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38E)-20-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-38-fluoro-27-isobutyl-N,N,4,17,17,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-(p-tolylmethyl)-1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-en-23-carboxamide, and PP3529: (1S,4S,9S,12S,16S,19S,25S,27R,31S,37S,41E)-19-Cyclopentyl-27-ethoxy-42-fluoro-31-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,13,17,20,23,35-octamethyl-9-[(1S)-1-methylpropyl]-3,8,11,14,18,21,24,30,33,36,44-undecaoXO-12-propyl-37-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,7,10,13,17,20,23,29,32,35,38-undecaazatetracyclo[36.5.1.0 4, 7 .0 25,29 tetratetracont-41-ene-22,1′-cyclobutane]-16-carboxamide.

2. The cyclic compound or a salt or a solvate thereof according to claim 1, wherein, the formula (1) is represented by formula (2): wherein, R1, P1, R2, R3, P3, P4, R5, P6, R7, R8, P8, R9, P9, Q9, R 10 , P 10 , R 11 , P 11 and T are the same as defined in claim 1, and the cyclic compound represented by formula (2) is selected from the group consisting of: PP3169: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-[(1S)-1-methoxyethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3194: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3198: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10 ,14 tetracosa-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3230: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-prop-2-ynyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3234: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoXO-27-prop-2-ynyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetracosa-38-ene-17,1'-cyclobutane]-23-carboxamide, PP3236: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-12-ethoxy-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaooxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3238: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3240: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-20-cyclopentyl-12-ethoxy-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoXO-27-prop-2-ynyl-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3255: (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-Cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,19,22,25,31,34,37,45-undecaooxo-13-prop-2-ynyl-38-(p-tolylmethyl)spiro[2,8,11,14,18,21,24,30,33,36,39-undecaazatetracyclo[37.5.1.0 4,8 .0 26,30 tetratetracont-42-en-23,1′-cyclobutane]-17-carboxamide, PP3290: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3-methoxy-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, PP3299: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-6′,16′-bis((S)-sec-butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaoxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, PP3327: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-16′-((S)-sec-butyl)-6′-cyclopentyl-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaoxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, PP3328: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-16′-cyclopentyl-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-29′-(4-methylbenzyl)-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopyrrolo[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, PP3356: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-16′-((S)-sec-butyl)-6′-cyclopentyl-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,2′,5′,8′,12′,18′,21′,31′-nonamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopyrrolo[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, PP3406: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-16′-((S)-sec-Butyl)-35′-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, PP3418: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-16′-((S)-sec-Butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-6′-neopentyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, PP3438: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-16′-((S)-sec-Butyl)-6′-cyclopentyl-35′-(3-methoxy-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, PP3440: (6′S,9′S,13′S,16′S,22′S,29′S,35′S,40a′S,Z)-16′-((S)-sec-Butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-6′-cyclopentyl-N,N,5′,8′,12′,18′,21′,31′-octamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaooxo-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratetracontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanoptero[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclotetracontatriene-39′,1″-cyclopropane]-9′-carboxamide, PP3456: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-27-butyl-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3′,3′,4,19,22,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3457: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-N,N,3′,3′,4,19,22,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3484: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-isobutyl-N,N,4,16,19,22,26,32,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide, and PP3496: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-2-[[4-(Difluoromethyl)phenyl]methyl]-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-20-(1-ethylpropyl)-12-isopropoxy-30-isopropyl-N,N,4,16,19,22,26,35-octamethyl-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-32-prop-2-ynyl-27-(2,2,2-trifluoroethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1′-cyclobutane]-23-carboxamide.

3. A cyclic compound represented by formula (3) or a salt thereof or a solvate thereof: wherein, L1 is a single bond or -CHM1-, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m -, where n and m are each independently 1 or 2, R1 is any one of the following (a1) to (a6): (a1)R1 is a hydrogen atom, C1-C7 alkyl, C2-C7 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy C1-C6 alkyl, C2-C6 alkenyloxy C1-C6 alkyl, C1-C6 alkylthio C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, C3-C8 cycloalkyloxy C1-C6 alkyl, C7-C 14 arylalkyl or 5- to 10-membered heteroaryl C1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, a C1-C6 alkyl group, a C1-C6 alkylsulfonyl group, and an aminocarbonyl group where the amino group is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino; (a2) R1, the carbon atom to which P1 and R1 are attached, and the nitrogen atom to which P1 is attached are linked together to form a 4- to 7-membered saturated heterocycle; (a3) R1, Q1, and the carbon atom to which R1 and Q1 are attached are linked together to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle; (a4)R1 is connected to M1, the carbon atom to which R1 is attached, and the carbon atom to which M1 is attached to form a 3- to 8-membered alicyclic ring; (a5)R1 and R5 are connected together to form a divalent group selected from the group consisting of C1 to C 10 alkylene, C2 to C 10 alkenylene, C2 to C 10 alkynylene, C3 to C8 cycloalkylene, C6 to C 10 arylene, -CO-NR A -, -NR A -CO-, and combinations of two or more thereof, wherein one or more carbon atoms constituting the divalent group are optionally replaced by one or more heteroatoms selected from the group consisting of N, O, and S, the divalent group is optionally substituted by one or more groups independently selected from the group consisting of halogen atoms and C1 to C6 alkyl groups, and R A is a hydrogen atom or a C1 to C6 alkyl group; and (a6)R1 and R9 are connected together to form a divalent group selected from the group consisting of C1 to C 10 alkylene, C2 to C 10 alkenylene, C2 to C 10 alkynylene, C3 to C8 cycloalkylene, C6 to C 10 arylene, -CO-NR B -, -NR B -CO- and combinations of two or more thereof, wherein one or more carbon atoms constituting the divalent group are optionally replaced by one or more heteroatoms selected from the group consisting of N, O and S, and the divalent group is optionally substituted by one or more groups independently selected from the group consisting of halogen atoms and C1 to C6 alkyl groups, and R B is a hydrogen atom or a C1 to C6 alkyl group; Except when R1 and P1 form a 4- to 7-membered saturated heterocycle, P1 is a hydrogen atom or a C1-C6 alkyl group, wherein the C1-C6 alkyl group is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group, and an aminocarbonyl group having an amino group of -NH2, a mono-C1-C6 alkylamino group, a di-C1-C6 alkylamino group, or a 4- to 8-membered cyclic amino group; Except when R1 and Q1 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle, Q1 is a hydrogen atom or a C1-C6 alkyl group, and Except when R1 and M1 form a 3- to 8-membered alicyclic ring, M1 is a hydrogen atom or a C1-C6 alkyl group, R2 is any one of the following (b1) to (b4): (b1) R2 is a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl C1-C6 alkyl group, a C3-C8 cycloalkoxy C1-C6 alkyl group, or a 4- to 7-membered heterocyclic group, each of which is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, and a C1-C6 alkylsulfonyl group; (b2) R2 is connected to P2, the carbon atom to which R2 is attached, and the nitrogen atom to which P2 is attached to form a 4- to 7-membered saturated heterocycle; (b3) R2 is connected to Q2 and the carbon atoms to which R2 and Q2 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle; and (b4)R2 is connected to R 11 to form a divalent group selected from the group consisting of C1 to C 10 alkylene, C2 to C 10 alkenylene, C2 to C 10 alkynylene, C3 to C8 cycloalkylene, C6 to C 10 arylene, -CO-NR C -, -NR C -, -CO-, -C3 to C8 alkylene-NR C -, -C3 to C8 alkenylene-NR C - and combinations of two or more of them, wherein one or more carbon atoms constituting the divalent group are optionally replaced by one or more heteroatoms selected from the group consisting of N, O and S, the divalent group is optionally substituted by one or more groups independently selected from the group consisting of halogen atoms and C1 to C6 alkyl groups, and R C is a hydrogen atom or a C1 to C6 alkyl group; Except when R2 and P2 form a 4- to 7-membered saturated heterocycle, P2 is a hydrogen atom or a C1-C6 alkyl group, wherein the C1-C6 alkyl group is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group, and an aminocarbonyl group having an amino group of -NH2, a mono-C1-C6 alkylamino group, a di-C1-C6 alkylamino group, or a 4- to 8-membered cyclic amino group; Except when R2 and Q2 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle, Q2 is a hydrogen atom or a C1-C6 alkyl group, R3 is any one of the following (c1) to (c3): (c1)R3 is a hydrogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl C1-C6 alkyl group, a C3-C8 cycloalkoxy C1-C6 alkyl group, or a C7-C 14 arylalkyl group, each of which is optionally substituted by one or more groups independently selected from the group consisting of a hydroxyl group and an amino group which is -NH2, a mono-C1-C6 alkylamino group, a di-C1-C6 alkylamino group or a 4- to 8-membered cyclic amino group carbonyl group; (c2) R3 is connected to P3, the carbon atom to which R3 is attached, and the nitrogen atom to which P3 is attached to form a 4- to 7-membered saturated heterocycle, wherein the 4- to 7-membered saturated heterocycle is optionally substituted by one or more groups selected from the group consisting of a C1-C6 alkyl group and a C1-C6 alkoxy group; and (c3) R3 is connected to Q3 and the carbon atoms to which R3 and Q3 are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle; Except in the case where R3 and P3 form a 4- to 7-membered saturated heterocycle, P3 is a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy C1-C6 alkyl group, or a C3-C8 cycloalkyl group, each of which is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, a C1-C6 alkoxy group, and a C1-C6 aminoalkyl group in which the amino group is -NH2, a mono-C1-C6 alkylamino group, a di-C1-C6 alkylamino group, or a 4- to 8-membered cyclic amino group and the 4- to 8-membered cyclic amino group is optionally substituted by one or more halogen atoms, Except in the case where R3 and Q3 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle, Q3 is a hydrogen atom or a C1-C6 alkyl group, R4 is any one of the following (d1) to (d4): (d1) R4 is a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C2-C6 alkenoxy C1-C6 alkyl group, or a C1-C6 carboxyalkyl group, each of which is optionally substituted by one or more hydroxyl groups; (d2) R4, the carbon atom to which R4 is attached, and the nitrogen atom to which P4 is attached are joined together to form a 4- to 7-membered saturated heterocycle, where the 4- to 7-membered saturated heterocycle is optionally substituted by one or more C1-C6 alkyl groups; (d3) R4, Q4, and the carbon atom to which R4 and Q4 are attached are joined together to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle; and (d4)R4 is connected to P5 to form a divalent group selected from the group consisting of C1 to C 10 alkylene, C2 to C 10 alkenylene, C2 to C 10 alkynylene, C3 to C8 cycloalkylene, 3- to 7-membered heteroalkylene, C6 to C 10 arylene, -CO-NR D -, -NR D -, -CO- and combinations of two or more of them, wherein one or more carbon atoms constituting the divalent group are optionally replaced by one or more heteroatoms selected from the group consisting of N, O and S, and the divalent group is optionally substituted by one or more groups independently selected from the group consisting of halogen atoms and C1 to C6 alkyl groups, and R D is a hydrogen atom or a C1 to C6 alkyl group; Except in the case where R4 and P4 form a 4- to 7-membered saturated heterocycle, P4 is any one of the following (e1) to (e2): (e1) P4 is a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, or a C1-C6 alkoxy C1-C6 alkyl group, each of which is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group, and an aminocarbonyl group in which the amino group is -NH2, a mono-C1-C6 alkylamino group, a di-C1-C6 alkylamino group, or a 4- to 8-membered cyclic amino group; and (e2) P4 and P5 are connected together to form a divalent group selected from the group consisting of C1 to C 10 alkylene, C2 to C 10 alkenylene, C2 to C 10 alkynylene, C3 to C8 cycloalkylene, C6 to C 10 arylene, -CO-NR E -, -NR E -CO-, and combinations of two or more thereof, wherein one or more carbon atoms constituting the divalent group are optionally replaced by one or more heteroatoms independently selected from the group consisting of N, O, and S, the divalent group is optionally substituted by one or more groups independently selected from the group consisting of halogen atoms and C1 to C6 alkyl groups, and R E is a hydrogen atom or a C1 to C6 alkyl group; Except in the case where R4 and Q4 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle, Q4 is a hydrogen atom or a C1-C6 alkyl group, Except in the case where R1 and R5 form a divalent group, R5 is any one of the following (f1) to (f4): (f1)R5 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkenyloxycarbonyl C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxy C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, C3-C8 cycloalkoxy C1-C6 alkyl, C7-C 14 arylalkyl, C6-C 10 aryloxy C1-C6 alkyl, C7-C 14 arylalkoxy C1-C6 alkyl, or 5- to 10-membered heteroaryl C1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C2-C6 alkenyloxy, C1-C6 haloalkoxy, a cyano group, C1-C6 alkylsulfonyl, C2-C6 alkenyl, C3-C8 cycloalkyl, and C1-C6 alkylcarbonyl; (f2) R5 and R8 are joined together to form a C4-C8 alkylene group; (f3) R5, the carbon atom to which R5 is attached, and the nitrogen atom to which P5 is attached are joined together to form a 4- to 7-membered saturated heterocycle; and (f4) R5, Q5, and the carbon atom to which R5 and Q5 are attached are joined together to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle; Except for the cases where R5 and P5 form a 4- to 7-membered saturated heterocycle, R4 and P5 form a divalent group, and P4 and P5 form a divalent group, P5 is a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy C1-C6 alkyl group, or a C3-C8 cycloalkyl C1-C6 alkyl group, wherein the C1-C6 alkyl group is optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group, an amino group, and an aminocarbonyl group where the amino group is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or a 4- to 8-membered cyclic amino group. Except for the cases where R5 and Q5 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle, Q5 is a hydrogen atom or a C1-C6 alkyl group. R6 is any one of the following (g1) to (g3): (g1) R6 is a hydrogen atom or a C1-C6 alkyl group; (g2) R6, the carbon atom to which R6 is attached, and the nitrogen atom to which P6 is attached are joined together to form a 4- to 7-membered saturated heterocycle; and (g3) R6, Q6, and the carbon atom to which R6 and Q6 are attached are joined together to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle; Except for the case where R6 and P6 form a 4- to 7-membered saturated heterocycle, P6 is a C1-C6 alkyl group or a C3-C8 cycloalkyl group, each of which is optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group, and an aminocarbonyl group where the amino group is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or a 4- to 8-membered cyclic amino group. Except for the cases where R6 and Q6 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle, Q6 is a hydrogen atom or a C1-C6 alkyl group. R7 is any one of the following (h1) to (h6): (h1)R7 is C6 to C 10 aryloxy C1-C6 alkyl, C7-C 14 arylalkyl, C7-C 14 arylalkoxy C1-C6 alkyl, or 5- to 10-membered heteroaryl C1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, C1-C6 alkylsulfonyl, SF5, and C3-C8 cycloalkyl; (h2) R7, the carbon atom to which R7 is attached, and the nitrogen atom to which P7 is attached are joined together to form a 4- to 7-membered saturated heterocycle; and (h3) R7, Q7, and the carbon atom to which R7 and Q7 are attached are joined together to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle; Except for the case where R7 and P7 form a 4- to 7-membered saturated heterocycle, P7 is a hydrogen atom or a C1-C6 alkyl group, wherein the C1-C6 alkyl group is optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group, and an aminocarbonyl group where the amino group is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or a 4- to 8-membered cyclic amino group. Except for the cases where R7 and Q7 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle, Q7 is a hydrogen atom or a C1-C6 alkyl group. Except for the case where R5 and R8 form a C4-C8 alkylene group, R8 is any one of the following (i1) to (i3): (i1) R8 is a hydrogen atom, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy C1-C6 alkyl, C2-C6 alkenyloxycarbonyl C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, C6-C 10 aryloxy C1-C6 alkyl, C7-C 14 aralkyl, C7-C 14 aralkoxy C1-C6 alkyl, 5- to 10-membered heteroaryl C1-C6 alkyl, or 5- to 10-membered heteroaryloxy C1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a carboxyl group, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, a cyano group, an amino group being -NH2, a mono-C1-C6 alkylamino, a di-C1-C6 alkylamino or a 4- to 8-membered cyclic amino group and each of which is optionally substituted with a halogen atom, an aminocarbonyl group, a 4- to 7-membered heterocycloalkylidene group, a protected 4- to 7-membered heterocycloalkylidene group, a 4- to 7-membered heterocyclic group and a protected 4- to 7-membered heterocyclic group; (i2) R8 is linked to P8, the carbon atom to which R8 is attached, and the nitrogen atom to which P8 is attached to form a 4- to 7-membered saturated heterocycle, wherein the 4- to 7-membered saturated heterocycle is optionally fused to a saturated carbocyclic ring or an aromatic ring, and the 4- to 7-membered saturated heterocycle is optionally substituted by one or more halogen atoms, oxo, one or more C1-C6 alkyl groups, C1-C6 haloalkyl, C3-C8 spiroalkyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, a 4- to 8-membered cyclic amino group or OS8 optionally substituted by one or more halogen atoms, and S8 is a hydrogen atom, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C8 cycloalkyl C1-C6 alkyl, 4- to 7-membered heterocyclic group, C7-C optionally substituted by one or more halogen atoms, C1-C6 alkyl, C1-C6 alkoxy or C1-C6 haloalkoxy 14 aralkyl, 5- to 10-membered heteroaryl C1-C6 alkyl, or C3-C8 cycloalkyl; and (i3) R8, Q8, and the carbon atom to which R8 and Q8 are attached are joined together to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocycle; Except when R8 and P8 form a 4- to 7-membered saturated heterocycle, P8 is a hydrogen atom, C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy C2-C6 alkenyl, C3-C8 cycloalkyl, 4- to 7-membered heterocyclic group, 4- to 7-membered heterocyclic group C1-C6 alkyl, C6-C 10 aryl, C7-C 14 aralkyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl C1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group, and an amino group where the amino group is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino carbonyl Except when R8 and Q8 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, Q8 is a hydrogen atom or a C1-C6 alkyl group, Except when R1 and R9 form a divalent group, R9 is any one of the following (j1) to (j2): (j1) R9 is a hydrogen atom, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy C1-C6 alkyl, C2-C6 alkenyloxy C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, C7-C 14 arylalkyl, or 5- to 10-membered heteroaryl C1-C6 alkoxy C1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylsulfonyl, and an aminocarbonyl group where the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino; and (j2) Q9, and the carbon atom to which R9 and Q9 are attached are joined together with R9 to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, each of which is optionally substituted with one or more halogen atoms or one or more C1-C6 alkyl groups; Except when R9 and Q9 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, Q9 is a hydrogen atom or a C1-C6 alkyl group, R 10 any one of the following (k1) to (k3): (k1)R 10 is C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxy C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, C3-C8 cycloalkoxy C1-C6 alkyl, or C7-C 14 arylalkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, and a C1-C6 alkylsulfonyl group; (k2)R 10 is connected to P 10 , R 10 The carbon atom connected to and P 10 The nitrogen atom connected to are joined together to form a 4- to 7-membered saturated heterocycle; and (k3)R 10 with Q 10 and R 10 and Q 10 The carbon atoms linked thereto are joined together to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; Except for R 10 and P 10 In the case of forming a 4- to 7-membered saturated heterocycle, P 10 is a hydrogen atom or a C1-C6 alkyl group, wherein the C1-C6 alkyl group is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group, and an amino group which is -NH2, a mono-C1-C6 alkylamino group, a di-C1-C6 alkylamino group, or an aminocarbonyl group of a 4- to 8-membered cyclic amino group Except for R 10 and Q 10 In the case of forming a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, Q 10 is a hydrogen atom or a C1 to C6 alkyl group, and L 11 is a single bond or -CHM 11 -, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m -, where n and m are each independently 1 or 2, Except when R2 and R 11 form a divalent group, R 11 is any one of the following (11) to (15): (l1)R 11 is a hydrogen atom, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy C1-C6 alkyl, C7-C 14 arylalkyl, C3-C8 cycloalkyl, or an aminocarbonyl group where the amino group is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, N-C1-C6 alkyl-N-C2-C6 alkenylamino or a 4- to 8-membered cyclic amino group, each of which is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, oxo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, a 4- to 7-membered heterocyclic group, C1-C6 alkylsulfonyl, and an aminocarbonyl group where the amino group is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino or a 4- to 8-membered cyclic amino group; (l2)R 11 is a peptide chain containing 1 to 4 amino acid residues; (l3)R 11 connected to P 11 , R 11 The carbon atom connected to and P 11 The nitrogen atom connected to form a 4- to 7-membered saturated heterocycle; (l4)R 11 is linked to Q 11 and R 11 and Q 11 are connected to the carbon atom to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; and (l5)R 11 and M 11 、R 11 the carbon atom(s) linked to M 11 and the carbon atom(s) linked to M are joined together to form a 3- to 8-membered alicyclic ring; Except for R 11 and P 11 In the case of forming a 4- to 7-membered saturated heterocycle, P 11 is a hydrogen atom, a C1-C6 alkyl group, a C3-C8 cycloalkyl C1-C6 alkyl group, or a C7-C 14 arylalkyl group, wherein the C1-C6 alkyl group is optionally substituted by one or more groups independently selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkoxy group, and an amino group which is -NH2, a mono-C1-C6 alkylamino group, a di-C1-C6 alkylamino group, or an aminocarbonyl group having a 4- to 8-membered cyclic amino group Except for R 11 and Q 11 In the case of forming a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, Q 11 is a hydrogen atom or a C1 to C6 alkyl group, Except for R 11 and M 11 in the case of forming a 3- to 8-membered alicyclic ring, M 11 is a hydrogen atom, and At least three of P1 to P 11 are not hydrogen atoms.

4. A cyclic compound represented by formula (3), or a salt or solvate thereof: wherein L1 is a single bond; R1 is a C1-C6 alkyl group, a C2-C6 alkynyl group, or a C3-C8 cycloalkyl group optionally substituted with one or more groups independently selected from the group consisting of halogen atoms, C3-C6 cycloalkyl groups, and C1-C6 alkoxy groups, P1 is a hydrogen atom or a C1-C6 alkyl group; Q1 is a hydrogen atom; R2 is a C1-C6 alkyl group or a C3-C6 cycloalkyl group; P2 is a hydrogen atom; Q2 is a hydrogen atom; R3 is a hydrogen atom, or R3, the carbon atom to which R3 is attached, and the nitrogen atom to which P3 is attached are joined together to form a 4- to 7-membered saturated heterocyclic ring; Except when R3 and P3 form a 4- to 7-membered saturated heterocyclic ring, P3 is a C1-C6 alkyl group or a C2-C6 alkynyl group; Q3 is a hydrogen atom; R4 and P5 are joined together to form a divalent group, and in this case, the partial structure *-CR4Q4-CO-NP5-* in the cyclic compound represented by formula (3) is represented by the following formula: wherein T is a hydrogen atom or a halogen atom; P4 is a C1-C6 alkyl group; Q4 is a hydrogen atom, R5 is a benzyl group optionally substituted with one or more groups selected from the group consisting of C1-C6 alkyl groups and C1-C6 haloalkyl groups; Q5 is a hydrogen atom, R6 is a hydrogen atom; P6 is a C1-C6 alkyl group, Q6 is a hydrogen atom, R7 is a phenethyl group optionally substituted with one or more groups independently selected from the group consisting of halogen atoms, C1-C6 haloalkyl groups, and C1-C6 alkoxy groups; P7 is a hydrogen atom, Q7 is a hydrogen atom, R8, the carbon atom to which R8 is attached, and the nitrogen atom to which P8 is attached are joined together to form a 4- to 7-membered saturated heterocyclic ring, wherein the 4- to 7-membered saturated heterocyclic ring is optionally substituted with one or more groups independently selected from the group consisting of C1-C6 alkyl groups, C3-C6 cycloalkyl groups, and C1-C6 alkoxy groups; Q8 is a hydrogen atom, R9 is a C1-C6 alkyl group, or is joined together with Q9 and the carbon atom to which R9 and Q9 are attached to form a 3- to 8-membered alicyclic ring, wherein the 3- to 8-membered alicyclic ring is optionally substituted with one or more C1-C6 alkyl groups; Except when Q9, and the carbon atom to which R9 and Q9 are attached are joined together to form a 3- to 8-membered alicyclic ring, Q9 is a C1-C6 alkyl group, R 10 is a C1-C6 alkyl or a C3-C8 cycloalkyl; P 10 is a C1 to C6 alkyl group, Q 10 is a hydrogen atom, L 11 is -CH2- R 11 is di-C1 to C6 alkylaminocarbonyl or 4- to 8-membered cyclic aminocarbonyl; P 11 is a C1 to C6 alkyl group, and Q 11 is a hydrogen atom.

5. A cyclic compound or a salt or a solvate thereof, wherein the formula (3) is represented by the formula (4): wherein R1, P1, R2, R3, P3, P4, R5, P6, R7, R8, P8, R9, Q9, R 10 , P 10 , R 11 , P 11 and T are the same as defined in claim 4.

6. The cyclic compound or a salt or a solvate thereof according to claim 5, wherein the cyclic compound represented by the formula (4) is selected from the group consisting of the following items: PP3376: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoXO-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[16-oxa-1,4,7,10,19,22,26,29,32,35-decaazatricyclo[34.5.1.0 10,14 tetracosa-38-ene-17,1′-cyclobutane]-23-carboxamide, PP3382: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-12-ethoxy-27-isobutyl-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-(p-tolylmethyl)spiro[16-oxa-1,4,7,10,19,22,26,29,32,35-decaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene,17,1'-cyclobutane]-23-carboxamide, and PP3394: (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-Cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo,2-(p-tolylmethyl)spiro[16-oxa-1,4,7,10,19,22,26,29,32,35-decaazatricyclo[34.5.1.0 10,14 tetratetracont-38-ene-17,1'-cyclobutane]-23-carboxamide.

7. A cyclic compound, or a salt or solvate thereof, wherein, The cyclic compound is selected from the group consisting of: PP3141, PP3151, PP3158, PP3160, PP3167, PP3169, PP3171, PP3176, PP3178, PP3185, PP3187, PP3194, PP3198, PP3200, PP3207, PP3217, PP3226, PP3230, PP3231, PP3233, PP3234, PP3235, PP3236, PP3237, PP3238, PP3239, PP3240, PP3242, PP3243, PP3244, PP3245, PP3246, PP3247, PP3248, PP3249, PP3250, PP3252, PP3253, PP3254, PP3255, PP3256, PP3257, PP3276, PP3282, PP3283, PP3284, PP3285, PP3286, PP3287, PP3288, PP3289, PP3290, PP3292, PP3294, PP3299, PP3300, PP3302, PP3306, PP3308, PP3310, PP3314, PP3316, PP3318, PP3322, PP3324, PP3326, PP3327, PP3328, PP3329, PP3331, PP3352, PP3353, PP3356, PP3358, PP3364, PP3367, PP3370, PP3373, PP3376, PP3379, PP3382, PP3388, PP3394, PP3397, PP3404, PP3406, PP3408, PP3410, PP3416, PP3418, PP3419, PP3436, PP3438, PP3440, PP3442, PP3444, PP3447, PP3448, PP3452, PP3455, PP3456, PP3457, PP3475, PP3478, PP3484, PP3496, PP3499, PP3500, PP3510, PP3511, PP3512, PP3513, PP3514, PP3515, PP3516, PP3517, PP3518, PP3519, PP3520, PP3521, PP3522, PP3523, PP3524, PP3525, PP3526, PP3527, PP3528, PP3529 and PP3530.

8. The cyclic compound according to claim 7 or a salt thereof.

9. The cyclic compound according to claim 7 or a solvate thereof.

10. The solvate of the cyclic compound according to claim 7 or a salt thereof.

11. The cyclic compound according to claim 7.

12. The cyclic compound according to any one of claims 1 to 11, or a salt or solvate thereof, which inhibits KRAS.

13. The cyclic compound according to any one of claims 1 to 11, or a salt or solvate thereof, the KRAS inhibitory activity of which is more than 3 times the NRAS inhibitory activity and the HRAS inhibitory activity.

14. A pharmaceutical composition comprising the cyclic compound according to any one of claims 1 to 11, or a salt or solvate thereof.

15. A pharmaceutical composition for selectively inhibiting KRAS in a subject, the pharmaceutical composition comprising the cyclic compound according to any one of claims 1 to 11, or a salt or solvate thereof.

16. A pharmaceutical composition for treating or preventing cancer in a subject, the pharmaceutical composition comprising an effective amount of the cyclic compound according to any one of claims 1 to 11, or a salt or solvate thereof.

17. The pharmaceutical composition according to claim 16, wherein, The cancer is lung cancer.

Images